0000930413-11-005153.txt : 20110805 0000930413-11-005153.hdr.sgml : 20110805 20110805164030 ACCESSION NUMBER: 0000930413-11-005153 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20110630 FILED AS OF DATE: 20110805 DATE AS OF CHANGE: 20110805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENZON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000727510 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222372868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-12957 FILM NUMBER: 111014711 BUSINESS ADDRESS: STREET 1: 20 KINGSBRIDGE ROAD STREET 2: ATT: GENERAL COUNSEL CITY: PISCATAWAY STATE: NJ ZIP: 08854 BUSINESS PHONE: 732-980-4500 MAIL ADDRESS: STREET 1: 20 KINGSBRIDGE ROAD STREET 2: ATT: GENERAL COUNSEL CITY: PISCATAWAY STATE: NJ ZIP: 08854 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICALS INC DATE OF NAME CHANGE: 20021211 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICAL INC DATE OF NAME CHANGE: 20021210 FORMER COMPANY: FORMER CONFORMED NAME: ENZON INC DATE OF NAME CHANGE: 19920703 10-Q 1 c66462_10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)


x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011


o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission file number 0-12957

Enzon Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)


Delaware	22-2372868
(State of incorporation)	(I.R.S. Employer Identification No.)

20 Kingsbridge Road, Piscataway, New Jersey	08854
(Address of principal executive offices)	(Zip Code)

(732) 980-4500
(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer o	Accelerated filer x	Non-accelerated filer o	Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Shares of Common Stock outstanding as of August 1, 2011: 48,688,085

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements.

ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)


	June 30, 2011			December 31, 2010*


ASSETS

Current assets:
Cash and cash equivalents	$	317,867		$	397,530
Short-term investments		41,083			31,170
Other current assets		4,189			5,916

Total current assets		363,139			434,616
Property and equipment, net of accumulated depreciation of $39,983 at June 30, 2011 and $38,286 at December 31, 2010		19,485			21,574
Marketable securities		3,316			31,394
Other assets		759			1,273

Total assets	$	386,699		$	488,857


LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	1,430		$	4,192
Accrued expenses and other		11,050			14,195

Total current liabilities		12,480			18,387

Notes payable		134,499			134,499
Other liabilities		4,266			4,114

Total liabilities		151,245			157,000


Commitments and contingencies

Stockholders’ equity:
Preferred stock - $.01 par value, authorized 3,000,000 shares; no shares issued and outstanding at June 30, 2011 and December 31, 2010		—			—
Common stock - $.01 par value, authorized 170,000,000 shares; issued and outstanding 50,631,943 shares at June 30, 2011 and 58,817,561 shares at December 31, 2010		506			588
Additional paid-in capital		365,331			454,657
Accumulated other comprehensive income		556			914
Accumulated deficit		(130,939	)		(124,302	)

Total stockholders’ equity		235,454			331,857

Total liabilities and stockholders’ equity	$	386,699		$	488,857


*	Condensed from audited financial statements.

	The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)


	Three months ended June 30,						Six months ended June 30,

	2011			2010			2011			2010

Revenues:
Royalties	$	9,172		$	10,588		$	20,934		$	23,489
Sale of in-process research and development		—			—			5,000			40,900
Contract research and development		231			2,602			1,325			5,211
Miscellaneous revenue		196			527			362			2,277

Total revenues		9,599			13,717			27,621			71,877


Operating expenses:
Research and development – pipeline		10,061			10,131			20,609			21,646
Research and development – specialty and contracted services		184			1,759			831			4,818
General and administrative		4,627			5,772			9,713			15,611
General and administrative – contracted services		54			421			112			1,821
Restructuring charge		674			710			1,033			10,599

Total operating expenses		15,600			18,793			32,298			54,495


Operating (loss) income		(6,001	)		(5,076	)		(4,677	)		17,382


Other income (expense):
Investment income, net		386			811			845			1,782
Interest expense		(1,479	)		(1,480	)		(2,959	)		(4,156	)
Other, net		31			(31	)		159			(30	)

Total other expense		(1,062	)		(700	)		(1,955	)		(2,404	)


(Loss) income from continuing operations, before income tax expense (benefit)		(7,063	)		(5,776	)		(6,632	)		14,978
Income tax expense (benefit)		5			(205	)		5			(205	)

(Loss) income from continuing operations		(7,068	)		(5,571	)		(6,637	)		15,183
(Loss) income and gain from discontinued operations, net of income tax		—			(51	)		—			179,002

Net (loss) income	$	(7,068	)	$	(5,622	)	$	(6,637	)	$	194,185


(Loss) earnings per common share - continuing operations
Basic	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	0.27

Diluted	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	0.23

Earnings per common share – discontinued operations
Basic		—			—			—		$	3.16

Diluted		—			—			—		$	2.38

(Loss) earnings per common share – net (loss) income
Basic	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	3.43

Diluted	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	2.61


Weighted average shares – basic		53,054			60,849			55,368			56,640

Weighted average shares - diluted		53,054			60,849			55,368			75,209

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)


	Six months ended June 30,

	2011			2010

Cash flows from operating activities:
Net (loss) income	$	(6,637	)	$	194,185
Income and gain from discontinued operations		—			179,002

(Loss) income from continuing operations		(6,637	)		15,183
Adjustments to reconcile (loss) income from continuing operations to net cash (used in) provided by operating activities:
Depreciation		2,555			2,858
Amortization and write-off of debt issuance costs		269			1,851
Share-based compensation		1,965			4,737
Write-down of property and equipment		—			895
Loss on disposal of fixed assets		61			—
Gain on sale of marketable securities		(80	)		(128	)
Changes in operating assets and liabilities		(3,127	)		14,625

Net cash (used in) provided by operating activities of continuing operations		(4,994	)		40,021
Net cash provided by operating activities of discontinued operations		—			436

Net cash (used in) provided by operating activities		(4,994	)		40,457


Cash flows from investing activities:
Proceeds from sale of business, net		—			262,608
Purchases of property and equipment		(530	)		(397	)
Proceeds from sales of fixed assets		4			—
Proceeds from sales and maturities of marketable securities		18,043			44,034
Purchases of marketable securities		(759	)		(1,544	)

Net cash provided by investing activities of continuing operations		16,758			304,701
Net cash used in investing activities of discontinued operations		—			(105	)

Net cash provided by investing activities		16,758			304,596


Cash flows from financing activities:
Repurchases of common stock		(96,054	)		(18,136	)
Proceeds from issuance of common stock		5,563			25,289
Withholding taxes – share-based compensation		(894	)		(3,328	)
Redemptions from employee stock purchase plan, net		(42	)		(138	)

Net cash (used in) provided by financing activities		(91,427	)		3,687


Net (decrease) increase in cash and cash equivalents		(79,663	)		348,740

Cash and cash equivalents at beginning of period		397,530			50,440


Cash and cash equivalents at end of period	$	317,867		$	399,180

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

(1) Description of Business

Enzon Pharmaceuticals, Inc. and subsidiaries (Enzon or the Company) is a biotechnology company dedicated to the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Operations are funded in part by the receipt of royalty revenues from licensing arrangements with other companies related to sales of products developed using the Company’s proprietary Customized PEGylation Linker Technology (Customized Linker Technology®) – primarily PEGINTRON, marketed by Merck & Co., Inc. The Company operates in one business segment. The Company’s Principal Executive Officer (chief operating decision maker) reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating unit. The Company’s operations and assets reside almost exclusively in the United States.

The Company’s pipeline drug development programs utilize two platforms – Customized Linker Technology and third-generation messenger ribonucleic acid (mRNA)-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. The Company currently has four compounds in clinical development: PEG-SN38 and the Hypoxia-Inducible Factor-1α (HIF-1α), Survivin and Androgen Receptor (AR) messenger RNA (mRNA) antagonists. In addition, the Company has other novel LNA targets in various stages of preclinical research.

On January 29, 2010, the Company sold its specialty pharmaceutical business, comprised principally of the Company’s products and contract manufacturing segments, for approximately $309 million in cash with the potential for subsequent milestone payments and royalties.

(2) Basis of Presentation

Interim Financial Statements
The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and Rule 10-01 of the U.S. Securities and Exchange Commission Regulation S-X. Accordingly, these financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the year. Interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010.

Principles of Consolidation
The condensed consolidated financial statements include those of Enzon Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.

Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include the valuation of certain investments, long-lived assets, legal and contractual contingencies and assumptions used in the calculation of share-based compensation and income taxes. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience, the current economic environment and other factors that management believes to be reasonable under the circumstances. Management adjusts such estimates and assumptions when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in estimates will be reflected in the financial statements in future periods. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in these financial statements.

Reclassifications
Certain prior-period amounts have been reclassified to conform to the current period presentation. In 2010, cash flows from discontinued operations were previously included in continuing operations within cash flows from operating and investing activities. The Company has made the appropriate reclassification to the current period presentation of the prior period statement of cash flows. There is no change in either the net cash provided by operating activities or the net cash provided by investing activities to the prior period statement of cash flows, and the reclassification between continuing and discontinued operations in the prior period is not deemed material.

ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(Unaudited)

(3) Financial Instruments and Fair Value

The carrying values of cash, cash equivalents, other current assets, accounts payable, and accrued expenses in the Company’s condensed consolidated balance sheets approximated their fair values at June 30, 2011 and December 31, 2010 due to their short-term nature. Short-term investments and marketable securities are carried on the balance sheets at fair value based on quoted market prices. All fair value measures are Level 1. Fair values and carrying amounts of the Company’s financial instruments are indicated below (in thousands):


Description	Fair Value		Carrying Amount

Investments and Marketable Securities (Note 4)	$	44,399	$	44,399


4% Convertible Senior Notes (Note 5)	$	160,807	$	134,499

(4) Short-term Investments and Marketable Securities

The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major security type at June 30, 2011 were as follows (in thousands):


	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value*


Corporate debt	$	35,120	$	445	$	—		$	35,565
Non-U.S. government debt		5,473		45		—			5,518
Other		3,250		78		(12	)		3,316

	$	43,843	$	568	$	(12	)	$	44,399

* Included in short-term investments of $41,083 and marketable securities of $3,316 at June 30, 2011.

The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major security type at December 31, 2010 were as follows (in thousands):


	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value*


Corporate debt	$	52,079	$	738	$	—		$	52,817
U.S. government-sponsored entities debt		1,000		4		—			1,004
Non-U.S. government debt		5,553		86		—			5,639
Other		3,019		111		(26	)		3,104

	$	61,651	$	939	$	(26	)	$	62,564

* Included in short-term investments of $31,170 and marketable securities of $31,394 at December 31, 2010.

All corporate, U.S. government-sponsored entity and non-U.S. government debt investments are classified as available-for-sale securities. Other securities include investments of participants in the Company’s Executive Deferred Compensation Plan (predominantly mutual fund shares) totaling $3.3 million fair value as of June 30, 2011 and $3.1 million fair value as of December 31, 2010. There is a non-current liability that offsets the aggregate deferred compensation plan assets.

Fair value is determined from readily available quoted prices in active markets (Level 1, the preferred approach pursuant to applicable accounting guidance). As of June 30, 2011 and December 31, 2010, the Company’s short-term investments and marketable securities are all valued based on Level 1 inputs.

ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(Unaudited)

Maturities of marketable debt securities, excluding securities related to the Company’s Executive Deferred Compensation Plan, at June 30, 2011 were as follows (in thousands):


Twelve-Month Periods Ending June 30,	Amortized Cost		Fair Value


2012	$	40,593	$	41,083

Sales during the quarter ended June 30, 2011 of investments in the deferred compensation plan resulted in a realized gain of approximately $58,000, bringing the year-to-date total realized gains to approximately $80,000. However, because the Company maintains a liability for the fair value of the deferred compensation due to plan participants, any realized gains or losses related to these investment holdings are off-set by a corresponding increase or decrease in the liability to operating expenses. Realized gains and losses on sales are computed on the basis of specific identification of the securities sold.

Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is other than temporary and, if it is other than temporary, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date. As of June 30, 2011, only certain assets of the Company’s Executive Deferred Compensation Plan have unrealized holding losses. None of the underlying investments has been in a continuous loss position longer than twelve months.

(5) Notes Payable

The 4% convertible senior notes mature on June 1, 2013 unless earlier redeemed, repurchased or converted. The 4% notes are senior unsecured obligations and rank equal to all future senior unsecured debt of the Company. The 4% notes are convertible at the option of the holders into the Company’s common stock at a conversion price of $9.55 per share (104.712 shares per $1,000 of principal amount). If the closing price of the Company’s common stock for at least 20 trading days in the 30-consecutive-trading-day period ending on the date one day prior to the date of a notice of redemption is greater than 140 percent of the applicable conversion price on the date of such notice, the Company, at its option, may redeem the 4% notes in whole or in part, at a redemption price in cash equal to 100 percent of the principal amount of the 4% notes to be redeemed, plus accrued and unpaid interest, if any, to the redemption date. Upon occurrence of a “fundamental change,” as defined in the indenture governing the 4% notes, holders of the notes may require the Company to redeem the notes at a price equal to 100 percent of the principal amount plus accrued and unpaid interest or, in certain cases, to convert the notes at an increased conversion rate based on the price paid per share of the Company’s common stock in the transaction constituting the fundamental change.

During the first quarter of 2010, notes totaling $115.6 million principal amount were converted into approximately 13.5 million shares of the Company’s common stock, reducing the outstanding principal balance of the notes outstanding to $134.5 million. The net effect of forgone interest and the write-off of deferred debt issuance costs amounted to $0.8 million and was charged to interest expense during the first quarter of 2010 at the time of the notes conversion. The $0.8 million was adjusted in the fourth quarter of 2010 to credit interest expense and charge additional paid-in capital to reflect the capital nature of the transaction. The noncash adjustment was not material to the first or fourth quarters nor to the full year 2010 results of operations.

Interest on the 4% notes is payable on June 1 and December 1 of each year. Accrued interest amounted to $0.4 million as of June 30, 2011 and December 31, 2010.

ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(Unaudited)

(6) Stockholders’ Equity

On December 21, 2010, the Company announced a share repurchase program, under which the Company may use up to $200.0 million to purchase the Company’s outstanding common shares. Transactions in the Company’s stock are recorded on a settlement date basis. During the three months ended June 30, 2011, the Company repurchased and retired 5,125,169 shares at a cost of $54.8 million, or an average cost per share of approximately $10.69. This brings the cumulative number of shares repurchased and retired under this program through June 30, 2011 to 9,008,242 shares at a total cost of $96.7 million. The plan continues to be in effect.

(7) Comprehensive (Loss) Income

The following table reconciles net (loss) income to comprehensive (loss) income (in thousands):


	Three months ended June 30,						Six months ended June 30,

	2011			2010			2011			2010


Net (loss) income	$	(7,068	)	$	(5,622	)	$	(6,637	)	$	194,185

Other comprehensive loss:
Unrealized loss on securities that arose during the period ⁽¹⁾		(153	)		(1,053	)		(278	)		(737	)
Currency translation adjustment ⁽¹⁾		—			(226	)		—			(39	)
Reclassification adjustments for gain on sale of securities included in net income ⁽¹⁾		(58	)		(16	)		(80	)		(128	)

Total other comprehensive loss		(211	)		(1,295	)		(358	)		(904	)

Comprehensive (loss) income	$	(7,279	)	$	(6,917	)	$	(6,995	)	$	193,281


⁽¹⁾	Information has not been tax-effected due to an estimated annual effective tax rate of zero.

(8) Supplemental Cash Flow Information

The Company considers all highly liquid investment securities with original maturities of three months or less to be cash equivalents. During the six months ended June 30, 2011, there were payments of interest related to the Company’s 4% notes in the amount of $2.7 million. During the six months ended June 30, 2010, the Company had a noncash conversion of $115.6 million principal amount of the 4% notes into approximately 13.5 million shares of its common stock. This first-quarter conversion resulted in a waiver of accumulated interest which amounted to approximately $0.8 million in interest savings for the Company. Income tax payments were $5,000 and $0.1 million for each of the six month periods ended June 30, 2011 and 2010, respectively.

(9) Sale of In-Process Research and Development

When the Company sold its specialty pharmaceutical business in January 2010, it retained its research and development organization. Prior to the sale, the Company’s research and development function was engaged in, among other things, studies oriented towards the next-generation formulations of Oncaspar and Adagen, two products that were among those sold as part of the specialty pharmaceuticals business. The in-process research and development related to those two products was included in the sale. The $40.9 million selling price was management’s best estimate of its standalone fair value based on the stage of development and consideration of future milestone payments. During the first quarter of 2011, the Company earned a $5.0 million milestone payment from the purchaser of the specialty pharmaceutical business resulting from the approval of a supplemental Biologic License Application (sBLA) for the manufacture of SS Oncaspar.

(10) Loss Per Common Share

Basic earnings per common share is computed by dividing the income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Restricted stock units are not considered to be outstanding shares until the service vesting period has been satisfied. For purposes of calculating diluted earnings per common share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and nonvested shares using the treasury stock method, shares issuable under the employee stock purchase plan (ESPP) and the number of shares issuable upon conversion of the Company’s convertible notes payable. In the case of notes payable, the diluted earnings per share calculation is further affected by an add-back of interest to the numerator under the assumption that the interest would not have been incurred if the notes payable were converted into common stock.

ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(Unaudited)


	Three months ended June 30,						Six months June 30,

	2011			2010			2011			2010

(Loss) Earnings Per Common Share – Basic:
(Loss) income from continuing operations	$	(7,068	)	$	(5,571	)	$	(6,637	)	$	15,183

Discontinued operations	$	—		$	(51	)	$	—		$	179,002

Net (loss) income	$	(7,068	)	$	(5,622	)	$	(6,637	)	$	194,185


Weighted average common shares outstanding		53,054			60,849			55,368			56,640


Basic (loss) earnings per share:
Continuing operations	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	0.27

Discontinued operations	$	—		$	—		$	—		$	3.16

Net (loss) income	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	3.43


(Loss) Earnings Per Common Share – Diluted:
(Loss) income from continuing operations	$	(7,068	)	$	(5,571	)	$	(6,637	)	$	15,183
Add back interest expense on 4% convertible notes, net of tax		—	⁽¹⁾		—	⁽¹⁾		—	⁽¹⁾		2,305

Adjusted (loss) income from continuing operations	$	(7,068	)	$	(5,571	)	$	(6,637	)	$	17,488

Discontinued operations	$	—		$	(51	)	$	—		$	179,002

Adjusted net (loss) income	$	(7,068	)	$	(5,622	)	$	(6,637	)	$	196,490


Weighted average common shares outstanding		53,054			60,849			55,368			56,640
Weighted-average incremental shares related to assumed exercise of stock options, vesting of share awards, and ESPP shares		—	⁽¹⁾		—	⁽¹⁾		—	⁽¹⁾		1,416
Weighted-average incremental shares assuming conversion of 4% notes ⁽²⁾		—	⁽¹⁾		—	⁽¹⁾		—	⁽¹⁾		17,153

Weighted-average number of common shares outstanding and common share equivalents		53,054			60,849			55,368			75,209


Diluted (loss) earnings per share:
Continuing operations	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	0.23

Discontinued operations	$	—		$	—		$	—		$	2.38

Net (loss) income	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	2.61


	⁽¹⁾	For the three and six months ended June 30, 2011 and the three months ended June 30, 2010, the potential dilutive effects of the 4% notes conversion, exercises of stock options, vesting of share awards, and ESPP shares were excluded from the computation of diluted weighted-average shares outstanding as the shares would have an antidilutive effect on the loss from continuing operations. These securities could potentially dilute earnings per share in the future. Additionally, without the 4% notes conversion, there is no adjustment to loss from continuing operations for the interest payments that would have been forfeited by the note holders on conversion. Accordingly, for these periods, the diluted loss per share is the same as the basic loss per share.
	⁽²⁾	Assumes conversion at the rate of 104.712 shares per $1,000 principal amount of notes.

ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(Unaudited)

(11) Restructurings

During the second quarter of 2011, the Company recorded a restructuring charge in the amount of $0.7 million for severance payments and benefits related to the departure of the Company’s Executive Vice President, Human Resources & Administration that are payable under the terms of the Severance and Release Agreement. This amount was partially offset by the reversal of an unused restructuring accrual of approximately $61,000 for outplacement services and benefits for former employees. As of June 30, 2011, the entire $0.7 million was included in accrued expenses under current liabilities.

During the first quarter of 2011, the Company recorded a restructuring charge in the amount of $0.4 million related to the excess of committed lease costs over potential sublease income for office space in Bridgewater, New Jersey that was vacated during the quarter when the Company relocated its corporate offices to Piscataway, New Jersey.

A fourth quarter 2010 workforce reduction resulted in an expense of $3.0 million for separation benefits. The affected employees were notified in December 2010, and the majority of the terminations occurred during the first quarter of 2011. Separation payments will be made for up to a year following the respective separations. As of December 31, 2010, the full $3.0 million was an accrued expense, of which $2.7 million was reported as a current liability. The Company made separation payments of $0.4 million and $1.0 million during the first and second quarters of 2011, respectively. As of June 30, 2011, there is $1.6 million remaining in accrued expenses under current liabilities.

During the first quarter of 2010, the Company’s workforce reduction involved 64 employees and resulted in an expense of $6.1 million for separation benefits. These actions related primarily to the sale of the specialty pharmaceutical business and affected employees who were previously engaged in activities related to the divested business but who did not transfer to the employment of the purchaser. These employees were provided with separation benefits after certain transition periods, during which they assisted with an orderly transfer of activities and information to the purchaser. In addition, the Company reassessed its staffing requirements subsequent to the sale in light of the lessened demands on many of its general and administrative functions. As of June 30, 2011, all of the required separation payments have essentially been completed.

Effective February 22, 2010, the Company’s then President and Chief Executive Officer resigned from the Company. For the quarter ended March 31, 2010, the Company expensed $3.8 million for severance payments and benefits that were payable under the terms of this individual’s employment agreement. This amount was reduced during the quarter ended June 30, 2010 by approximately $0.2 million once the termination agreement was executed. Payments due pursuant to the termination agreement were made during the third quarter of 2010.

(12) Share-Based Compensation

Stock Option and Nonvested Share Awards

In May 2011, the Company’s stockholders approved a new share-based compensation plan, the 2011 Stock Option and Incentive Plan, which authorized 5,000,000 new shares of common stock for future issuance under this plan. As of June 30, 2011, awards providing for the issuance of 200,000 shares have been granted under this plan.

For the quarter ended June 30, 2011, the Company recognized share-based compensation expense of $0.7 million. Shares were withheld to pay $0.2 million of taxes on behalf of employees related to share-based compensation resulting in a net incremental credit to additional paid-in capital of $0.5 million. For the quarter ended June 30, 2010, the Company recognized share-based compensation expense of $0.8 million. Shares were withheld to pay $1.4 million of taxes on behalf of employees related to share-based compensation resulting in a net incremental debit to additional paid-in capital of $0.6 million.

During the six months ended June 30, 2011, the Company recognized share-based compensation expense of $1.9 million. Shares were withheld to pay $0.9 million of taxes on behalf of employees related to share-based compensation resulting in a net incremental credit to additional paid-in capital of $1.0 million. During the six months ended June 30, 2010, the Company recognized share-based compensation expense of $5.3 million, of which $0.6 million is included in discontinued operations. Shares were withheld to pay $3.3 million of taxes on behalf of employees related to share-based compensation resulting in a net incremental credit to additional paid-in capital of $2.0 million.

ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(Unaudited)

In connection with the sale of the specialty pharmaceutical business, in December 2009 the board of directors of the Company elected to accelerate the vesting of certain share-based awards granted under the Company’s 2001 Incentive Stock Plan as of the consummation of the sale. The acceleration applied to all employees other than executives and members of the board of directors. The acceleration resulted in a noncash expense of $1.0 million in the first quarter of 2010. These charges primarily represent an acceleration of expense recognition pursuant to the original award and, to a lesser extent, an adjustment, in certain cases, to recognize the modification of the award in contemplation of the sale. In addition, certain stock awards granted to the Company’s former President and Chief Executive Officer were subject to accelerated vesting as of the date of termination of his employment in February 2010. The acceleration of vesting of these share-based awards constituted a noncash charge to general and administrative expense in the first quarter 2010 of approximately $2.1 million.

As of June 30, 2011, there was $0.5 million of total unrecognized compensation cost related to unvested options that the Company expects to recognize over a weighted-average period of 17 months and $5.4 million of total unrecognized compensation cost related to nonvested shares to be recognized over a weighted-average period of 27 months.

The weighted average grant price of the options granted during the six months ended June 30, 2011 was $12.00 per share and fair values ranged from $3.13 to $4.41 per share. The aggregate fair value of the options granted during the six months ended June 30, 2011 was $0.7 million. The nonvested shares granted during the six months had a weighted-average grant date fair value of $11.37 per share for an aggregate fair value of $1.9 million. The Company uses historical data to estimate forfeiture rates.

Activity in options and nonvested shares during the six months ended June 30, 2011 and related balances outstanding as of that date are reflected below (in thousands):


	Options			Nonvested Shares

Outstanding at January 1, 2011		3,993			753
Granted		166			170
Exercised and vested		(655	)		(231	)
Expired and forfeited		(298	)		(46	)

Outstanding at June 30, 2011		3,206			646


Options vested and expected to vest at June 30, 2011		3,177


Options exercisable at June 30, 2011		3,016

(13) Income Taxes

During the three and six months ended June 30, 2011, the Company recorded $5,000 of income tax expense related to the Canadian subsidiary. During the three and six months ended June 30, 2010, the Company recorded a net income tax benefit of $0.2 million consisting principally of a Canadian transfer pricing refund. The Company did not recognize a U.S. Federal income tax provision for the first half of 2011 or 2010 because the estimated annual effective tax rate was zero. The sale of the specialty pharmaceutical business in January 2010, including the sale of in-process research and development, was a taxable transaction for federal income tax purposes, although it resulted in no federal income tax liability due to the tax basis the Company had in divested assets and the net operating loss generated in 2010. As of June 30, 2011, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not its deferred tax assets will not be realized.

ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(Unaudited)

(14) Commitments and Contingent Liabilities

The Company has employment and separation agreements with certain members of its management that provide for severance payments and payments following a termination of employment occurring for various reasons, including a change in control of the Company.

The Company has been involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.

The Company has non-cancelable lease obligations for certain office and production facilities that have been vacated. Some of these facilities have been sublet, and the Company is actively seeking to sublet the remaining unused space.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Overview

We are a biotechnology company dedicated to the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Our Principal Executive Officer reviews our operating results on an aggregate basis and manages the operations as a single operating unit. We currently have four compounds in human clinical development: PEG-SN38, which utilizes our PEGylation technology, and the mRNA antagonists of Hypoxia-Inducible Factor-1α (HIF-1α), Survivin and Androgen Receptor (AR), which utilize the LNA technology. In addition, the Company has other novel LNA targets in various stages of preclinical research. We receive royalty revenues from licensing arrangements with other companies related to sales of products developed using our proprietary Customized Linker Technology – primarily PEGINTRON marketed by Merck & Co., Inc. (Merck).

In order to better focus on our portfolio of innovative oncology programs, we divested our specialty pharmaceutical business comprised principally of what had previously been our Products and Contract Manufacturing segments. Prior to the January 29, 2010 closing of the transaction, we were a biopharmaceutical company involved in the development, manufacture and commercialization of medicines for patients with cancer and other life-threatening conditions. We operated in three business segments: Products, Royalties and Contract Manufacturing. We had a portfolio of four marketed products and manufactured products for other pharmaceutical companies through our contract manufacturing business.

In 2011, we are not influenced so heavily by the restructuring, reorganization and consolidation activities that significantly impacted the Company in 2010. Our results of operations are now expected to be more reflective of our ongoing activities, which are directed towards advancing our research and development pipeline. We have completed enrollment in our Phase II PEG-SN38 metastatic colorectal trial as well as our Phase I HIF-1α clinical trials, and we anticipate completing enrollment in 2011 in our Phase II PEG-SN38 trial in metastatic breast cancer as well as our Phase I clinical trial of Survivin. We intend to continue our efforts to seek a collaborative partnership designed to finance our development activities in the future. The enrollment of patients for clinical trials is an inherently uncertain process and there can be no assurance we will be able to complete the enrollment of patients for our clinical trials within the timeframe anticipated. As we previously disclosed on May 19, 2011, we will discontinue our PEG-SN38 clinical program in metastatic colorectal cancer following conclusion of the Phase II study. During the second quarter of 2011, we decided not to pursue development of three mRNA antagonists and have therefore returned these early stage LNA targets to Santaris in accordance with our license agreement.

Throughout Management’s Discussion and Analysis, the primary focus is on the results of operations, cash flows, financial condition and future outlook of our continuing operations. Percentage changes throughout the following discussion are based on amounts stated in thousands of dollars and not the rounded millions of dollars reflected in this section.

Results of Continuing Operations

Revenues:

Royalties (millions of dollars):


	Three Months Ended June 30,					Six Months Ended June 30,

	2011		% Change	2010		2011		% Change	2010

Royalty revenue	$	9.2	(13)	$	10.6	$	20.9	(11)	$	23.5

We receive income from royalties on sales of products by other companies that use our proprietary PEGylation technology, including PEGINTRON, marketed by Merck, Macugen, marketed by Pfizer, Inc. outside the U.S. and Eyetech, Inc. in the U.S., and CIMZIA, marketed by UCB Pharma. Notification from the third-party licensee of the royalties earned under the license agreement is the basis for royalty revenue recognition. This information generally is received from the licensees in the quarter subsequent to the period in which the sales occur. Royalty revenue for the three months ended June 30, 2011 decreased 13 percent to $9.2 million from $10.6 million for the three months ended June 30, 2010. For the six months ended June 30, 2011, royalty revenue decreased 11 percent to $20.9 million from $23.5 million for the six months ended June 30, 2010. The decline in royalty revenue was primarily attributable to lower sales of PEGINTRON, which continues to constitute the most significant source of our royalty revenues.

As we have previously indicated, based upon information we have reviewed, we believe that a significant number of patients suffering from hepatitis C may be deferring treatment until new therapies become available. In May 2011, the U.S. Food and Drug Administration (“FDA”) approved VICTRELIS^™ (boceprevir), for the treatment of chronic hepatitis C (CHC). VICTRELIS is approved for the treatment of CHC genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years of age and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy. In addition, in May 2011, the FDA also approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.

We believe that the approval of these drugs may result in increased sales of PEGINTRON in the future, however we have no clear evidence at this point of what the impact may be, if any, that these new therapies for hepatitis C may have on sales of PEGINTRON.

During the three months ended June 30, 2011, we had royalties on export sales of $8.1 million, of which $2.9 million were in Japan and $2.7 million were in Europe. This compares to $9.0 million of royalties on export sales in the comparable three-month period of 2010, of which $2.9 million were in Japan and $3.4 million were in Europe. On a six-month basis, we had royalties on export sales in 2011 of $17.2 million, of which $6.2 million were in Japan and $5.6 were in Europe, and $19.7 million of royalties on export sales in 2010, of which $6.1 million were in Japan and $6.9 million were in Europe.

Sale of In-process Research and Development

When we sold our specialty pharmaceutical business, we retained our research and development organization. We had been engaged in studies oriented towards the next-generation formulations of Oncaspar and Adagen, two products that were among those sold as part of the specialty pharmaceutical business. The in-process research and development related to Oncaspar and Adagen was sold to the purchaser of the specialty pharmaceutical business and $40.9 million was recognized as revenue in connection with the sale in the first quarter of 2010. The selling price of the in-process research and development represented management’s best estimate of its standalone fair value based on the stage of development and consideration of future milestone payments at that time potentially amounting to $27.0 million. All necessary technology and know-how was transferred to the purchaser at the time of the sale, and the purchaser could resell the in-process research and development asset. At the time of the sale, the activities necessary to complete the work on Oncaspar and Adagen next-generation formulas could have been performed by the purchaser or others.

During the first quarter of 2011, the Company earned a $5.0 million milestone payment from the purchaser of the specialty pharmaceutical business resulting from the approval of a supplemental Biologic License Application (sBLA) for the manufacture of SS Oncaspar. This milestone payment relates to our transfer of technology that was included in the 2010 sale of in-process research and development. During the latter half of 2010, circumstances emerged that caused us to determine that it would be unlikely that we will be able to earn another of the milestones, valued at $5.0 million. Of the remaining $17.0 million of potential milestone payments, it is very unlikely that any will be received in 2011 and there can be no assurance that we will receive any such payments in the future.

Contract Research and Development

During the three months ended June 30, 2011, $0.2 million was earned for contract research and development services. This compares to $2.6 million for the three months ended June 30, 2010. For the six month period ended June 30, 2011, $1.3 million was earned for contract research and development services, compared to $5.2 million for the period from January 29, 2010 through June 30, 2010. Pursuant to a transition services agreement entered into at the time of the sale of the specialty pharmaceutical business, we began performing product-support research and development, consulting, and technology transfer functions for the purchaser effective with the close of the sale transaction on January 29, 2010. The transition services associated with product-support research and development are being reported in continuing operations due to our on-going involvement in the research and development related to the divested products. We are being compensated for this work at actual cost plus a mark-up per the terms of the transition services agreement. Our contractual obligation is to assist with these transition services for a period of up to three years subsequent to the date of the sale, although we anticipate the level of such activity to decline significantly from 2010 levels throughout the remainder of 2011.

Miscellaneous Income

As part of the transition services agreement referred to above, we are being compensated for various general and administrative services provided to the purchaser of the specialty pharmaceutical business. The compensation for this work includes reimbursement of costs incurred plus a mark-up defined in the agreement. The expenses incurred in relation to these services are reported as general and administrative – contracted services. Our involvement in the transitioning of general and administrative activities is essentially complete, and we expect the revenue and associated expenses to be de minimis going forward. During the three months ended June 30, 2011, approximately $54,000 was earned for these services. This compares to approximately $0.5 million for the three months ended June 30, 2010. For the six months ended June 30, 2011, approximately $112,000 was earned for these services, compared to $2.3 million for the period from January 29, 2010 through June 30, 2010.

Also reflected in miscellaneous income are rental receipts from the sublease of unused manufacturing and excess office space for which we have on-going lease commitments. The underlying lease expense is reflected in general and administrative expenses. We received $0.1 million of sublease income during the second quarter of 2011 and $0.3 million for the six months ended June 30, 2011. This compares to $0.1 million during the second quarter of 2010 and $0.1 million for the six months ended June 30, 2010.

Operating Expenses:

Research and Development (millions of dollars):


	Three Months Ended June 30,					Six Months Ended June 30,

	2011		% Change	2010		2011		% Change	2010

Research and development - pieline	$	10.1	0	$	10.1	$	20.6	(5)	$	21.6

Research and development – specialty and contracted services	$	0.2	n.m.	$	1.7	$	0.8	n.m.	$	4.8

n.m. – not meaningful

Research and development – pipeline. During the second quarter of 2011, total spending on our research and development programs was unchanged at $10.1 million compared to the second quarter of 2010. However, included in the prior year quarter expenses was a $1.0 million milestone payment related to the HER 3 mRNA antagonist. There was no similar milestone payment in the current year quarter. Adjusting for this, spending increased by 10% or $1.0 million quarter over quarter. For the six months ended June 30, 2011, research and development spending was $20.6 million compared to $21.6 million for the first half of 2010. However, included in the first half 2010 expenses was the aforementioned $1.0 million HER 3 mRNA antagonist milestone payment as well as a $1.0 million milestone payment for the beta-catenin mRNA antagonist recorded in the first quarter of 2010. Adjusting for these two milestone payments in the prior year, spending for the current year to date increased by 5% or $1.0 million.

During the second quarter of 2011, we decided not to pursue development of three mRNA antagonists and have therefore returned these early stage LNA targets to Santaris in accordance with our license agreement.

Research and development – specialty and contracted services. As a result of the sale of our specialty pharmaceutical business in January 2010, the programs related to the next-generation Oncaspar and Adagen formulations became the responsibility of the purchaser. We continue to assist in the development of these programs through a transition services arrangement. During the first half of 2011, our spending related to these products decreased substantially, as expected, as the purchaser assumed greater control. These costs amounted to $0.2 million during the second quarter of 2011 and $0.8 million for the six months ended June 30, 2011. Our spending related to these products totaled $1.7 million during the second quarter of 2010 and $4.8 million for the six months ended June 30, 2010.

General and Administrative (millions of dollars):


	Three Months Ended June 30,					Six Months Ended June 30,

	2011		% Change	2010		2011		% Change	2010

General and administrative	$	4.6	(20)	$	5.8	$	9.7	(38)	$	15.6

General and administrative – contracted services	$	0.1	n.m.	$	0.4	$	0.1	n.m.	$	1.8

n.m. – not meaningful

General and administrative. General and administrative expenses declined approximately 20 percent in the second quarter of 2011 to $4.6 million compared to $5.8 million incurred in the second quarter of 2010. For the six months ended June 30, 2011, general and administrative expenses declined approximately 38% to $9.7 million compared to $15.6 million for the first half of 2010. The reduction in our general and administrative expenses is attributable to our efforts to contain costs and to reduce the overhead necessary to support our structure subsequent to the sale of the specialty pharmaceutical business.

Savings to the Company from reductions in staffing and consolidation of facilities are expected to continue over the remainder of 2011. A number of general and administrative positions in human resources, information technology and accounting services that had supported the divested specialty pharmaceutical operations have been eliminated. We have reduced contracted services, accounting and consulting fees from 2010 levels. We have completed the consolidation of our corporate offices from Bridgewater, New Jersey into our Piscataway, New Jersey location in an effort to further reduce costs and improve operating efficiencies. The benefits of these efforts are reflected in our second quarter and year-to-date 2011 operating results. A restructuring program announced in the fourth-quarter 2010 and implemented during the first few months of 2011 is expected to have a further favorable impact on our general and administrative expenses during 2011.

General and administrative – contracted services. As part of the transition services agreement with the purchaser of the specialty pharmaceutical business, we committed to provide certain general and administrative services for a period up to one year subsequent to the sale. We subsequently extended the agreement by ninety days. We were compensated for these services based upon costs incurred plus a mark-up per the terms of the agreement. As expected, the demand for such services from us declined significantly over the course of 2010 and has essentially ceased as of the end of the second quarter of 2011. General and administrative expenses representing transitional services to the purchaser amounted to approximately $0.1 million during the second quarter of 2011 as compared to $0.4 million for the second quarter of 2010. For the six months ended June 30, 2011, these expenses totaled $0.1 million versus $1.8 million for the first half of 2010.

Restructuring

As part of our continued efforts to streamline operations, we undertook reductions in the size of our workforce during the first and fourth quarters of 2010. We also incurred charges related to reductions in leased space at our corporate offices and the write-off of certain related leasehold improvements and furnishings during the second quarter of 2010 and the first quarter of 2011.

During the second quarter of 2011, the Company recorded a net restructuring charge of approximately $0.7 million primarily related to the severance payments and benefits due to the former Executive Vice President, Human Resources & Administration. This was partially offset by the reversal of an unused restructuring accrual for outplacement services for former employees.

During the first quarter of 2011, we completed the planned relocation of our corporate offices from Bridgewater, New Jersey to Piscataway, New Jersey. As a result of having vacated the excess office space in Bridgewater, we incurred a charge during the first quarter of 2011 in the amount of approximately $0.4 million. This amount represents the excess of committed lease costs over potential sublease income. We are actively attempting to sublet the vacated office space.

During the first quarter of 2010, our workforce reduction involved 64 employees and resulted in an expense of $6.1 million for separation benefits. These actions related primarily to the sale of the specialty pharmaceutical business and affected employees who were previously engaged in activities related to the divested business but who did not transfer to the employment of the purchaser. These employees were provided with separation benefits after certain transition periods, during which they assisted with an orderly transfer of activities and information to the purchaser. In addition, we reassessed our staffing requirements subsequent to the sale in light of the lessened demands on many of our general and administrative functions. Effective February 22, 2010, our then President and Chief Executive Officer resigned from the Company. For the quarter ended March 31, 2010, we expensed $3.8 million for severance payments and benefits that were payable under the terms of this individual’s employment agreement. This amount was reduced during the quarter ended June 30, 2010 by approximately $0.2 million once the termination agreement was executed. Payments due pursuant to the termination agreement were made during the third quarter of 2010.

Other Income (Expense) (millions of dollars):


	Three Months Ended June 30,							Six Months Ended June 30,

	2011			% Change	2010			2011			% Change	2010

Other income (expense):
Investment income, net	$	0.4		(50)	$	0.8		$	0.8		(56)	$	1.8
Interest expense		(1.5	)	—		(1.5	)		(3.0	)	(29)		(4.2	)
Other, net		—		n.m.		—			0.2		n.m.		—

	$	(1.1	)	n.m.	$	(0.7	)	$	(2.0	)	n.m.	$	(2.4	)

n.m. – not meaningful

Net investment income was $0.4 million for the second quarter of 2011, as compared to $0.8 million for the second quarter of 2010. For the six months ended June 30, 2011, net investment income was $0.8 million versus $1.8 million for the first half of 2010. The decline reflects the lower balances of investment holdings and a shift to shorter maturity and lower risk investments.

Interest expense was $1.5 million for the three months ended June 30, 2011 and 2010. Interest expense was $3.0 million for the six months ended June 30, 2011 versus $4.2 million for the first half of 2010. The prior year period includes a net effect related to the first quarter 2010 conversion of $115.6 million principal amount of our 4% notes subsequent to the sale of our specialty pharmaceutical business. The net effect of forgone interest and the write-off of a pro rata amount of deferred debt issuance costs amounted to $0.8 million and was charged to interest expense during the first quarter of 2010 at the time of the notes conversion. The $0.8 million was adjusted in the fourth quarter of 2010 to credit interest expense and charge additional paid-in capital to reflect the capital nature of the transaction. The noncash adjustment was not material to the first or fourth quarters nor to the full year 2010 results of operations. Additionally, the decline in interest expense is attributable to lower principal amounts outstanding in 2011 compared to 2010.

Income taxes

Discontinued operations

The cash proceeds received from the sale of the specialty pharmaceutical business, including a second-quarter 2010 working capital adjustment, amounted to approximately $309.0 million. Of this amount, $40.9 million was allocated to the sale of in-process research and development and included in continuing operations. The net proceeds then attributable to discontinued operations yielded a gain of $175.4 million. The results of operations of the specialty pharmaceutical business for the period in January 2010 preceding the sale amounted to income of $3.6 million comprising the remainder of the $179.0 reported in 2010 as income and gain from discontinued operations. The gain from discontinued operations was subsequently adjusted to $176.4 million in the fourth quarter of 2010 to recognize $1.0 million of currency translation gains that had been included in accumulated other comprehensive income but should have been recognized as part of the gain on sale.

Liquidity and Capital Resources

Total cash reserves, which include cash, cash equivalents, short-term investments and marketable securities, were $362.3 million as of June 30, 2011, as compared to $460.1 million as of December 31, 2010. The decrease was primarily attributable to the Company’s share repurchase program.

For the six months ended June 30, 2011, cash used in operating activities of continuing operations was $5.0 million compared to $40.0 million of cash provided in the first half of 2010. The Company incurred a loss from continuing operations of $6.6 million in the first half of 2011. Adjustments for non-cash expenses and changes in various working capital accounts comprised the partially offsetting $1.6 million. The $40.0 million provided in the first half of 2010 was primarily attributable to the Company’s sale of in-process research and development.

Investing activities generated approximately $16.8 million of cash in the first half of 2011 primarily from maturities of marketable securities. This compares to $304.6 million of cash provided by investing activities during the first half of 2010, which was primarily attributable to the $262.6 million net proceeds from the January 2010 sale of the specialty pharmaceutical business (exclusive of the amount apportioned to the sale of in-process research and development reported in operating revenue) and $44 million from sales and maturities of marketable securities.

Net cash used in financing activities was $91.4 million in the first half of 2011 versus $3.7 million provided in the first half of 2010. During the first half of 2011, we utilized $96.3 million to repurchase shares of the Company’s common stock on the open market as part of the program to repurchase up to $200.0 million of common stock initiated in December of 2010. Fees of approximately $0.3 million incurred to purchase the shares were reflected in cash flows from operating activities. The share repurchase program is designed as a means by which to return to shareholders value derived from the sale of the specialty pharmaceutical business.

As of June 30, 2011, we had outstanding $134.5 million of convertible senior notes that mature on June 1, 2013 and bear interest at an annual rate of 4%. Interest is payable on June 1 and December 1 for the 4% notes. Accrued interest on the notes was $0.4 million as of June 30, 2011 and December 31, 2010.

Our current sources of liquidity are our cash reserves, interest earned on such cash reserves, and royalties earned - primarily related to sales of PEGINTRON. Based upon our current planned research and development activities and related costs, our current sources of liquidity, and additional purchases of our outstanding stock which may be made under our share repurchase program, we anticipate our current cash reserves will be sufficient to meet our capital and operational requirements for the near future. While we believe that our current sources of liquidity will be adequate to satisfy our capital and operational needs for the near future, it is likely that we will need to obtain additional financing or enter into a collaborative arrangement to sustain our research and development efforts prior to the time we are able to commercialize any of our product candidates. There can be no assurance, however, that we will be able to obtain additional funds or engage a collaborator on acceptable terms, if at all. If we are unable to obtain adequate financing or collaborative support, we may be required to curtail our research and development activities and/or license our product candidates to third parties on terms that are not favorable to us.

Off-Balance Sheet Arrangements

As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (SPE), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually limited purposes. As of June 30, 2011, we were not involved in any SPE transactions.

Our 4% notes payable are convertible into shares of our common stock at a conversion price of $9.55 per share and pose a reasonable likelihood of potential significant dilution. As of June 30, 2011, the maximum potential dilutive effect of conversion of the 4% notes is approximately 14.1 million shares using the conversion rate of 104.712 shares per $1,000 principal amount currently in effect. If we were to experience a fundamental change as defined in the indenture agreement, the conversion rate could be enhanced for the benefit of the note holders which would yield greater dilution. Notes payable are discussed in greater detail in Liquidity and Capital Resources above and in the notes to our condensed consolidated financial statements.

In addition, stock options to purchase 3.2 million shares of our common stock at a weighted average exercise price of $13.05 per share and 0.6 million restricted stock units were outstanding at June 30, 2011, which represent additional potential dilution.

Contractual Obligations

Our major outstanding contractual obligations relate to our operating leases, convertible debt, and license agreements with collaborative partners. There have been no material changes since December 31, 2010 with respect to our contractual obligations.

Critical Accounting Policies and Estimates

A critical accounting policy is one that is both important to the portrayal of a company’s financial condition and results of operations and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Our condensed consolidated financial statements are presented in accordance with U.S. GAAP. All professional accounting standards effective as of June 30, 2011 have been taken into consideration in preparing the consolidated financial statements. The preparation of the consolidated financial statements requires estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Some of those estimates are subjective and complex, and, consequently, actual results could differ from those estimates. We base our estimates, to the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities. We evaluate our estimates on an ongoing basis and make changes when necessary. Actual results could differ from our estimates. The following accounting policies have been highlighted as significant because changes to certain judgments and assumptions inherent in these policies could affect our consolidated financial statements.

Revenues

Royalties under our license agreements with third-parties and pursuant to the sale of our specialty pharmaceutical business are recognized when reasonably determinable and earned through the sale of the product by the third-party and collection is reasonably assured. Notification from the third-party licensee of the royalties earned under the license agreement is the basis for royalty revenue recognition. This information generally is received from the licensees in the quarter subsequent to the period in which the sales occur.

Contingent payments due under the asset purchase agreement related to the sale of the specialty pharmaceutical business are recognized as income when the milestone has been achieved and collection is assured. Such payments are non-refundable and no further effort is required on the part of the Company or the other party to complete the earning process. Non-refundable payments received upon entering into license and other collaborative agreements where we have continuing involvement are recorded as deferred revenue and recognized ratably over the estimated service period.

The sale of the specialty pharmaceutical business involved the application of guidance regarding multiple deliverables in separating the revenues associated with the sale of in-process research and development from the other elements of the transaction, namely the assets sold as part of discontinued operations and our continuing involvement in contract research activities. We determined that the in-process research and development had value to the buyer of the specialty pharmaceutical business on a stand-alone basis and that there was objective and reliable evidence available to support the allocation of the total purchase price to the respective units of accounting.

Research and Development Expenses

We accrue expenses for costs for work performed by contract research organizations, contract manufacturing organizations and others based upon the estimated amount of the total effort completed on each order, study or project using factors such as number of lots produced, number of patients enrolled, the number of active clinical sites and the duration for which the patients will be enrolled in the study. We base the estimates on the information available at the time. Additional information may come available at a later date that would enable us to develop a more accurate estimate. Such changes in estimate are generally recognized in the period when the information is first known.

Income Taxes

Under the asset and liability method of accounting for income taxes, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. A valuation allowance is provided for when it is more likely than not some portion or all of the deferred tax assets will not be realized. As of June 30, 2011, we believe, based on future projections, that it is more likely than not that our net deferred tax assets will not be realized. We recognize the benefit of an uncertain tax position that we have taken or expect to take on the income tax returns we file if it is more likely than not we will be able to sustain our position.

Share-Based Payment

Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned. The impact that share-based payment awards will have on our results of operations is a function of the number of shares awarded, vesting and the trading price and fair value of our stock at date of grant or modification. Fair value of share-based payments is determined using the Black-Scholes valuation model which employs weighted average assumptions for expected volatility of our stock, expected term until exercise of the options, the risk free interest rate, and dividends, if any. Expected volatility is based on our historical stock price information.

Forward-Looking Information and Factors That May Affect Future Results

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words “believes,” “expects,” “may,” “will,” “should,” “potential,” “anticipates,” “plans” or “intends” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to:


	•	The risk that we will not achieve success in our research and development efforts, including clinical trials conducted by us or our collaborative partners.

	•	The risk that we may be unable to recruit and qualify a sufficient number of patients for our trials and/or there may be the need to delay, suspend or terminate trials for various reasons.

	•	The risk that we will experience operating losses for the next several years.

	•	The risk that there will be a decline in sales of one or more of the products sold by others from which we derive royalty revenues.

	•	Decisions by regulatory authorities regarding whether and when to approve our regulatory applications.

	•	The risk that we will fail to obtain adequate financing to meet our future capital and financing needs.

	•	The risk that key personnel will leave our company.

A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2010. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information contained herein is as of the date of this report and we undertake no duty to update this information.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The majority of our holdings of financial instruments consist of money market funds, classified as cash equivalents, and debt instruments, classified as available-for-sale securities. Apart from custodial accounts related to the Executive Deferred Compensation Plan, we do not invest in portfolio equity securities. We do not invest in commodities or use financial derivatives for trading purposes. We seek reasonable assuredness of the safety of principal and market liquidity by investing in rated fixed income securities while at the same time seeking to achieve a favorable rate of return. Our market risk exposure consists principally of exposure to changes in interest rates. Our holdings are also exposed to the risks of changes in the credit quality of issuers the majority of which are rated A1 or better. We typically invest the majority of our investments in the shorter-end of the maturity spectrum. Cash equivalents are primarily held in a number of AAA-rated institutional money market funds as well as several corporate and U.S. government-sponsored entities’ debt securities.

The table below presents the principal amounts and related weighted-average coupon rates of our marketable debt securities, excluding those related to our Executive Deferred Compensation Plan, by year of maturity (twelve-month intervals ending June 30 of the year indicated) as of June 30, 2011 (in thousands):


	2012			Fair Value

Fixed Rate	$	40,000		$	41,083
Average Interest Rate		5.00	%

	$	40,000		$	41,083

Our convertible senior unsecured notes have fixed interest rates. Accordingly, the quoted fair values of our notes will fluctuate as market rates of interest rise or fall. Fair values are also affected by changes in the price of our common stock. Our 4% Convertible Senior Notes in the principal amount of $134.5 million at June 30, 2011 are due June 1, 2013 and have a fair value of $160.8 million at June 30, 2011.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, under the direction of our Chief Operating Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the Exchange Act)) as of June 30, 2011. Based on the evaluation, our Chief Operating Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2011.

Changes in Internal Controls

There were no changes in our internal controls over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the period covered by this report that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

Part II – OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Common Stock

In the second quarter of 2011, we repurchased shares of our Common Stock as set forth in the following table:

ISSUER PURCHASES OF EQUITY SECURITIES


Period	(a) Total Number of Shares Purchased		(b) Average Price Paid per Share		(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)		(d) Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs


April 1 – April 30, 2011		1,858,491	$	10.90		1,858,491	$	137,801,756

May 1 – May 31, 2011		1,016,975	$	11.09		1,016,975	$	126,491,102

June 1 – June 30, 2011		2,249,703	$	10.28		2,249,703	$	103,303,501


Total		5,125,169	$	10.66		5,125,169	$	103,303,501


	(1) Share repurchase program announced December 21, 2010 whereby Enzon’s board of directors authorized the repurchase of up to $200.0 million of its outstanding shares of common stock. Through December 31, 2010, the Company had repurchased 30,000 shares at an average cost of $12.45 per share for a total expenditure of $373,642.

Item 4. (Removed and Reserved)

Item 6. Exhibits.

(a) Exhibits required by Item 601 of Regulation S-K.


Exhibit Number	Description	Reference No.

3(i)	Amended and Restated Certificate of Incorporation dated May 18, 2006, together with that Certificate of Amendment to the Amended and Restated Certificate of Incorporation date July 13, 2010	(1)
3(ii)	Second Amended and Restated By-laws effective March 11, 2011	(2)
4.1	Rights Agreement dated May 17, 2002 between the Company and Continental Stock Transfer & Trust Company, as rights agent	(3)
4.2	First Amendment to the Rights Agreement, dated as of February 19, 2003 between the Company and Continental Stock Transfer & Trust Company, as rights agent	(4)
4.3	Second Amendment to the Rights Agreement, dated as of January 7, 2008 between the Company and Continental Stock Transfer & Trust Company, as rights agent	(5)
4.4	Third Amendment to the Rights Agreement, dated as of July 23, 2009, between the Company and Continental Stock Transfer and Trust Company, as rights agent	(6)
10.1	Enzon Pharmaceuticals, Inc. 2011 Stock Option and Incentive Plan	(7)
10.2	Form of Non-Qualified Stock Option Agreement for Company Employees	(7)
10.3	Form of Non-Qualified Stock Option Agreement for Non-Employee Directors	(7)
10.4	Form of Restricted Stock Unit Award Agreement for Company Employees	(7)
10.5	Form of Restricted Stock Unit Award Agreement for Non-Employee Directors	(7)
10.6	Offer Letter of Employment, dated May 26, 2011, by and between Ana I. Stancic and Enzon Pharmaceuticals, Inc.	(8)
10.7	General Severance Agreement, effective June 8, 2011, by and between Ana I. Stancic and Enzon Pharmaceuticals, Inc.	(8)
10.8	Severance Agreement and Release of Claims, dated as of May 26, 2011, by and between Paul Davit and Enzon Pharmaceuticals, Inc.	*
31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	*
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	*
32.1	Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	*
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	*
101	The following materials from Enzon Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements.	*


*	Filed herewith.

Referenced exhibit was previously filed with the Commission as an exhibit to the Company’s filing indicated below and is incorporated herein by reference to that filing:


(1)	Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed August 9, 2010


(2)	Current Report on Form 8-K filed March 17, 2011

(3)	Form 8-A12G (File No. 000-12957) filed May 22, 2002

(4)	Form 8-A12G/A (File No. 000-12957) filed February 20, 2003

(5)	Form 8-A12G/A (File No. 000-12957) filed January 8, 2008

(6)	Form 8-A12G/A (File No. 000-12957) filed July 24, 2009

(7)	Registration Statement on Form S-8 filed May 10, 2011

(8)	Current Report on Form 8-K filed May 31, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	ENZON PHARMACEUTICALS, INC.
	(Registrant)

Date: August 5, 2011	/s/Ralph del Campo

	Ralph del Campo
	Chief Operating Officer
	(Principal Executive Officer)

Date: August 5, 2011	/s/Ana Stancic

	Ana Stancic
	Senior Vice President, Finance and
	Chief Financial Officer

EX-10.8 2 c66462_ex10-8.htm

Exhibit 10.8

SEVERANCE AGREEMENT AND RELEASE OF CLAIMS

May 26, 2011


This Severance Agreement and Release of Claims (the “Agreement”) is made and entered into by Paul S. Davit for himself and his attorneys, heirs, dependents, beneficiaries, executors, administrators, successors, and assigns (hereinafter referred to as “you”), and Enzon Pharmaceuticals, Inc., any parent, subsidiary, affiliate, successor, predecessor, or otherwise related companies, and the past and present employees, agents, officers, attorneys, directors, shareholders, and employee benefit programs of any of them, and their agents and insurers, (hereinafter the “Company”).

1.	You acknowledge that your employment with the Company will terminate effective close of business on July 1, 2011 (the “Separation Date”). Regardless of whether you sign this Agreement, you will receive your regular salary through the Separation Date, and any earned and unused compensated time off. Your medical insurance coverage under the Company’s health care plan will end on July 31, 2011. After that date, you may be eligible to participate in Company’s health care plans as offered to active employees under the provisions of COBRA. COBRA information will be sent to you by CIGNA, our third party administrator.

2.	Provided that you return a signed copy of this Agreement within the time period set forth under Section 12, and you remain employed in good standing through your Separation Date you also will receive the following additional benefits:

	a.	You will receive severance equal to one (1) times the sum of the following: (i) your current Base Salary and (ii) your Target Bonus (50% of your Base Salary) for the current fiscal year. These amounts, less applicable tax withholdings, will be payable bi-weekly, in substantially equal installments over a fifty-two (52) week period in accordance with Company’s regular payroll cycle, beginning on the next regular payday following the Separation Date that is also at least eight (8) days after you return a signed copy of this letter.

	b.	You will receive a pro-rated portion of your Target Bonus (50% of your Base Salary), based on the number of months worked, which would have been payable for fiscal year 2011 had you remained employed by the Company; to be received as a lump sum payment. This amounts to six (6) months.

	c.	If you timely and validly elect to purchase COBRA benefits continuation, you may continue coverage under COBRA. For the period of eighteen (18) months commencing on the first of the month following your Separation Date, the Company will pay for any difference between COBRA costs to you and your current health/vision coverage contribution. COBRA benefits will begin on the first day of the month following your Separation Date. All COBRA benefits are available only during the time that you are not eligible for comparable health coverage through another employer. Should you obtain such coverage, it is your obligation to immediately notify the Company.

	d.	The Company shall provide you outplacement assistance, of a type and for a period selected by the Company in its discretion. You must initiate your outplacement benefits within three months after the Separation Date.

	e.	The Company will not contest any application for unemployment compensation which you might make. The Company does not, however, provide you any assurance or legal guidance regarding the laws and regulations concerning unemployment compensation.

	f.	You shall continue to be entitled to any deferred compensation earned and vested prior to your separation. As per the terms of the Executive Deferred Compensation Plan all amounts earned and vested by you will be distributed based on your current election decisions and the plan terms and conditions.


	g.	The remaining unvested restricted stock units from the equity award granted on September 22, 2010 will accelerate and vest on the Separation Date.

3.	Notwithstanding anything to the contrary contained in this agreement, if a Change in Control (as defined in Section 7(c)(i)-(vi) of the Amended and Restated Severance Agreement, dated as of May 7, 2004, as amended on November 6, 2007 (the “CIC Severance Agreement”), shall occur on or before September 28, 2011the amount of severance payments you shall receive under Section 2a hereof shall be doubled and shall be payable within the 52 week period and in the manner set forth in Section 2a. In the event a Change in Control occurs on or before September 28, 2011, Section 4 of the CIC Severance Agreement shall be applicable with respect to all payments made to you under this Agreement.

4.	All benefits of any kind, other than as expressly provided in this Agreement, will cease as of the Separation Date. Except as otherwise provided in this Agreement, vesting or forfeiture of stock options and/or restricted stock units, if any, will be in accordance with the terms of the applicable plan and award agreements. However all vested stock options will remain exercisable for the full term life of the grant subject to and in accordance with the terms of the applicable plan and award agreements with the exception of the 50,000 stock options granted on March 1, 2002, which will be forfeited in accordance with the terms and condition of the 1987 Stock Option Plan.

5.	You agree not to engage in any conduct, or make any statements or representations that disparage, demean or impugn the Company. You agree that this Agreement shall not be construed as an admission of wrongdoing by the Company and that the Company expressly denies such wrongdoing. The Company agrees not to engage in any conduct or make any statements or representations that disparage, demean or impugn you.

6.	You agree that, after the Separation Date, you remain bound by and will continue to comply with the terms of the Employee Confidentiality Agreement that you signed, according to its terms.

7.	You agree that, unless otherwise required by court order, you have kept and will keep the terms and conditions of this Agreement, including without limitation the amount of consideration paid here under, strictly confidential and you agree not to reveal, publish, communicate, or otherwise disseminate this information to any person or entity not a party hereto. Notwithstanding the foregoing, you may disclose the terms of this Agreement to your spouse and attorney or other professional advisor as necessary for the purposes of obtaining legal, tax or financial advice, or as otherwise required by law, so long as such persons agree to maintain the confidentiality of the information and in any event you shall be responsible for such person’s compliance with the confidentiality provision contained herein. Because disclosure of this confidential information may be extremely detrimental to the interests of Company, and because the parties agree that measuring the actual monetary amount of such damages would be extremely difficult, you agree that you will pay back to the Company any and all sums paid by the Company to you or on your behalf pursuant to this Agreement, should you, your spouse, and/or your legal, tax or financial advisors violate this paragraph, without limitation of any and all other equitable and legal relief to which the Company may be entitled.

8.	In consideration of the benefits you will receive under this Agreement, to which you would not otherwise be entitled, you hereby release and discharge Company, from any and all claims and/or causes of action, known and unknown, which you may have or could claim to have against the Company up to and including the date of signing this Agreement. This general release includes, but is not limited to, all claims arising from or during your employment or as a result of the end of your employment and all claims arising under federal, state or local laws prohibiting employment discrimination and/or harassment based upon age, race, sex, religion, handicap, national origin, sexual orientation, veteran status, or any other protected characteristic, including but not limited to any and all claims arising under Title VII of the Civil Rights Act of 1964 and 1991, the Age Discrimination in Employment Act, the Employee Retirement Income Security Act, the Americans with Disabilities Act, the Rehabilitation Act, the Equal Pay Act, the Family and Medical Leave Act, the Fair Labor Standard Act, the Sarbanes-Oxley Act, the Health Insurance Portability and Accountability Act, the New Jersey Law Against Discrimination, the New Jersey Conscientious Employee Protection Act, the New Jersey Family Leave Act, New Jersey Paid Leave Insurance Act, any applicable state wage and hour laws, and/or any other state, federal, or municipal employment discrimination statutes (including but not limited to claims based on age, sex, attainment of benefit plan rights, race, national origin, religion, handicap, sexual orientation, sexual harassment, marital status, retaliation, and veteran status), and/or any other federal, state, or local statute, law, ordinance, or regulation and/or pursuant to any other theory whatsoever, including but not limited to claims related to breach of implied or express employment contracts, breach of the implied covenant of good faith and fair dealing, defamation, wrongful discharge, constructive discharge, negligence of any kind, intentional infliction of emotional distress, whistle-blowing, estoppel or detrimental reliance, public policy, constitutional or tort claims, violation of the penal statutes and common law claims, or pursuant to any other theory or claim whatsoever, arising out of or related to employment with the Company and/or any other occurrence from the beginning of time to the date of this Agreement, whether presently asserted or otherwise.




	This Agreement specifically includes any and all claims, demands, obligations, and/or causes of action for damages or penalties relating to or in any way connected with the matters referred to herein, whether or not now known or suspected to exist, and whether or not specifically or particularly described or referred to herein. You expressly waive any right or claim of right to assert hereafter that any claim, demand, obligation, damage, liability and/or cause of action has, through ignorance, oversight or error, been omitted from the terms of this Agreement. You represent that you have not heretofore assigned or transferred, or purported to assign or transfer, to any person or entity, any claim, known or unknown to exist, or any portion thereof or interest therein, which such person has or may have had against the Company.

	This Agreement and release does not, however, require you to waive the right to file a charge with or participate before the Equal Employment Opportunity Commission, provided, however, that you give up the right to recover damages and attorneys’ fees from such a proceeding. Nor does this Agreement and Release require you to waive vested rights, if any, to pension, retiree, health or similar benefits under the Company’s existing plans or your right to enforce this Agreement.

	Unless otherwise prohibited by law, you agree that should you file a lawsuit in court which is found to be barred in whole or part by this Agreement, you will pay back to the Company any and all sums paid by the Company to you or on your behalf pursuant to this Agreement and you will pay the legal fees incurred by the Company in defending those claims found to be barred.

9.	As a material condition of this Agreement, you further represent and warrant that you have transferred, or will transfer before execution of this Agreement, to the Company all property and information of the Company which came into your possession or was developed by you in the course of your employment with the Company, including but not limited to project files, keys, reports, customer lists, computers, facsimile machines, furniture, office supplies, pagers, and printers. You further represent and warrant that you have retained no copies of any such materials or other items; and further, if you should discover that any such materials or other items, or copies thereof, are in your possession or control, you will promptly return them to the Company without disclosure to others. If you fail to return the items detailed in this paragraph before execution of this release, or if the items returned are discovered to be damaged, incomplete, or otherwise not in the same condition as when provided to employee, this Agreement is void and the Company shall have no obligation to pay you the monies or provide you the benefits detailed in Section 2 of this Agreement.

10.	Except as provided herein, you acknowledge that the Company has paid all sums owed to you, including but not limited to all salary, bonuses, commissions, business expenses, allowances, vacation pay and other benefits and perquisites as a result of your employment with the Company and/or the termination of that employment. You further acknowledge that in the absence of this Agreement, you would not be entitled to, among other things, the payments and arrangements specified in this Agreement.

11.	Except as otherwise provided herein with respect to certain portions of the CIC Severance Agreement, this Agreement (a) supersedes any prior understanding, agreement, practice or contract, oral or written, between you and Company relating to your employment or compensation, including, without limitation the CIC Severance Agreement, (b) may be modified only by a writing signed by both parties; (c) is not assignable or transferable by you; and (d) will be interpreted, enforced and governed by the substantive law of the State of New Jersey. Notwithstanding the foregoing, the parties acknowledge and agree that the Employee Confidentiality Agreement that you signed shall remain in full force and effect according to its terms.


12.	By signing below you agree to be legally bound by the terms of this Agreement and acknowledge that you have carefully read and completely understand the terms of this Agreement and are signing it knowingly, voluntarily and without duress, coercion or undue influence. You further agree that this Agreement contains the entire Agreement between you and Company. You are advised to consult with an attorney before signing this Agreement. You have until twenty-one (21) days from the date of this Agreement to consider this document. If you have not returned a signed copy of the Agreement by that time, the Company will assume that you have elected not to sign it and the offer will be considered withdrawn. If you choose to accept the terms of this Agreement by signing below, you will have an additional seven (7) days following the date of your signature to revoke the Agreement in writing to the Company directed to Andrew Rackear at 20 Kingsbridge Road, Piscataway, New Jersey 08854 and the Agreement shall not become effective or enforceable until the revocation period has expired.


Acknowledged and agreed to	Enzon Pharmaceuticals, Inc.

/s/ Paul Davit	By:	/s/ Ralph del Campo

Paul Davit		Ralph del Campo, COO & PEO


Dated:	May 26, 2011	Dated:	May 26, 2011

EX-31.1 3 c66462_ex31-1.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO
SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002


I, Ralph del Campo, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 of Enzon Pharmaceuticals, Inc. (the registrant);
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
		(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
		(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
		(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
		(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):
		(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
		(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


August 5, 2011		/s/ Ralph del Campo

		Ralph del Campo Chief Operating Officer (Principal Executive Officer)

EX-31.2 4 c66462_ex31-2.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO
SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002


I, Ana Stancic, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 of Enzon Pharmaceuticals, Inc. (the registrant);
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
		(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
		(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
		(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
		(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):
		(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
		(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


August 5, 2011		/s/Ana Stancic

		Ana Stancic Senior Vice President, Finance and Chief Financial Officer

EX-32.1 5 c66462_ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report on Form 10-Q of Enzon Pharmaceuticals, Inc. (the Company) for the period ended June 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Ralph del Campo, Chief Operating Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


August 5, 2011		/s/Ralph del Campo

		Ralph del Campo Chief Operating Officer (Principal Executive Officer)

EX-32.2 6 c66462_ex32-2.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report on Form 10-Q of Enzon Pharmaceuticals, Inc. (the Company) for the period ended June 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Ana Stancic, Senior Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


August 5, 2011		/s/Ana Stancic

		Ana Stancic Senior Vice President, Finance and Chief Financial Officer

EX-101.INS 7 enzn-20110630.xml 0000727510 2011-06-30 0000727510 2010-12-31 0000727510 2011-04-01 2011-06-30 0000727510 2010-04-01 2010-06-30 0000727510 2011-01-01 2011-06-30 0000727510 2010-01-01 2010-06-30 0000727510 2009-12-31 0000727510 2010-06-30 0000727510 2011-08-01 iso4217:USD iso4217:USD xbrli:shares xbrli:shares Condensed from audited financial statements.

317867000

397530000

41083000

31170000

4189000

5916000

363139000

434616000

19485000

21574000

39983000

38286000

3316000

31394000

759000

1273000

386699000

488857000

1430000

4192000

11050000

14195000

12480000

18387000

134499000

4266000

4114000

151245000

157000000

0.01

3000000

506000

588000

0.01

170000000

50631943

58817561

50631943

58817561

365331000

454657000

556000

914000

-130939000

-124302000

235454000

331857000

386699000

488857000

9172000

10588000

20934000

23489000

0 0 5000000 40900000

231000

2602000

1325000

5211000

196000

527000

362000

2277000

9599000

13717000

27621000

71877000

10061000

10131000

20609000

21646000

184000

1759000

831000

4818000

4627000

5772000

9713000

15611000

54000 421000 112000 1821000

674000

710000

1033000

10599000

15600000

18793000

32298000

54495000

-6001000

-5076000

-4677000

17382000

386000

811000

845000

1782000

1479000

1480000

2959000

4156000

31000

-31000

159000

-30000

-1062000 -700000 -1955000 -2404000

-7063000

-5776000

-6632000

14978000

5000

-205000

5000

-205000

-7068000

-5571000

-6637000

15183000

-51000

179002000

-7068000

-5622000

-6637000

194185000

-0.13

-0.09

-0.12

0.27

-0.13

-0.09

-0.12

0.23

3.16

2.38

-0.13

-0.09

-0.12

3.43

-0.13

-0.09

-0.12

2.61

53054000

60849000

55368000

56640000

53054000

60849000

55368000

75209000

2555000

2858000

269000

1851000

1965000

4737000

895000

-61000

80000

128000

3127000

-14625000

-4994000

40021000

436000

-4994000

40457000

262608000

530000

397000

4000

18043000

44034000

759000

1544000

16758000

304701000

-105000

16758000

304596000

96054000

18136000

5563000

25289000

894000

3328000

-42000

-138000

-91427000

3687000

-79663000

348740000

50440000

399180000

ENZON PHARMACEUTICALS INC 10-Q --12-31 48688085 false 0000727510 Yes No Accelerated Filer No 2011 Q2 2011-06-30

(1) Description of Business           Enzon Pharmaceuticals, Inc. and subsidiaries (Enzon or the Company) is a biotechnology company dedicated to the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Operations are funded in part by the receipt of royalty revenues from licensing arrangements with other companies related to sales of products developed using the Company’s proprietary Customized PEGylation Linker Technology (Customized Linker Technology®) – primarily PEGINTRON, marketed by Merck & Co., Inc. The Company operates in one business segment. The Company’s Principal Executive Officer (chief operating decision maker) reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating unit. The Company’s operations and assets reside almost exclusively in the United States.           The Company’s pipeline drug development programs utilize two platforms – Customized Linker Technology and third-generation messenger ribonucleic acid (mRNA)-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. The Company currently has four compounds in clinical development: PEG-SN38 and the Hypoxia-Inducible Factor-1α (HIF-1α), Survivin and Androgen Receptor (AR) messenger RNA (mRNA) antagonists. In addition, the Company has other novel LNA targets in various stages of preclinical research.           On January 29, 2010, the Company sold its specialty pharmaceutical business, comprised principally of the Company’s products and contract manufacturing segments, for approximately $309 million in cash with the potential for subsequent milestone payments and royalties.

(2) Basis of Presentation Interim Financial Statements           The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and Rule 10-01 of the U.S. Securities and Exchange Commission Regulation S-X. Accordingly, these financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the year. Interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010. Principles of Consolidation           The condensed consolidated financial statements include those of Enzon Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Use of Estimates           The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include the valuation of certain investments, long-lived assets, legal and contractual contingencies and assumptions used in the calculation of share-based compensation and income taxes. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience, the current economic environment and other factors that management believes to be reasonable under the circumstances. Management adjusts such estimates and assumptions when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in estimates will be reflected in the financial statements in future periods. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in these financial statements. Reclassifications           Certain prior-period amounts have been reclassified to conform to the current period presentation. In 2010, cash flows from discontinued operations were previously included in continuing operations within cash flows from operating and investing activities. The Company has made the appropriate reclassification to the current period presentation of the prior period statement of cash flows. There is no change in either the net cash provided by operating activities or the net cash provided by investing activities to the prior period statement of cash flows, and the reclassification between continuing and discontinued operations in the prior period is not deemed material.

(3) Financial Instruments and Fair Value           The carrying values of cash, cash equivalents, other current assets, accounts payable, and accrued expenses in the Company’s condensed consolidated balance sheets approximated their fair values at June 30, 2011 and December 31, 2010 due to their short-term nature. Short-term investments and marketable securities are carried on the balance sheets at fair value based on quoted market prices. All fair value measures are Level 1. Fair values and carrying amounts of the Company’s financial instruments are indicated below (in thousands): <table border="0" cellspacing="0" cellpadding="0" width="100%"> <tr style="FONT-SIZE:1PX"> <td width="9%" valign="bottom">   </td> <td width="61%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Description </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Fair Value </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Carrying Amount </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td colspan="2" valign="bottom"> Investments and Marketable Securities (Note 4) </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> 44,399 </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> 44,399 </td> <td valign="bottom">   </td> </tr> <tr> <td colspan="2" valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td colspan="2" valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td colspan="2" valign="bottom"> 4% Convertible Senior Notes (Note 5) </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> 160,807 </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> 134,499 </td> <td valign="bottom">   </td> </tr> <tr> <td colspan="2" valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> </table>

(4) Short-term Investments and Marketable Securities           The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major security type at June 30, 2011 were as follows (in thousands): <table border="0" cellspacing="0" cellpadding="0" width="100%"> <tr style="FONT-SIZE:1PX"> <td width="42%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Amortized Cost </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Gross Unrealized Holding Gains </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Gross Unrealized Holding Losses </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Fair Value* </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Corporate debt </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 35,120 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 445 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> — </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 35,565 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom"> Non-U.S. government debt </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 5,473 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 45 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 5,518 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Other </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 3,250 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 78 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> (12 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 3,316 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> 43,843 </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> 568 </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> (12 </td> <td valign="bottom"> ) </td> <td valign="bottom"> $ </td> <td valign="bottom"> 44,399 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> </table>      * Included in short-term investments of $41,083 and marketable securities of $3,316 at June 30, 2011.           The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major security type at December 31, 2010 were as follows (in thousands): <table border="0" cellspacing="0" cellpadding="0" width="100%"> <tr style="FONT-SIZE:1PX"> <td width="42%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Amortized Cost </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Gross Unrealized Holding Gains </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Gross Unrealized Holding Losses </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Fair Value* </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Corporate debt </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 52,079 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 738 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> — </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 52,817 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom"> U.S. government-sponsored entities debt </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 1,000 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 4 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 1,004 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Non-U.S. government debt </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 5,553 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 86 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> — </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 5,639 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom"> Other </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 3,019 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 111 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> (26 </td> <td valign="bottom"> ) </td> <td valign="bottom">   </td> <td valign="bottom"> 3,104 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 61,651 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 939 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (26 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 62,564 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> </table>      *  Included in short-term investments of $31,170 and marketable securities of $31,394 at December 31, 2010.           All corporate, U.S. government-sponsored entity and non-U.S. government debt investments are classified as available-for-sale securities. Other securities include investments of participants in the Company’s Executive Deferred Compensation Plan (predominantly mutual fund shares) totaling $3.3 million fair value as of June 30, 2011 and $3.1 million fair value as of December 31, 2010. There is a non-current liability that offsets the aggregate deferred compensation plan assets.           Fair value is determined from readily available quoted prices in active markets (Level 1, the preferred approach pursuant to applicable accounting guidance). As of June 30, 2011 and December 31, 2010, the Company’s short-term investments and marketable securities are all valued based on Level 1 inputs.           Maturities of marketable debt securities, excluding securities related to the Company’s Executive Deferred Compensation Plan, at June 30, 2011 were as follows (in thousands): <table border="0" cellspacing="0" cellpadding="0" width="100%"> <tr style="FONT-SIZE:1PX"> <td width="13%" valign="bottom">   </td> <td width="56%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Twelve-Month Periods Ending June 30, </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Amortized Cost </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Fair Value </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td colspan="2" valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td colspan="2" valign="bottom">              2012 </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> 40,593 </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> 41,083 </td> <td valign="bottom">   </td> </tr> </table>           Sales during the quarter ended June 30, 2011 of investments in the deferred compensation plan resulted in a realized gain of approximately $58,000, bringing the year-to-date total realized gains to approximately $80,000. However, because the Company maintains a liability for the fair value of the deferred compensation due to plan participants, any realized gains or losses related to these investment holdings are off-set by a corresponding increase or decrease in the liability to operating expenses. Realized gains and losses on sales are computed on the basis of specific identification of the securities sold.           Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is other than temporary and, if it is other than temporary, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date. As of June 30, 2011, only certain assets of the Company’s Executive Deferred Compensation Plan have unrealized holding losses. None of the underlying investments has been in a continuous loss position longer than twelve months.

(5) Notes Payable           The 4% convertible senior notes mature on June 1, 2013 unless earlier redeemed, repurchased or converted. The 4% notes are senior unsecured obligations and rank equal to all future senior unsecured debt of the Company. The 4% notes are convertible at the option of the holders into the Company’s common stock at a conversion price of $9.55 per share (104.712 shares per $1,000 of principal amount). If the closing price of the Company’s common stock for at least 20 trading days in the 30-consecutive-trading-day period ending on the date one day prior to the date of a notice of redemption is greater than 140 percent of the applicable conversion price on the date of such notice, the Company, at its option, may redeem the 4% notes in whole or in part, at a redemption price in cash equal to 100 percent of the principal amount of the 4% notes to be redeemed, plus accrued and unpaid interest, if any, to the redemption date. Upon occurrence of a “fundamental change,” as defined in the indenture governing the 4% notes, holders of the notes may require the Company to redeem the notes at a price equal to 100 percent of the principal amount plus accrued and unpaid interest or, in certain cases, to convert the notes at an increased conversion rate based on the price paid per share of the Company’s common stock in the transaction constituting the fundamental change.           During the first quarter of 2010, notes totaling $115.6 million principal amount were converted into approximately 13.5 million shares of the Company’s common stock, reducing the outstanding principal balance of the notes outstanding to $134.5 million. The net effect of forgone interest and the write-off of deferred debt issuance costs amounted to $0.8 million and was charged to interest expense during the first quarter of 2010 at the time of the notes conversion. The $0.8 million was adjusted in the fourth quarter of 2010 to credit interest expense and charge additional paid-in capital to reflect the capital nature of the transaction. The noncash adjustment was not material to the first or fourth quarters nor to the full year 2010 results of operations.           Interest on the 4% notes is payable on June 1 and December 1 of each year. Accrued interest amounted to $0.4 million as of June 30, 2011 and December 31, 2010.

(6) Stockholders’ Equity           On December 21, 2010, the Company announced a share repurchase program, under which the Company may use up to $200.0 million to purchase the Company’s outstanding common shares. Transactions in the Company’s stock are recorded on a settlement date basis. During the three months ended June 30, 2011, the Company repurchased and retired 5,125,169 shares at a cost of $54.8 million, or an average cost per share of approximately $10.69. This brings the cumulative number of shares repurchased and retired under this program through June 30, 2011 to 9,008,242 shares at a total cost of $96.7 million. The plan continues to be in effect.

(7) Comprehensive (Loss) Income           The following table reconciles net (loss) income to comprehensive (loss) income (in thousands): <table border="0" cellspacing="0" cellpadding="0" width="96%" style="margin-left:4%"> <tr style="FONT-SIZE:1PX"> <td width="43%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="5" valign="bottom"> Three months ended June 30, </td> <td valign="bottom">   </td> <td colspan="5" valign="bottom"> Six months ended June 30, </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="5" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="5" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> 2011 </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> 2010 </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> 2011 </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> 2010 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Net (loss) income </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (7,068 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (5,622 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (6,637 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 194,185 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Other comprehensive loss: </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Unrealized loss on securities that arose during the period (1) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> (153 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> (1,053 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> (278 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> (737 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> </tr> <tr> <td valign="bottom"> Currency translation adjustment (1) </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> (226 </td> <td valign="bottom"> ) </td> <td valign="bottom">   </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> (39 </td> <td valign="bottom"> ) </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Reclassification adjustments for gain on sale of securities included in net income (1) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> (58 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> (16 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> (80 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> (128 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Total other comprehensive loss </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> (211 </td> <td valign="bottom"> ) </td> <td valign="bottom">   </td> <td valign="bottom"> (1,295 </td> <td valign="bottom"> ) </td> <td valign="bottom">   </td> <td valign="bottom"> (358 </td> <td valign="bottom"> ) </td> <td valign="bottom">   </td> <td valign="bottom"> (904 </td> <td valign="bottom"> ) </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Comprehensive (loss) income </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (7,279 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (6,917 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (6,995 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 193,281 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> </table> <table border="0" cellspacing="0" cellpadding="0" width="92%" style="margin-left:8%"> <tr style="FONT-SIZE:1PX"> <td width="4%" valign="top">   </td> <td width="96%" valign="top">   </td> </tr> <tr> <td valign="top"> (1) </td> <td valign="top"> Information has not been tax-effected due to an estimated annual effective tax rate of zero. </td> </tr> </table>

(8) Supplemental Cash Flow Information           The Company considers all highly liquid investment securities with original maturities of three months or less to be cash equivalents. During the six months ended June 30, 2011, there were payments of interest related to the Company’s 4% notes in the amount of $2.7 million. During the six months ended June 30, 2010, the Company had a noncash conversion of $115.6 million principal amount of the 4% notes into approximately 13.5 million shares of its common stock. This first-quarter conversion resulted in a waiver of accumulated interest which amounted to approximately $0.8 million in interest savings for the Company. Income tax payments were $5,000 and $0.1 million for each of the six month periods ended June 30, 2011 and 2010, respectively.

(9) Sale of In-Process Research and Development           When the Company sold its specialty pharmaceutical business in January 2010, it retained its research and development organization. Prior to the sale, the Company’s research and development function was engaged in, among other things, studies oriented towards the next-generation formulations of Oncaspar and Adagen, two products that were among those sold as part of the specialty pharmaceuticals business. The in-process research and development related to those two products was included in the sale. The $40.9 million selling price was management’s best estimate of its standalone fair value based on the stage of development and consideration of future milestone payments. During the first quarter of 2011, the Company earned a $5.0 million milestone payment from the purchaser of the specialty pharmaceutical business resulting from the approval of a supplemental Biologic License Application (sBLA) for the manufacture of SS Oncaspar.

(10) Loss Per Common Share            Basic earnings per common share is computed by dividing the income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Restricted stock units are not considered to be outstanding shares until the service vesting period has been satisfied. For purposes of calculating diluted earnings per common share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and nonvested shares using the treasury stock method, shares issuable under the employee stock purchase plan (ESPP) and the number of shares issuable upon conversion of the Company’s convertible notes payable. In the case of notes payable, the diluted earnings per share calculation is further affected by an add-back of interest to the numerator under the assumption that the interest would not have been incurred if the notes payable were converted into common stock. <table border="0" cellspacing="0" cellpadding="0" width="100%"> <tr style="FONT-SIZE:1PX"> <td width="42%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="5" valign="bottom"> Three months ended June 30, </td> <td valign="bottom">   </td> <td colspan="5" valign="bottom"> Six months June 30, </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="5" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="5" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> 2011 </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> 2010 </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> 2011 </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> 2010 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> (Loss) Earnings Per Common Share – Basic: </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom"> (Loss) income from continuing operations </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> (7,068 </td> <td valign="bottom"> ) </td> <td valign="bottom"> $ </td> <td valign="bottom"> (5,571 </td> <td valign="bottom"> ) </td> <td valign="bottom"> $ </td> <td valign="bottom"> (6,637 </td> <td valign="bottom"> ) </td> <td valign="bottom"> $ </td> <td valign="bottom"> 15,183 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Discontinued operations </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> — </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (51 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> — </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 179,002 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Net (loss) income </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> (7,068 </td> <td valign="bottom"> ) </td> <td valign="bottom"> $ </td> <td valign="bottom"> (5,622 </td> <td valign="bottom"> ) </td> <td valign="bottom"> $ </td> <td valign="bottom"> (6,637 </td> <td valign="bottom"> ) </td> <td valign="bottom"> $ </td> <td valign="bottom"> 194,185 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Weighted average common shares outstanding </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 53,054 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 60,849 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 55,368 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 56,640 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Basic (loss) earnings per share: </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Continuing operations </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.13 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.09 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.12 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 0.27 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Discontinued operations </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> 3.16 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Net (loss) income </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.13 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.09 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.12 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 3.43 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> (Loss) Earnings Per Common Share – Diluted: </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> (Loss) income from continuing operations </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (7,068 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (5,571 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (6,637 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 15,183 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom"> Add back interest expense on 4% convertible notes, net of tax </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> — </td> <td valign="bottom"> (1) </td> <td valign="bottom">   </td> <td valign="bottom"> — </td> <td valign="bottom"> (1) </td> <td valign="bottom">   </td> <td valign="bottom"> — </td> <td valign="bottom"> (1) </td> <td valign="bottom">   </td> <td valign="bottom"> 2,305 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Adjusted (loss) income from continuing operations </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (7,068 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (5,571 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (6,637 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 17,488 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Discontinued operations </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> (51 </td> <td valign="bottom"> ) </td> <td valign="bottom"> $ </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> 179,002 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Adjusted net (loss) income </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (7,068 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (5,622 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (6,637 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 196,490 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Weighted average common shares outstanding </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 53,054 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 60,849 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 55,368 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 56,640 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Weighted-average incremental shares related to assumed exercise of stock options, vesting of share awards, and ESPP shares </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> — </td> <td valign="bottom" style="background-color: #E5FFFF;"> (1) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> — </td> <td valign="bottom" style="background-color: #E5FFFF;"> (1) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> — </td> <td valign="bottom" style="background-color: #E5FFFF;"> (1) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 1,416 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom"> Weighted-average incremental shares assuming conversion of 4% notes (2) </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> — </td> <td valign="bottom"> (1) </td> <td valign="bottom">   </td> <td valign="bottom"> — </td> <td valign="bottom"> (1) </td> <td valign="bottom">   </td> <td valign="bottom"> — </td> <td valign="bottom"> (1) </td> <td valign="bottom">   </td> <td valign="bottom"> 17,153 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Weighted-average number of common shares outstanding and common share equivalents </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 53,054 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 60,849 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 55,368 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 75,209 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Diluted (loss) earnings per share: </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Continuing operations </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.13 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.09 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.12 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 0.23 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Discontinued operations </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> — </td> <td valign="bottom">   </td> <td valign="bottom"> $ </td> <td valign="bottom"> 2.38 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Net (loss) income </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.13 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.09 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> (0.12 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;"> $ </td> <td valign="bottom" style="background-color: #E5FFFF;"> 2.61 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> </table> <table border="0" cellspacing="0" cellpadding="0" width="100%"> <tr style="FONT-SIZE:1PX"> <td width="4%" valign="top">   </td> <td width="4%" valign="top">   </td> <td width="92%" valign="top">   </td> </tr> <tr> <td valign="top">   </td> <td valign="top"> (1) </td> <td valign="top"> For the three and six months ended June 30, 2011 and the three months ended June 30, 2010, the potential dilutive effects of the 4% notes conversion, exercises of stock options, vesting of share awards, and ESPP shares were excluded from the computation of diluted weighted-average shares outstanding as the shares would have an antidilutive effect on the loss from continuing operations. These securities could potentially dilute earnings per share in the future. Additionally, without the 4% notes conversion, there is no adjustment to loss from continuing operations for the interest payments that would have been forfeited by the note holders on conversion. Accordingly, for these periods, the diluted loss per share is the same as the basic loss per share. </td> </tr> <tr> <td valign="top">   </td> <td valign="top"> (2) </td> <td valign="top"> Assumes conversion at the rate of 104.712 shares per $1,000 principal amount of notes. </td> </tr> </table>

(11) Restructurings           During the second quarter of 2011, the Company recorded a restructuring charge in the amount of $0.7 million for severance payments and benefits related to the departure of the Company’s Executive Vice President, Human Resources & Administration that are payable under the terms of the Severance and Release Agreement. This amount was partially offset by the reversal of an unused restructuring accrual of approximately $61,000 for outplacement services and benefits for former employees. As of June 30, 2011, the entire $0.7 million was included in accrued expenses under current liabilities.           During the first quarter of 2011, the Company recorded a restructuring charge in the amount of $0.4 million related to the excess of committed lease costs over potential sublease income for office space in Bridgewater, New Jersey that was vacated during the quarter when the Company relocated its corporate offices to Piscataway, New Jersey.           A fourth quarter 2010 workforce reduction resulted in an expense of $3.0 million for separation benefits. The affected employees were notified in December 2010, and the majority of the terminations occurred during the first quarter of 2011. Separation payments will be made for up to a year following the respective separations. As of December 31, 2010, the full $3.0 million was an accrued expense, of which $2.7 million was reported as a current liability. The Company made separation payments of $0.4 million and $1.0 million during the first and second quarters of 2011, respectively. As of June 30, 2011, there is $1.6 million remaining in accrued expenses under current liabilities.           During the first quarter of 2010, the Company’s workforce reduction involved 64 employees and resulted in an expense of $6.1 million for separation benefits. These actions related primarily to the sale of the specialty pharmaceutical business and affected employees who were previously engaged in activities related to the divested business but who did not transfer to the employment of the purchaser. These employees were provided with separation benefits after certain transition periods, during which they assisted with an orderly transfer of activities and information to the purchaser. In addition, the Company reassessed its staffing requirements subsequent to the sale in light of the lessened demands on many of its general and administrative functions. As of June 30, 2011, all of the required separation payments have essentially been completed.            Effective February 22, 2010, the Company’s then President and Chief Executive Officer resigned from the Company. For the quarter ended March 31, 2010, the Company expensed $3.8 million for severance payments and benefits that were payable under the terms of this individual’s employment agreement. This amount was reduced during the quarter ended June 30, 2010 by approximately $0.2 million once the termination agreement was executed. Payments due pursuant to the termination agreement were made during the third quarter of 2010.

(12) Share-Based Compensation Stock Option and Nonvested Share Awards           In May 2011, the Company’s stockholders approved a new share-based compensation plan, the 2011 Stock Option and Incentive Plan, which authorized 5,000,000 new shares of common stock for future issuance under this plan. As of June 30, 2011, awards providing for the issuance of 200,000 shares have been granted under this plan.           For the quarter ended June 30, 2011, the Company recognized share-based compensation expense of $0.7 million. Shares were withheld to pay $0.2 million of taxes on behalf of employees related to share-based compensation resulting in a net incremental credit to additional paid-in capital of $0.5 million. For the quarter ended June 30, 2010, the Company recognized share-based compensation expense of $0.8 million. Shares were withheld to pay $1.4 million of taxes on behalf of employees related to share-based compensation resulting in a net incremental debit to additional paid-in capital of $0.6 million.           During the six months ended June 30, 2011, the Company recognized share-based compensation expense of $1.9 million. Shares were withheld to pay $0.9 million of taxes on behalf of employees related to share-based compensation resulting in a net incremental credit to additional paid-in capital of $1.0 million. During the six months ended June 30, 2010, the Company recognized share-based compensation expense of $5.3 million, of which $0.6 million is included in discontinued operations. Shares were withheld to pay $3.3 million of taxes on behalf of employees related to share-based compensation resulting in a net incremental credit to additional paid-in capital of $2.0 million.           In connection with the sale of the specialty pharmaceutical business, in December 2009 the board of directors of the Company elected to accelerate the vesting of certain share-based awards granted under the Company’s 2001 Incentive Stock Plan as of the consummation of the sale. The acceleration applied to all employees other than executives and members of the board of directors. The acceleration resulted in a noncash expense of $1.0 million in the first quarter of 2010. These charges primarily represent an acceleration of expense recognition pursuant to the original award and, to a lesser extent, an adjustment, in certain cases, to recognize the modification of the award in contemplation of the sale. In addition, certain stock awards granted to the Company’s former President and Chief Executive Officer were subject to accelerated vesting as of the date of termination of his employment in February 2010. The acceleration of vesting of these share-based awards constituted a noncash charge to general and administrative expense in the first quarter 2010 of approximately $2.1 million.           As of June 30, 2011, there was $0.5 million of total unrecognized compensation cost related to unvested options that the Company expects to recognize over a weighted-average period of 17 months and $5.4 million of total unrecognized compensation cost related to nonvested shares to be recognized over a weighted-average period of 27 months.           The weighted average grant price of the options granted during the six months ended June 30, 2011 was $12.00 per share and fair values ranged from $3.13 to $4.41 per share. The aggregate fair value of the options granted during the six months ended June 30, 2011 was $0.7 million. The nonvested shares granted during the six months had a weighted-average grant date fair value of $11.37 per share for an aggregate fair value of $1.9 million. The Company uses historical data to estimate forfeiture rates.           Activity in options and nonvested shares during the six months ended June 30, 2011 and related balances outstanding as of that date are reflected below (in thousands): <table border="0" cellspacing="0" cellpadding="0" width="90%"> <tr style="FONT-SIZE:1PX"> <td width="61%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="3%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> <td width="10%" valign="bottom">   </td> <td width="1%" valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Options </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> Nonvested Shares </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Outstanding at January 1, 2011 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 3,993 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 753 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom"> Granted </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 166 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 170 </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Exercised and vested </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> (655 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> (231 </td> <td valign="bottom" style="background-color: #E5FFFF;"> ) </td> </tr> <tr> <td valign="bottom"> Expired and forfeited </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> (298 </td> <td valign="bottom"> ) </td> <td valign="bottom">   </td> <td valign="bottom"> (46 </td> <td valign="bottom"> ) </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="1" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Outstanding at June 30, 2011 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 3,206 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 646 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom"> Options vested and expected to vest at June 30, 2011 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> 3,177 </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> <tr> <td valign="bottom" style="background-color: #E5FFFF;"> Options exercisable at June 30, 2011 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;"> 3,016 </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> <td valign="bottom" style="background-color: #E5FFFF;">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom"> <hr size="3" width="100%" noshade="noshade" /> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> </table>

(13) Income Taxes           During the three and six months ended June 30, 2011, the Company recorded $5,000 of income tax expense related to the Canadian subsidiary. During the three and six months ended June 30, 2010, the Company recorded a net income tax benefit of $0.2 million consisting principally of a Canadian transfer pricing refund. The Company did not recognize a U.S. Federal income tax provision for the first half of 2011 or 2010 because the estimated annual effective tax rate was zero. The sale of the specialty pharmaceutical business in January 2010, including the sale of in-process research and development, was a taxable transaction for federal income tax purposes, although it resulted in no federal income tax liability due to the tax basis the Company had in divested assets and the net operating loss generated in 2010. As of June 30, 2011, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not its deferred tax assets will not be realized.

(14) Commitments and Contingent Liabilities           The Company has employment and separation agreements with certain members of its management that provide for severance payments and payments following a termination of employment occurring for various reasons, including a change in control of the Company.           The Company has been involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.           The Company has non-cancelable lease obligations for certain office and production facilities that have been vacated. Some of these facilities have been sublet, and the Company is actively seeking to sublet the remaining unused space.

EX-101.SCH 8 enzn-20110630.xsd 001 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 004 - Statement - STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 005 - Disclosure - Description of Business link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Financial Instruments and Fair Value link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Short-term Investments and Marketable Securities link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Notes Payable link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Stockholders’ Equity link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Comprehensive (Loss) Income link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Sale of In-Process Research and Development link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Earnings Per Common Share link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Restructurings link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Share-Based Compensation link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Commitments and Contingent Liabilities link:presentationLink link:definitionLink link:calculationLink 000 - Disclosure - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 enzn-20110630_cal.xml EX-101.DEF 10 enzn-20110630_def.xml EX-101.LAB 11 enzn-20110630_lab.xml CONSOLIDATED BALANCE SHEETS CONSOLIDATED BALANCE SHEETS [Abstract] ASSETS ASSETS [Abstract] Current assets: Current assets: [Abstract] Cash and cash equivalents Short-term investments Other current assets Total current assets Property and equipment, net of accumulated depreciation of $39,983 at June 30, 2011 and $38,286 at December 31, 2010 Marketable securities Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY LIABILITIES AND STOCKHOLDERS’ EQUITY [Abstract] Current liabilities: Current liabilities: [Abstract] Accounts payable Accrued expenses and other Total current liabilities Notes payable Other liabilities Total liabilities Commitments and contingencies Stockholders’ equity: Stockholders’ equity: [Abstract] Preferred stock - $.01 par value, authorized 3,000,000 shares; no shares issued and outstanding at June 30, 2011 and December 31, 2010 Common stock - $.01 par value, authorized 170,000,000 shares; issued and outstanding 50,631,943 shares at June 30, 2011 and 58,817,561 shares at December 31, 2010 Additional paid-in capital Accumulated other comprehensive income Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Accumulated depreciation on Property and equipment (in Dollars) Preferred stock shares par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares par value (in Dollars per share) Common stock, authorized shares Common stock, issued shares Common stock, outstanding shares CONSOLIDATED STATEMENTS OF OPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Revenues: Revenues: [Abstract] Royalties Revenue earned from sale of in-process research and development by the Company. Revenue is recognized on the basis of best estimate of its standalone fair value based on the stage of development and future milestone payment consideration. Sale of in-process research and development Contract research and development Miscellaneous revenue Total revenues Operating expenses: Operating expenses: [Abstract] Research and development – pipeline Research and development – specialty and contracted services General and administrative The aggregate total of expenses of general and administrative expenses for contracted services. General and administrative – contracted services Restructuring charge Total operating expenses Operating (loss) income Other income (expense): Other income (expense): [Abstract] Investment income, net Interest expense Other, net The aggregate amount of income (expense) from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Also includes interest expense. Total other expense (Loss) income from continuing operations, before income tax expense (benefit) Income tax expense (benefit) (Loss) income from continuing operations (Loss) income and gain from discontinued operations, net of income tax Net (loss) income Earnings (loss) per common share - continuing operations Earnings (loss) per common share - continuing operations [Abstract] Basic (in Dollars per share) Diluted (in Dollars per share) Earnings per common share – discontinued operations Earnings per common share – discontinued operations [Abstract] Basic (in Dollars per share) Diluted (in Dollars per share) Earnings (loss) per common share – net (loss) income Earnings (loss) per common share – net (loss) income [Abstract] Basic (in Dollars per share) Diluted (in Dollars per share) Weighted average shares – basic (in Shares) Weighted average shares - diluted (in Shares) STATEMENTS OF CASH FLOWS STATEMENTS OF CASH FLOWS [Abstract] Cash flows from operating activities: Cash flows from operating activities: [Abstract] Net (loss) income Income and gain from discontinued operations (Loss) income from continuing operations Adjustments to reconcile (loss) income from continuing operations to net cash (used in) provided by operating activities: Adjustments to reconcile (loss) income from continuing operations to net cash (used in) provided by operating activities: [Abstract] Depreciation Amortization and write-off of debt issuance costs Share-based compensation Write-down of property and equipment Loss on disposal of fixed assets Gain on sale of marketable securities Changes in operating assets and liabilities Net cash (used in) provided by operating activities of continuing operations Net cash provided by operating activities of discontinued operations Net cash (used in) provided by operating activities Cash flows from investing activities: Cash flows from investing activities: [Abstract] Proceeds from sale of business, net Purchases of property and equipment Proceeds from sales of fixed assets Proceeds from sales and maturities of marketable securities Purchases of marketable securities Net cash provided by investing activities of continuing operations Net cash used in investing activities of discontinued operations Net cash provided by investing activities Cash flows from financing activities: Cash flows from financing activities: [Abstract] Repurchases of common stock Proceeds from issuance of common stock Withholding taxes – share-based compensation Redemptions from employee stock purchase plan, net Net cash (used in) provided by financing activities Net (decrease) increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Description of Business Nature of Operations [Text Block] Basis of Presentation Basis of Accounting [Text Block] Financial Instruments and Fair Value Fair Value, by Balance Sheet Grouping [Table Text Block] Short-term Investments and Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Notes Payable Debt Disclosure [Text Block] Stockholders’ Equity Stockholders' Equity Note Disclosure [Text Block] Comprehensive (Loss) Income Comprehensive Income (Loss) Note [Text Block] Supplemental Cash Flow Information Cash Flow, Supplemental Disclosures [Text Block] Sale of In-Process Research and Development Disclosure relating to sale of In-process research and development by the Company during the reporting period. Sale OfIn Process Research And Development Disclosure [Text Block] Earnings Per Common Share Earnings Per Share [Text Block] Restructurings Restructuring and Related Activities Disclosure [Text Block] Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Income Taxes Income Tax Disclosure [Text Block] Commitments and Contingent Liabilities Commitments and Contingencies Disclosure [Text Block] Scenario, Unspecified [Domain] Statement, Scenario [Axis] Document and Entity Information [Abstract] SaleOfInProcessResearchAndDevelopmentDisclosureTextBlock NonoperatingIncomeExpenseIncludingInterestExpense Payments Related to Tax Withholding for Share-based Compensation Gain (Loss) on Disposition of Property Entity Common Stock, Shares Outstanding Payments to Acquire Marketable Securities Weighted Average Number of Shares Outstanding, Diluted Payments to Acquire Property, Plant, and Equipment Entity Central Index Key Earnings Per Share, Basic Weighted Average Number of Shares Outstanding, Basic Operating Expenses Revenue, Net Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Operating Activities Document Period End Date Income (Loss) from Continuing Operations, Per Diluted Share Restructuring Charges Accrued Liabilities, Current Amendment Flag Net Cash Provided by (Used in) Financing Activities Other Revenue, Net Retained Earnings (Accumulated Deficit) Income (Loss) from Discontinued Operations, Net of Tax, Per Diluted Share Document Type Assets Amendment Description Proceeds from Stock Plans Income (Loss) from Continuing Operations, Per Basic Share Payments for Repurchase of Common Stock Other Liabilities, Noncurrent Cash Provided by (Used in) Investing Activities, Discontinued Operations Document Fiscal Period Focus Current Fiscal Year End Date Liabilities and Equity Other Assets, Current Operating Income (Loss) Other Nonoperating Income (Expense) Increase (Decrease) in Operating Capital Earnings Per Share, Diluted Marketable Securities, Gain (Loss) Cash Provided by (Used in) Operating Activities, Discontinued Operations Entity Voluntary Filers Interest Expense Liabilities Entity Public Float Other Assets, Noncurrent Entity Filer Category Document Fiscal Year Focus Stockholders' Equity Attributable to Parent Entity Well-known Seasoned Issuer Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share Entity Registrant Name Entity Current Reporting Status Income Tax Expense (Benefit) Statement [Table] Statement [Line Items] EX-101.PRE 12 enzn-20110630_pre.xml XML 13 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)
In Thousands, except Share data

Jun. 30, 2011

Dec. 31, 2010

Accumulated depreciation on Property and equipment (in Dollars)

$ 39,983

$ 38,286

^[1]

Preferred stock shares par value (in Dollars per share)

$ 0.01

^[1]

Preferred stock, shares authorized

3,000,000

^[1]

Preferred stock, shares issued

^[1]

Preferred stock, shares outstanding

^[1]

Common stock, shares par value (in Dollars per share)

$ 0.01

^[1]

Common stock, authorized shares

170,000,000

^[1]

Common stock, issued shares

50,631,943

58,817,561

^[1]

Common stock, outstanding shares

50,631,943

58,817,561

^[1]

[1]	Condensed from audited financial statements.

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References+ Details

- Definition

Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.

+ References+ Details

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References+ Details

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Revenues:
Royalties	$ 9,172	$ 10,588	$ 20,934	$ 23,489
Sale of in-process research and development	0	0	5,000	40,900
Contract research and development	231	2,602	1,325	5,211
Miscellaneous revenue	196	527	362	2,277
Total revenues	9,599	13,717	27,621	71,877
Operating expenses:
Research and development – pipeline	10,061	10,131	20,609	21,646
Research and development – specialty and contracted services	184	1,759	831	4,818
General and administrative	4,627	5,772	9,713	15,611
General and administrative – contracted services	54	421	112	1,821
Restructuring charge	674	710	1,033	10,599
Total operating expenses	15,600	18,793	32,298	54,495
Operating (loss) income	(6,001)	(5,076)	(4,677)	17,382
Other income (expense):
Investment income, net	386	811	845	1,782
Interest expense	(1,479)	(1,480)	(2,959)	(4,156)
Other, net	31	(31)	159	(30)
Total other expense	(1,062)	(700)	(1,955)	(2,404)
(Loss) income from continuing operations, before income tax expense (benefit)	(7,063)	(5,776)	(6,632)	14,978
Income tax expense (benefit)	5	(205)	5	(205)
(Loss) income from continuing operations	(7,068)	(5,571)	(6,637)	15,183
(Loss) income and gain from discontinued operations, net of income tax	0	(51)	0	179,002
Net (loss) income	$ (7,068)	$ (5,622)	$ (6,637)	$ 194,185
Earnings (loss) per common share - continuing operations
Basic (in Dollars per share)	$ (0.13)	$ (0.09)	$ (0.12)	$ 0.27
Diluted (in Dollars per share)	$ (0.13)	$ (0.09)	$ (0.12)	$ 0.23
Earnings per common share – discontinued operations
Basic (in Dollars per share)	$ 0	$ 0	$ 0	$ 3.16
Diluted (in Dollars per share)	$ 0	$ 0	$ 0	$ 2.38
Earnings (loss) per common share – net (loss) income
Basic (in Dollars per share)	$ (0.13)	$ (0.09)	$ (0.12)	$ 3.43
Diluted (in Dollars per share)	$ (0.13)	$ (0.09)	$ (0.12)	$ 2.61
Weighted average shares – basic (in Shares)	53,054	60,849	55,368	56,640
Weighted average shares - diluted (in Shares)	53,054	60,849	55,368	75,209

XML 15 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2011	Aug. 01, 2011
Document and Entity Information [Abstract]
Entity Registrant Name	ENZON PHARMACEUTICALS INC
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		48,688,085
Amendment Flag	false
Entity Central Index Key	0000727510
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2011
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q2

XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 17 R12.htm IDEA: XBRL DOCUMENT

Comprehensive (Loss) Income

3 Months Ended

Jun. 30, 2011

Comprehensive Income (Loss) Note [Text Block]

(7) Comprehensive (Loss) Income

The following table reconciles net (loss) income to comprehensive (loss) income (in thousands):


	Three months ended June 30,						Six months ended June 30,

	2011			2010			2011			2010


Net (loss) income	$	(7,068	)	$	(5,622	)	$	(6,637	)	$	194,185

Other comprehensive loss:
Unrealized loss on securities that arose during the period ⁽¹⁾		(153	)		(1,053	)		(278	)		(737	)
Currency translation adjustment ⁽¹⁾		—			(226	)		—			(39	)
Reclassification adjustments for gain on sale of securities included in net income ⁽¹⁾		(58	)		(16	)		(80	)		(128	)

Total other comprehensive loss		(211	)		(1,295	)		(358	)		(904	)

Comprehensive (loss) income	$	(7,279	)	$	(6,917	)	$	(6,995	)	$	193,281


⁽¹⁾	Information has not been tax-effected due to an estimated annual effective tax rate of zero.

- Definition

The entire disclosure for comprehensive income. Includes, but is not limited to, the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains (losses) on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains (losses) on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealized holding gains (losses) on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain (loss) and net prior service cost or credit for pension plans and other postretirement benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e689-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14-26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e640-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e709-108580

+ Details

XML 18 R17.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

3 Months Ended

Jun. 30, 2011

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

(12) Share-Based Compensation

Stock Option and Nonvested Share Awards

Activity in options and nonvested shares during the six months ended June 30, 2011 and related balances outstanding as of that date are reflected below (in thousands):


	Options			Nonvested Shares

Outstanding at January 1, 2011		3,993			753
Granted		166			170
Exercised and vested		(655	)		(231	)
Expired and forfeited		(298	)		(46	)

Outstanding at June 30, 2011		3,206			646


Options vested and expected to vest at June 30, 2011		3,177


Options exercisable at June 30, 2011		3,016

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

XML 19 R8.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value

3 Months Ended

Jun. 30, 2011

Fair Value, by Balance Sheet Grouping [Table Text Block]

(3) Financial Instruments and Fair Value


Description	Fair Value		Carrying Amount

Investments and Marketable Securities (Note 4)	$	44,399	$	44,399


4% Convertible Senior Notes (Note 5)	$	160,807	$	134,499

- Definition

Tabular disclosure of the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such certain disclosures about the financial instruments, assets, and liabilities include: (1) the fair value of the required items together with their carrying amounts (as appropriate) and (2) the methodology and assumptions used in developing such estimates of fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 14
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15
-Subparagraph b-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13476-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13467-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 18
-Subparagraph c(2), d, e, f
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-Subparagraph a, c(1), c(2), c(3), d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 19
-Subparagraph a, b, c(1), d(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 20 R14.htm IDEA: XBRL DOCUMENT

Sale of In-Process Research and Development

3 Months Ended

Jun. 30, 2011

Sale OfIn Process Research And Development Disclosure [Text Block]

(9) Sale of In-Process Research and Development

XML 21 R19.htm IDEA: XBRL DOCUMENT

Commitments and Contingent Liabilities

3 Months Ended

Jun. 30, 2011

Commitments and Contingencies Disclosure [Text Block]

(14) Commitments and Contingent Liabilities

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

XML 22 R15.htm IDEA: XBRL DOCUMENT

Earnings Per Common Share

3 Months Ended

Jun. 30, 2011

Earnings Per Share [Text Block]

(10) Loss Per Common Share


	Three months ended June 30,						Six months June 30,

	2011			2010			2011			2010

(Loss) Earnings Per Common Share – Basic:
(Loss) income from continuing operations	$	(7,068	)	$	(5,571	)	$	(6,637	)	$	15,183

Discontinued operations	$	—		$	(51	)	$	—		$	179,002

Net (loss) income	$	(7,068	)	$	(5,622	)	$	(6,637	)	$	194,185


Weighted average common shares outstanding		53,054			60,849			55,368			56,640


Basic (loss) earnings per share:
Continuing operations	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	0.27

Discontinued operations	$	—		$	—		$	—		$	3.16

Net (loss) income	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	3.43


(Loss) Earnings Per Common Share – Diluted:
(Loss) income from continuing operations	$	(7,068	)	$	(5,571	)	$	(6,637	)	$	15,183
Add back interest expense on 4% convertible notes, net of tax		—	⁽¹⁾		—	⁽¹⁾		—	⁽¹⁾		2,305

Adjusted (loss) income from continuing operations	$	(7,068	)	$	(5,571	)	$	(6,637	)	$	17,488

Discontinued operations	$	—		$	(51	)	$	—		$	179,002

Adjusted net (loss) income	$	(7,068	)	$	(5,622	)	$	(6,637	)	$	196,490


Weighted average common shares outstanding		53,054			60,849			55,368			56,640
Weighted-average incremental shares related to assumed exercise of stock options, vesting of share awards, and ESPP shares		—	⁽¹⁾		—	⁽¹⁾		—	⁽¹⁾		1,416
Weighted-average incremental shares assuming conversion of 4% notes ⁽²⁾		—	⁽¹⁾		—	⁽¹⁾		—	⁽¹⁾		17,153

Weighted-average number of common shares outstanding and common share equivalents		53,054			60,849			55,368			75,209


Diluted (loss) earnings per share:
Continuing operations	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	0.23

Discontinued operations	$	—		$	—		$	—		$	2.38

Net (loss) income	$	(0.13	)	$	(0.09	)	$	(0.12	)	$	2.61


	⁽¹⁾	For the three and six months ended June 30, 2011 and the three months ended June 30, 2010, the potential dilutive effects of the 4% notes conversion, exercises of stock options, vesting of share awards, and ESPP shares were excluded from the computation of diluted weighted-average shares outstanding as the shares would have an antidilutive effect on the loss from continuing operations. These securities could potentially dilute earnings per share in the future. Additionally, without the 4% notes conversion, there is no adjustment to loss from continuing operations for the interest payments that would have been forfeited by the note holders on conversion. Accordingly, for these periods, the diluted loss per share is the same as the basic loss per share.
	⁽²⁾	Assumes conversion at the rate of 104.712 shares per $1,000 principal amount of notes.

- Definition

The entire disclosure for earnings per share.

+ References+ Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information

3 Months Ended

Jun. 30, 2011

Cash Flow, Supplemental Disclosures [Text Block]

(8) Supplemental Cash Flow Information

- Definition

The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References+ Details

XML 24 R6.htm IDEA: XBRL DOCUMENT

Description of Business

3 Months Ended

Jun. 30, 2011

Nature of Operations [Text Block]

(1) Description of Business

XML 25 R9.htm IDEA: XBRL DOCUMENT

Short-term Investments and Marketable Securities

3 Months Ended

Jun. 30, 2011

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

(4) Short-term Investments and Marketable Securities

The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major security type at June 30, 2011 were as follows (in thousands):


	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value*


Corporate debt	$	35,120	$	445	$	—		$	35,565
Non-U.S. government debt		5,473		45		—			5,518
Other		3,250		78		(12	)		3,316

	$	43,843	$	568	$	(12	)	$	44,399

* Included in short-term investments of $41,083 and marketable securities of $3,316 at June 30, 2011.

The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major security type at December 31, 2010 were as follows (in thousands):


	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value*


Corporate debt	$	52,079	$	738	$	—		$	52,817
U.S. government-sponsored entities debt		1,000		4		—			1,004
Non-U.S. government debt		5,553		86		—			5,639
Other		3,019		111		(26	)		3,104

	$	61,651	$	939	$	(26	)	$	62,564

* Included in short-term investments of $31,170 and marketable securities of $31,394 at December 31, 2010.

Maturities of marketable debt securities, excluding securities related to the Company’s Executive Deferred Compensation Plan, at June 30, 2011 were as follows (in thousands):


Twelve-Month Periods Ending June 30,	Amortized Cost		Fair Value


2012	$	40,593	$	41,083

- Definition

Tabular disclosure of investments in certain debt and equity securities (and certain other trading assets) which include all debt and equity securities (other than those equity securities accounted for under the equity or cost methods of accounting) with readily determinable fair values. Other trading assets include assets that are carried on the balance sheet at fair value and held for trading purposes. A debt security represents a creditor relationship with an enterprise that is in the form of a security. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities (and other trading assets).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27405-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Equity Security
-URI http://asc.fasb.org/extlink&oid=6511694
-Topic 320

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Debt Security
-URI http://asc.fasb.org/extlink&oid=6509901
-Topic 320

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 3, 19, 20, 21, 22, 137
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27232-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

+ Details

ZIP 26 0000930413-11-005153-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000930413-11-005153-xbrl.zip M4$L#!!0````(`"*%!3^6\*:#J5\``%F9!@`1`!P`96YZ;BTR,#$Q,#8S,"YX M;6Q55`D``V!5/$Y@53Q.=7@+``$$)0X```0Y`0``[%UM<]LVMOY^9^Y_X/7> MZ20SD<4WD9*3>$:UX];;Q/;:3KM[OW1H$I*PI4@5)!VKO_X>D'HA04@$25!R M.YMI$ULB<)[SX+P`X"'XX7]Z/>4'%"#BQ,A3GI8*OG@3S]\J/>4BG"\>7*Q< M!S%\Z\;X&<%GP3,B\#M\/XOCQ5F__^W;MU,7+HU<3%`4)L1%$?U`Z?7.%?KG MO__K`Q5R01`5<:8\SA)EG$P5U514^TQ3STQ;^?IXH>BJIF6-H,7+$_&5E[D? M1!]/VS;(7VSULR_7ER91+UXN MT!;-Q(F>THO7W_0I_IZJ]0QMW2GQ\LU(86BCT:B??KNY-.)=!W"U_C^_?'YP9VCN]#;#>IY:FZ)\H%V< M1>FW]VBBI%V>T5'Z>!+A^<*GE*>?S0B:?#RAJO;62IV^1-Y)_SSKR`W!^%]B M!7L?3USUUW%T.S'4OR@;M;_79IJ=M MNTS'_DK)#7L%I;5,:>T2N="K^KJ55GN:#H;66FG]URL2SK7Q@E`F'\/7/.:@ M*(DO(;2N1MT$9_O0WWZJ*/FK4>#EKLTL9/U90[*,/%GJEJS7:"L%LM0:9*F2 MR#(SLO[N!'\^R](.;5F#/%E_,LL2)DN695GY0*V.7B%%VT"MCB0%:KN0DE^C M712RDYR4/$R5UF`.O0D'R0W_]H;+MC[;/_9[O[@Z1AYE#Z(1QU:F'GT'C@A:TP4TRIPNCD)QOOQ"! ML.FDS_92[/\2!>$#+2-S M=%8]"<,X"&-$ERR%R3>,+T0YY*VGWR3TT9X5"?TZ726=;/@O"BATOEY]UNE\ MW=&ZC>\$5B%3>(@_C5;WL!'P90N$7I?'T[.8?T+CA'!2GD"F4EQ$@_39?,$ M>`]<[/@*6'D,3A;$T>F'?@$KHX(?N@7T\#L=.@;(KQ=.-!L''OWGT^$?G9\ MVO)@^K/C)ZA7FJ47EC=_:]I+?P?M8U+$[A!W+1%^K.!]=06L6=VX MQ_)/66VM=1QN1S`D'B(?3[3UBJXF_0^SD,2/B,RO@V<4Q>G`5K(MUJB?BVF' M9;>64KO(5!J9\VT\0V0<12B.+A)"0'(EFR)-RG@.1F8-C792V8#(>AR^7OH. MS]P="6'N$2_O(+#'$&1H@%E0'[A!U436:WQ$7AMI*=5`73>9)S[=\KU$"X(@ M.\8X#.!G']$?`--X#G$(_Y%^OA-OM6UW)NAHZ:]S[B1FR"\.^0W%SI./'I"; M$!QC%-V$@2L8F>HV/U[6;*AH9_FS!LF"K?J%=+VC6 M5T]NO&S`JS"AQV%4!I5-B`R#*5TRW@"BM9M44RG4Z'C664NI#A)Y;BSK9G/! MID=/Z?54E)RNXA#]S>Q+4:A-DR./.!J6%RA MW5RV9O+.(;?D@>X0>RF&]7V(FN2*=W/4#8A6FLO=\5&XR2>A03_@;R: MY%JX>#:2.F][9_ M;72+*"N9\XMP/@^#&BFQNL$Q6156ISL:&^?#1GT<+RZW45EN<,XAJ9T':[4] MWJWC!AI*W,\IB1=,?<+MCCBEJZN;S#E<27:=;%>O\6MBN%6::[(=Z7F8WE)R M_#L'>]?!A;/`L>/G<%7O2S;HXECKPA;J2ETFYF[XI;LF]-$;@F8HB/`SN@[< M<(X^AU%T@^+;R:/S4N>>:+/^7L.MSU9,2`SI]RAV<("\3PX)P`^CPMW9"79Q M]99=DRZ.Y1,MU)7J$ZG[S4(?NHGH'>UX65UX)=#DB-&]AD92M^ZW&XCCP&M` M:_T.CA8^&NNZ+UXPA9R?X9=ME7+VP-V94,6B0HME[RFIM*99654\IQ^4'BY3 M/.3BN>-''T]ZQLFYH=E#RU95]4._ELA\G6\MJ+0@N'$=YAX]2]H[L@:$V MT;.@(Z_$L07[IJ8.C0(HG@`.UUP<*;6"19@MF-0T6Q7#7(!<+FAL1=QP5,!0 M[IW#&@="RIE0K65SQ@8CS:H&6T`JBR?#,C2CR%0-N2DYW?%B&J;%,%,>P0*\ M?=6'+5C21N9P4,"Q3]!Y#4PI@S5K)IL3JFL#VZRA!SOXDLH#V]CK:,0$1%F@ MRL8D3=W,3;JKK6P1JX?ZT.J.SB*?^PL9VQB%P42)_9+*(UV!+!V_VF68;3*H M,3);*<2M:FS!L#W8F4T9&"(XV)S:$8V:;ALBJ#D)KHTQ#BUKQ,NHY7":BB-9G"Y9$M'!`('=10H:"!7#)UA2GY*7=><#8VA78F4 MY8I33]B&+<,TF1#&D\`2Q@.14296[MB"-%'`_`3%K15LL_C4+U,9H.4S7J"<1T'7/(#36 M=8^B;('&%N+J*`KAD;B^N8(I/QL4]DLKQ8D*Q5B"Q1; MY+B!6IP(LEWS[I*QTK,;8M5%DRWN/PR'+5`>*L<)B.3.P*I@LOP>+[.):;A+ M0CEY3(!4MGP7P,;G]XN4YD`QT5]BAN!E96&K>X>#PQ#*^[P M58:@YUW\D0DMP7.WN1L M6$79?+A&S)Y5??V+!%37([88K)YFJ".F\*):("=8":!,1Z91=67SP>AINFFH M>@/]BF5,I4*Z%ISKQ@![>">66 M(Y#T]F];I5=%I8@-,6P^RQRUF,A1IK=8-A]Q'$.#/1E M#FT+L9%472/(N00EY:17L+E?EA9_R1L(>G!W:(2SV5"%#:AXT$4 MMK#!>EE8!ZA,I,)V:*JC)E#9V0+OLC$A3C!-3P^F-X_H.W<>PSM$)B&97X4D MG3U%=/H$TZHMF\/SBMX49Z\SZ02K"4I@\E/K"+J);I4F27/V/1("P`VJ& M/O@K$B#LUP-=Z]8#.!4&-'A$J_Q541DM[,C:B%/SP`AJC4;8KP:ZW3T:82,W M++U[-.(S&MT6(X=9"75@-*,!LZ20B4)\JFO8FET)HS$.\>FN;>E:=SB$#<36 MAG9=/OA1Z],+C4=RED3`C"42*5%;=X/)(SV5D^)V^W0E)??68129[AUU!=W"O;9`=GZ M'XD`89\;RESAO)KQ%U^W#K7A`<<_O3![KZQ/GU7RYCC`$?1'7R,K,QV9%F^* M62&95^[;`JSX=-BV.3/0PX(5=IB1K7&>VSDL6&'SU@86LWX30YO;0ZJX=NT. MR'M`Y!F[^XMZA>UW=2>D&8+MO%R^!L)&;:XFRRU4Z$H'\>T/37^M.HB[P+#E M0+`9+":)&R<$!].+F4.FD@S>LDOSL)(@WG2B%AIAX[4UM7LTXF:H&H80G'9X MQ$U*93<&=@)BXOZ"OO$0+EF9FZ0I?%I:40CRK!S.,[AUH(A/IX?VR.@4BOBN MEJZ/AIU"$=]$-4WF2<,Z4+;%(%*LI0?&HO'!;"65)Z[UT`@;3&^@VE;7:(1M MIF=:[.:C?#3B8<8VAGIM--M3;+*+9&V&&LQ1#!PYYZV0"-O,D)G22D@)'@8I[D:V:AE,RCF8!KRD^BKHJ[$D MLFTV8_^'/O$`8ED&.Q7^#WWB"PES9`]?&WW0Z2HV?H\"--G_;(OX/0:.FB5) M_&!<"Y"XY^NJ*"8)/-6J0CX$3S42;$N>]AFSM!18UXLX.SEML-;(-P.;W5`Y M,-9:P=T^+M8:]UZU8=UI4`762QRY62OD;1NMGQ$(\6]"#4 M8/H)&NQ_MJK.4QW2@56ES(YTKN$>^YSCSZ>XL*_]A72NL8TZ4M5]L\=VNA@.D>^="+O" M1]8(V8H.5*FGFE$G,Q60-$BIM341LKI,$W7TJC41LM_5F.BO6A,A3T@/#M+M M-HK4U^,2^PFMVGD-?I+'%#MNO>X8VK7O=,= M4SM1O]-/C:$D!0OJK0]J6L-+7;3#N1]7GBQ,#:=PG6)J.!/K%)-XL#>KAZZ4 MI]CK5M9W0*-:292+39)Q=8)-DI%U@DT\PN7/O]P'K8#L%X2G,_AF_`R!;XIN MDOD3(K>3TJ&9C'-PC^D4O^EIJ,PI<[5@E)*,3"6$-QHM=6B.7JD2XK=5!P:S M6_MZE!!_M,&R3+5[)?+3@!J'\@9Q3IAO"J_$<+',CNQ(?CXLLKG M[]:&)/[4A,W<212$].@$4_SDH_1=EM?SA8-)>FB$Q*=AR'ONAK.FE0K8* MN9R=YQ9(Q:LM-=/22_66U5C+Y2X73C0#JWW&'O*^7WZ%6)IK.'9C_)R]1[2S MZD%SQ+RYNAVH0RI9XR1>E3FF3[:2@IWQ]W9EI\!68'BO5^E*.?$!-)BW`X(>AV\GT2X0!%LHZ^R,$5 M$%E*T"UABB_G+-U2BZE:"&X1K+-,'QUY#,?N[PDF:#TMNO.=@#YX0A\UD7@B M._-0J[AX-GO+`2Y,MC&R90'/C5%VSGNWE)L[+:1">D?`FTSAZZ&NP`U7?W'H M44/Q\G;"F]S*690/5=/82WTECKV1I;4FXD'<5(W]1M1`$]9].AL']H!2(#(C04GQM*":MBJT7*BC9?64 MFM/;\=8+PF`.J5R-]3GS-&1+%1N:Z-%]KHU_R?*E`?.:B9KH^4'[*B3W:)$0 M=^9$,'.X$'LYIOB!MA9[[[-:\,Y\V`QKC9L8&K,Z;H(UE_WI^U^=P$7K&]1? M`P^1:_@@H*>"TM>KO+Z3!+VMS2=R\L-J+V+D2%`-68#!B[=U0*B(12Y>:NL.Q- MP9%FZD(;:QP$XGN:->&+6ZHU;`.^-(&$@$3_H7L`S[`<'Y?KFXD-_5]_G6]&7H9O0I/&X7(B+U-3>/[+> M\\W/"SI=T-=Z!/$5K)H<_U_((9\"[Q+2DK"07D_3>X:6R=G5VSE+8FXB6[=* M;9B.M39.IFP8N+ZYHJ\^L89#=3C(T[I/VGF>C3&0Y%&BKGQG*DS!!*2C3%ZA M@_.2[5P@>A"_?PWSMI>?T%)8`K5=6[<'FEI0J]C;>=E65^.Q.;+A(7;B)!(6 M^R\4%>1Q>^,ZR<^AGP2Q0Y97V$=$7.)-F!?(],*5E'YU`38V#8DXH6/713[= M'$">DO:0%UOHLF2ZOR#?_RD(OP4/$'7#`!(BS,H1::CBCMXXKK]UJBOX1)Q2 M^GBI8Z?JJ[/NZH8?^W5.MGJ$6919Z*\\)G>S> M6VZ_2K"Z^OP[/WZ_4!P?3X./W_V>A/'[?R=1C"?+[)?OIO#_WUZ\]ZE`^HNYB^/J)_O!&>ZM%$6=\:I-?TG]97]VEO6SDK M0>DWBTV/I+_^42I89[YX_S?-4CO\Z5/P1QBL5-O@NH.0/7=P0.@-^DS960J+$,Z30A9,3+-^RG>%(<90G',;(G06A'TYI MS$@OA43B@0`:$>(P[8.L7II%9;']>+DW3<-HX2`(GQVZ"J<8ZYZV?7V#Q9\RP],99+XYBI5Y"L17`KK".55RADJ?89PD$.\] MD`@]DKA@!XKRM%PA=Q&8$D5&LA>GPT?IBR0!$EBWXF,7EI40PXLFX&Q?"!9E ML$*JSHHBRC+)%JV4HHB^GQ)$E!5:D-!+7.ABQ1)]+HD*RX],-NA#7;/?1[3! M`@:1AGI&H0NPV7`.!NDI=Y]^6/K9NOPS#GX#6(_;07R3NS#[M@QK>_G*XFSS M_5ME`T1[#SA@*D&POZ3"KF\>[V]OWBGS],X.]/NT9*W@"R+N;UD/]'_0[71E MGH];397LG%S@"L8,0KSRM';M-<)U=Q&:4NH+K0L\W1$,"Z\%V,:G%^0FJ;W= M3B8PF(3A[8T[PVBB;([H3:=)$>5N[@`Y;ZD]8/0MVC4D1;O8=@,^D?@PLM"1 M`_]-IP1-:C,&??=PN\`+Y8+B*1Y)I(0""^TZ),X\4L$@?E%#B;R'K*@MP7?I>P:C@<"6O MS?OT)NRN^XAGF'B]:?JRJS0.S&GM#`0LHA#\%`:)ZR/L*HZ+/>7-_/YF_+87 MTXKL>!/HMI%NFITMFP)>AZ;/L$``)#>K?L9I/Y^A&V6;+DXY<27GZVXV1P9C MFCDT_"=9\`PA:*?^[P*#-+B7K#G'YQF-/KV'&V.8&C%%]N-R$;Y@IP=S_<2E ME>>E]E>.&X>DIV7LCLS!>^7-C]=7^0_>OE,>$O*,GW&0=@SK7Q@X%"CWD"X6 MT+JLVIOQ_=L['3^E)$LHD"V1KP"U M2C9`*3?/$'I#F&O"TFQ:R"S;O(+6_&V2,\\__V+>>1N4!P;FPPED2T4?O5/H MEL>[?"!7HM"'&0*P&BWH@T20_SE)NC"MVB2E=ZF]$AR!(RS6Z0;,&:82<2X( M[X\4Z_Q/K8Q.KNG+YVAB2";.ZFUBZUP7O6-LA]3CZT)C%'2`(-9`^%JL]M]3 M=-GT".^*\_M,*;=/6EI2<#9SZ9.AT>T$5IX0#-+4)GW9D1\7X:6'_E9)H=$1 MOJ->!8Y-==B_\#AP#OS_]KZ$N8WC6O>O]/.5JZ@$A+$07&1'5=3FR)$E1J1C M)[=NI1HS#6#DP0P\"TGXU[]SNF=?N(@$T3TXJNM&S+)`,P8./9SO(G M,%O'ENGU+.6O0GZ8<0O.%)*_J0#W#6X12@%\"E-[-(JI[_^>X%M8?F#GSC0/ MI;FWP'!@X=>P4%&654J!F(JXX`4JU8*%80.^QG-,)RX#*X.]7_KG??;CZ>G9 M8R,4?@8TP,5UY'RSS'D@7EL+K%^0 MLZ43RG3WLYC'2=5POO];GYU*3C'+7$N?&3;H*B>J(&_;AZ@5`9DXCXK)I)O2 M5:"\0>]`U\SW(WA6ED]RL9BM"D.0OPN5!7P'G+E;4WJ3VC'6*A-(,W&L"9$P M#X)X&*KJQ?%D*8OE03V*)J6M?#A:<'3,:P`29,(0+**$-OS2&@)L]KZRM&^# M;5%PX<*/(1Q-\:T<"]U7.,#*W!):MN,^S MW#H!NZ\S$:?NOL5[;MUYW@=NJ8%&"S\LP#\=2G6)VGM*,FLJ])7`8[ANG2+I MS-+.T92[Z#J5Q\7IFY!;J@C-G3243DL@%\BN^*U0]G%27V(5=7+_G&1CR/E% MRI*]A<$P+;LYV#(-XJT*BCQMI[9`!>6-SAM/VE:!#V),64(8P%*_'2;=#5GU M@F_!7@H3J4S2ED.\5*MK&H+!U(\CIM8G8@&:-BCP0=?A4RA&Y6P^.&4$`Z*\ M-?%N\XF)?T??A:%YB9%9FGO6`6QH9XKT8EA;9>?Y&#*HRX8ZQ-[86A3832RM M8F#XZ"5WXTSTE@@B[F#JGMV(TF.N[\WW70A0:9.FYCM=,0?>BA4$QLA,=I93 M%SB+0Y$'F")!8.16F@8`27)B<7_*E4Y0:%Z356!16J+C!C:%>Y MC,9J7+]"1HZ<4NB9PEB5\;[$=M('_#E_IIH2""5C5`.HMYT@U:@#:?NH2=FF M*].E.K,+*.3]0%:"B`7P?.#05%&9M#089)*>OW0LB'N73N![1;**V8ZJ\&>R M'Y%E&)G53,$1`A!#-!^5$H2^Q[..1D85+FU3KW<"*U[B=*V%WC@7">,V.C=T MUT58-J=@19%<+<`?(WU)@5I\`8/$"/-\CE-V2!-=I0F;)7,EV8,@`?/+<!CD']`MTI%GK6A7^H!8G*"-A5:A)"_&TDM:%X@XU MT[9[16DP_2PL%P`I5:LBA2;)UVOEJAOPZOC!OE)^%E)R7009/VIF*`FJR3Q: M+=U/_$DR7%&_$E>JG26[/#/7OPK+P,\;IH6%_L6^_Y5`G.+TAA^'LA;*@-)0 M>"0[/4H#@,6F;::<@,*41&/AX:2+W]&BDU5QY6D@['XNN*?!EC+YVV5_ZBEJ2IA#MMVV$!NL8,3!D-_#5` MS&4#*)R20`$K!Q@,YUS&49*9M METJP'P_5?`@4,B+Q'S!0N(!*9A]S,N;)7CW4,MF?:DM$"G=/J@GM=&HWQ;DRT\A%SE16(S"$E$A?@F[%RJJ.=*!32)\*CRXA98Z#A(0/ M.&W(AGUI-)G`,*M-P%)3?EX0MG7#BCW9@F4&U4HOZ3*B?@4X7;8GD0)1%]X? M/G]Q_V1+"7GJ!Y`;)C8W4/\/BDC7#5<<5YTW?++"V.'2V2OPT'@V]O MFRZ)`"C1VDW-_=VGCQ?[Y^__\_;%\.RWAF?31Y.'[=+[3I*WH4IRIS/UHPAR MF1:?DPZU:B8Q^4+N*2J:K8BV,K3\)++;AFY@X7!X#QYT96)LOA[NHP9=61@\ M"$JEP!W@2:,WFN/3\D8(TX*%#B/,+/6H#X.V\J#T28WMNRBO@)N5N9LWQ,/[TR?![!U^#>;2AB;I'3K2"6V7]> M)9.6.ZGE='-BXY1K>21V*NL\\FB&1+!%T,!M2P7+/#]<<#O] M76WN!G./Y[D(B:0L4M;#@L`CYA$/2!?>5QK9^1&%K:MHU;^]CWXDV,'SQNR! M?+)NS!54_DS;A.]K.BPW\WIPT!N?G&C+,$&4($H0W;GXVVDS-HFY*UA1>%JQP%`S#U!:FT4SYU6:*>9([3JQ9RIP;78"?@6MUM? MBB!R5/_5P_T#'^5.==EN;7@G8Y/F%BSA13/F=K2]!2KL'0^.&CG6@F4"*8%T M.#[H';0T8;5@66>0FAIY.VW()C%G=,?):.()5KIJQFCBM895:[A2'\AC1O`S MMV&+]5WW3U>N82HLLGGOO1'32-ZZFBZTP;M%HG6^V@:O'%%G+%P$'+OCKLX-;M,N"NE.F[0/GA=VR;+VU415!!86%Z'8=WG+-E_B$4I_ROW0 M8=1C\\`/\;*F0'!7_CFY](O-`1+RN`2`02C4^055N1;V`-^P>[>X?7FZ9DO^ MI>E@WV0G\YI%>*-,;8>U/$1#'F#LRA,P]K+#,](!:*.O^N;!B';)ZL""69OD MFEGH\!Y&0I@6+!#"M%9/!U@@A&FMG@ZPT&&$F:6>!S6'N]A^V`WF--\D?9J6 MW*KF;#N8.OGW&F^$:JM?MPN&1Q,.H:2.DA^Q$5-'2`4=OV2-FEN_^O>DD?,C M-G)N['81J@A5]T75!]D5)$>U>Y"2AZ'>)9+)N8N_-'H>'4"B,Q8HD=TE;6_` M\LT^AH'\-VF1M$A:)"WN0OBC9&>7M$W,W=G;TD8O8DYKY@BMQ)PYS!%:B3ES MF".TZL7<9JJ4TK+?*;=^GP=^[-G[4+?ZP0OV/V\G[^#?]QN17O$<;S]8^0%> M[FN+Z=:FG[%HT`WID*5\K23(4FX7S,'! MI%$T!@J'#.5K)4&&#)B]BW6=,:K'IB[FE=VJ1W<#36E=U.Z[+3 MS&V@IFLIZ73@MM.J[#1S'2VI=EFEG69N$PG`9'BL*[LZZW(S18HF+8!/T4($ M.]D'T`T(&8H9AC+NC8>'G9"-SBC93.EKL$"(N1N8,WH3J]'$$ZQTU8S1 MQ!.L=-6,T<03K'35C-'$:PTKRJ1W2=M/SIP>BWJ?O`MP,.X='S2N:M."88(H M071RV#(#H@6_A%!"Z);G'#:GQ.[<)KZCR#PXZ(U;KC+6@6&=G2?5&[ND[<>M M^PV[HM5HX@E6NFK&:.()5KIJQFCB"5:Z:L9HXK6&56LFK3YHN&2]7@VU7.5= M??'Z;'_&GAT,>X/CL;SQ?)G=>)Y> MGXU7G)<&PB?D2JS:E=K]=FT4]/`5,KM)7G3]^5VO/W\C++&.MP;V`WF-+\REFY`)Y3*$7^F[1(6B0MDA9W(?Q1LK-+VB;F[NQMZ=Y38DYKY@BMQ)PYS!%: MB3ESF".TZL7<9JH430ZTI1O0];(336!!]V^V'9HRZ@V.MKCQGRQ%!TF0I=PN MF*/Q5H\7(D/101)D*+<+1HOK^LA<=)`$F';:E[F\BCS@@QM\U3YX:]P6![5_SMLBX[S=P& MCD?<7GC>945VFKF.%EZ[K-).,[>9\-_H675@5V==;J:4T:11\-'W]BNU#\WE M:>$@2!*&=)1ZDTGC51W&R8900I+8O+T<-UYO:Z!H""0DB1TI,PDL)`FSS&;2 M.QPW+K0R3C8ZHV0SI?'FJMU/T4($U`,AYAZ7N<=W7^/>8+@]][7+NNPT6<%OQV6IF=9FX#UT&.6AH/6O#[@*2F.]=![CA"Q[TAS=!UM@PQ"MQ= M9L[H$WF,)IY@I:MFC":>8*6K9HPFGF"EJV:,)EYK6&TFD]Z5Z1"2A!F2H(V2 MMPOF<-@[G#3W=HV3#EG*UTJ"+.5VP9PT+S0P43AD*%\K"3*4VP6SY1D83>"Q MQ>D:321`!M*6L]S8%G9%/(['PH4?1/N1");PVZ4((SPG(63^C#T;#WO#HP'C MGLV6//A=*)XK$`F%%0?R%+GTF?')`>,1>R,LL9R*@,&?V&@P'/1OJ/X*.OH* M>=XDR]I^P_O(\OX_G;INF28K/4>^QVXYB&\M)>TEIU94Y5PYQ**D+!X(9KD\ M#)V9`Z/QL*)F?LD=%Y6W/_.#_9"[HJ"V/I-;AXJ*=!1::F`IP6/%@\BQG!7' MWP%(,`A[[2_A]W6VL?/H^Y"]O8:!(^=2E.7R1LQ$@+SC,\(+>>3X'CMSN8..!A.-02AN^/ZP.UOIX'='L`B0GF`,J*'.'6@1Q!J@NU^%3 MQT7]1@NP"W\V"P6(#.7%Y_-`S-4E`THZ*513/"L4#>H;GFZVI<_8DKU8N MXU"I!&1N"W1;C@<@F@7^D@6"VPX`)H,[0U+ATU7@6!+69?:XA;!,?%O(]CZ( M2^$RT"VJ!C"8`)2O5H'/K05;Q4$8`R8!;I6!5BO7L>0;N67Y,5@S8'$>.S;W M+/&\STZ;X5=%7@U@O5:K:G;;5;LO>>ZBA:/'X*ZK9&FS*0_A?P%@B0AJ*'2\ M5=R"N8X![F<>)4*J:@"Q9K[K^E>`:^F<_3@$.(3/7WQ-%%8L3_W`%D&BED&2-UK" MQ?M$+6"\X9,5M^WZ)\WI:7M^%`6E]NV[3Q\O]L_?_^?MB^'9;SP`$_=1A*8L##O`PN!!4/J:F2)"&"&L(P@S M2SU;F1Q\M-O2"XG@Q95P+\7^S_"-A4I5VOI7\M^9"!S?ANS*PV2DZ8':(VE* M=6.5]2!E=+IYMAO,63ZFOEX9GX_@Y1[)2DZ74"/")_:=$/_:#[=V-.I3N1!" M21TELL-R%X#\"WL%Y"_,"+NTCXA"FQY.BY!(RB)E/2P(/&(*H;.,.@T`8N[. M*?[7KS@WBN=.*[33S!%:]6+.U.#ZQ'/;-_\T&@Q'FC:`=,;>DS.GQW:SI_&0 MQ:L3![W)2>-M-%HP3!`EB!X,>X-C@JAAJZV?.`B?<[>^MLR.`UPYALO"_HAY M$(F`"<\6=F5IES\KK<)5JVXK2DA7DC:L'`U$&+NX(!(>Y+A+GR\=I8\$NZ:/9L6#P.18&S;+!DQ1Q;PEB1'(\75M?._$"25%BW"_*Z MJX#L&.E7XQ?&/*1F4HQ12\U_7#,%_NEZSP`R9R;;&%[^+LLUQ[667, MG\WV0Q&QZ1HXLGR@#M>&R\6$CF?!RV$H>(LMDI^+BD_'*"PS]IF_$@&7JU#% M-?*(R[P_EU6!BT,3LGVO2A"N$4_6E8.0XDBM#D7I3GGHR-6LX4I8SLRQF&/C M\G7X20DR!U(Z&#Y66!,9@B!V9/7R>\"K$Z#ZJS+!1=QAF"_?7W);X%).E)4# MFK]T;%STGHAMS5RY,%=P:U%W:H%8X40O*'LE%SKTV:\+X378`D"[`$@GK%D\ M*!T7IN/W@"[+#Z.4IBEW<2TS"Q<"<&K+_0P\6X$M-5]E$6"BN))F?[40\P!Y]?Z0$\REX^+R&[B,!"6/_>D&8`1 M@?/RI$V*/U#:R<)&![X24L$Z/&2Q?]EQU9SD/=>4LP6_++FE&(O<]Z)[TK\ M19]]]+W4N<+7;!&X:^6KJBO1L\$6@((I2E*&'LO')?*Q'X=*42L_="0QKN_- M,]W*13XU'I>XZ.?>2]%_^"X.]^>]R7/0803.^(RO96Z% M,INFW^GX$O^+:N@\^!95`ME'Y*A]$IX#T=:3`EKB?@"!T4^:I=J8,0;4HZ^L M@1,`?<^SUW7+B;8Q8CK36B:B/)O0N)^28NHXV<=(RB?)*0X*^2>"]_ M0Q%.]9P M,QC;&PX.^D?#4;(W3'[R#&\$'\A=:I"L8B;GHEN.O>AYG[UO3%#02&4(35_< MMD6C1#;FG#RJ)&*0HD6`$A8ICP&N?IWMD!L/]H'+,'')^\E7('VNACP5RK$* MP"&2Y$MFV>A[X?M(*6:\?N&36;H/+1\'])DPA)A<*IU!$)V#JAPS#$4B'I@9NO$:.1@&1!!;%<`+4Q_ MRP,Y*DWO*>04>%-$P<<6#Q>Y?0P'&8OE@1)55X&2_CVC!,:8BH)AK]RXMM_* ML@+<3H76&7N0BV"2`4*&>"/3%\EXHK`"Q<54(!WJEQ6:EJ7V$"K]<9;B<#3X M'G=#<@QB0#!X%XB:O>S3X??U+:!0],B-<@D,(<6$9]&QJ7VE:3F7?,=<0J55M1A)1^ZE[NI02B5]3A?X^A"W*\+W MT'U$3A1'J<[J4-B)G=9O9,ND%NRD1)P`=)\V4D#T:B]E:L?I7N'A<-(_3+?[ M5D5>0Y[<5I>%;Q7GRKV,X;@_J:`@W4ND7T%`FKA$SK(BJ=RZE1R*E%7I0IJXC?:1N].9'P?1HO8^ M]#,@"*=*5XT/Y%7QR7##)-HY*!5=R+[T6BLGDBZRH9R=N:@MF<$D7_.2C%4Q M6'`=B8Y]#R-C7?"**5D](X\@&4Q^(0W)*V-E6)!UE!D.RS#U\K1D%D-:BCU" M)1#5@)1VD'2HP)GMA+=ZGZB\DGMXE6P'TE=5D.4%AP1'MC-<]H#S-E`Z$(JX MSTZ32)@;;-G:#G+CRAH-=1R4#DBXTRD>=ZJ[6XKAAK+Y''U@DG^H>AQKU2'6FJ+^YN.X0*=>9+DG0Z89^]R:->M`B$ M2%IBE1FC*K.JF5@45;$U(1L*(G(P;D]ZPQ'\=WB2IBV\WKY6O4VLSR<'_>-4 MP#V,#7A$"413/ESD\P3`%CE!.,ZEC4JQX&;M<]C"]6,*H M,%N52TL1V\:5`DR$0R<@0NGY\7Q14V1YT@U0#A(2?9.1C%\T&6D$@[WKXK9M&+ M@_KA(D55/N;)(@==.%F$CDS0@H4.'YE`"-."!4*8UNKI``N$,*W5TP$6.HPP ML]33NGHWS;(;]=#AY>D/*8))S]UZ3P< M[5!S[ES?AAGS$*,S,"AX[)*V-^`&S#ZTA)QY%[2HL[+(P>Z2MEM,4[MS!W'2 ML$$$.JBW2RY91[T/2.\[J7>R]]W4NZ[VKK-Z*6G;)6UOP)C-KJ?()9,628ND M1=+B+H0_2G:>1""EM:Y3;OT^#_S8L_?!1/S@!?N?MY-W\._[C4BO4!%\K"Y* M;A+B$^6,VQ2)7MFS)N#8XGF!CRF!QS]<<.^H-S@\[H9T'H"/YSLO`;*0-@N9 M]`Y'34<8&R@=LA"RD`U8R&'O<'S4#>F0A9"%/+Z%#$\.>L/C"54DAI:X!@N$ MF+N!.:-[;T833[#253-&$T^PTE4S1A-/L-)5,T83KS6LC,BD"S76)WE^?^D4 M&GD,?./Q,AJ8G=;*)^:>H$%@%,^=5FBGF2.T$G/F,$=H)>;,88[0JA=SFRE: M'G5RJ3C6SZ>??WS_=$"#YT-_+!^P8_Z5S@,/[D\!M\7QE(W>T,U MZ9G\VJ34!AG0!!=)PCA); Q'#2=*NO<9)Y0,]F1Y=,D)7<'2)[P]Z@T4X, ME`Y9"ED*VYREC(Z:%G(;)QFR$K(2MCDK.6I' MVPKS!D9N@B>YTYU2::>9VX`['9\TXE0/?G7TJ)NIA8R>B?PL+)>'H3-SK&K1 M%.*UX&S.'8_E%ZI61@^Y*^^?+LQ>.I[EQK:Z,1LO)4P._FB'N&8%-2!*& MM<\FS8>%&"@<':.&WA(@0[D[1/:&3?5GT\NU%PX9"AD*VYRA'#<=Y-ST8*6K9HPF MGF"EJV:,)EYK6'4X_RY>'>Y'W&5^RT$EFEJLUK@AYIZX!S'2]KH]'=L*!,^G M;I'U1B?-Q^SJP#!!E""Z-VZ<0=>!68(GP7/O9'!`\*2ZQ3!#Z+*5&]UU,)IX M@I6NFC&:>(*5KIHQFGB"E:Z:,9IXK6&UF?Q;D]5.KTM3!'2WK6X>2Q.8T*UK M[7?;CHZ:]RT:)QT=FQ_&2(`LI/WFSI,AW=Q)%D(6 M;3ONC8Z;5H68*!^=*Y+-%+L&"X28NW/3:6Q6T\EHX@E6NFK&:.()5KIJQFCB M"5:Z:L9HXK6&56LFK3[@4U?(S^"W:?!=^J/\.YOZ@2V"A.A!(F%+N&ZXXI;C MS1L^67';KG]25.3)*-5CL999\F#N>/NNF$4OCK^M2KV<^Y<>?/?IX\7^^?O_ MO'TQ//OMQ@(O47*1EH.4E)+F(W]5'^A^2L^UNH'JN23-P[NSH`$/CU?7-7%8 M;P$T+!^\^'3V8G]\"U;2$6YH!N#'][@;;&,1XD&":)3#O<3PWIOYP5(=+H*1H/A\,(?#WZ*/?SQFY?U!A@>/^G,UNW:O@/'`O34J+W0@H(;`D,L6 MSGSAKIGK_!$[>*KGI5#G@Q8._:PYIBLG6C`_<"!4@N!!M.GIH/Z,18M`"+8$ MWA?P>\!<$89H8%/!+-!0F20!+P4O@L>1]MF;_-[#T+E.AQ`>GC8*B!)L/.@Q MQ%4/OQ.(JIZOX&]LQ=?J=%,@Q0&0`FPC%@A7VC60@:,G@LA.A#[Z/F00@FNV M!SY$GG@J'^)+/P:IP+#/1OTCMG1<%P#50G5]K#H;@UZ1&'!:X'?@E1Y*"75T M"1I";Y:ZG&RH9\/AI'^84L!6\'[+68$BR*@P\*<%!N6?$RE@JI,);IZVKA6(N$':6V,KG/!OWCC%S'JP(A&R?D MEZ`;==)M0=9]IIRA=.L98*X*D"H(>](;#`80$6Q\ZS![*PXI.%"92#O3?7)G M9]UH&H`LAU50`'I7*MBXZZ90PFYR3P67?T.PM\ M"ZSULP@%#ZS%J6>_$4"/O\)Q\E$V&`;N'01.(`@DAQ2_]_83!EC*`O4#XO^ MB4.Z%*P3)#OH;R,.WU9#!@5E,+L@_I*,_&#./>=/&:7[[`Q,*$C=-9Y"W6MU MW.GP%>XJ+V.SV+-D")0N2>F&K&ZH2BLN^Y/Z-U7/)#DG=I`!%`07?G@Q'T[ MMJ+D=F`9R11AT<(/A=1/E<$07%>0>?LVQ869YM!Y5S("J'17BR`?B92BOJ?H MV--4/0U2801D<]?W*@S.N!-@F0(Y_I2'0).?T!3!T/APD=/<61182Y,EI5UX M8A9#MB.0"R`"7I@%D%(J(*-BA;4T1L(@61:362`('PV&0\#I#S(996^I2DF] MD\W`XZJ+HF/0'7`8W(:'.H>99:N`C1QDP\JP>XDG:$#<9F$AJ)3E_,KQ77_N M6.P#:,\#D)S"-],SY_?"5Q].GV=!&/0:S[@EI0C#GI]7T90:27,8O#D./BB> MO4SD\L/_V]]G__OKS_\:_]___F:MXNM_>Y,3^\^CR_F_U]XO;^*K'X^"DZ-_ MC+[\@?1^O+FR7LVM?YY.;/O7 M?W\8_?7\UP-Q^=?KX^B[X)^3OW^A=_O7\ M7X/WOZU_/_SQW?6'4)R=G[^=_W/RF_7YM^/QAW/WL[7\)3R>!/_^PJ?>(!A$ M[C_?^:>?+\Z\U9O?/JZ^S#[\9@7__J?[UKX*?AY\]]?IG]_]'WM]_GE__V6J MF:R6?`N`1F]Z)H)S3"CU*AZ'@^?L`][-#N2A#6***\G5P17&+LP@(:OZ#>*)M1 MV(BJ)A7@&\.9(X"D=^`8P7^O(+@JWKAKR10"V7%<*>ZB4LHT%36D0HHM/'\) ME7D$XR;!&$B`#*=)V`^3-B8+F?;SNCD;HO1@H=AGCHI2DKRDRH7P8BV:>:L_ M'BK)0+D$83?YJ?3UUCX#6T%1#$KC+A22B7A2SE8J;4.N/%]V0JH]PU3K81KH MHT!P""+K9(BE@"3)[J7?<\(PE@800_$75$6.SXOERO77(B4AC>-LY7*(G&_/ MS\Z>IU+.Y5K+P&NO6X$<2CV$MORY,>.!QR('QU$-!,@V<%0LF^4P%A((0Y8^ M[34`H0F]B2_)0(X5/%3H<2`S<)YT:L$UU`"*M]?8^[C:K-3<2:H$$`YF:8!Y M*6N5OH`\EE*I==%#FJT0F/8<_-BUI0]8@"FHWC'``V\>M5.X2H;+@$BX5RE[ M(CJ9^U9<7GM[N#6<;'#R*Y_%;.\Z/^H$UZAQ>JAE;G/[\T.-3(SOP8.F+`P[ MP,+@05#ZFM6XA#!"&"%,&_5T@`5"F-;JZ0`+'4:86>IYO*5&7WM*G86S%L%M MSVU_B>".S7P?(HCB2=K%=1WEN>R;^O2$B,XBXCQ?I',#$G2` M@<[:IOA`WN")O8'9AV.1%KN@19V512Z9C/DKC'FD6X*&RR@TS],% MSZ3W[NN=['TW]:ZKO>NL7DKSR/R?V/S-KME(BZ1%TB)ID;1(Z9$.!_VWWLJE M;N!Z_-N$\>,8?]C[(&\&2/>XU'>1M.DT77D]_%[MMG@AI1RG@]-QGCM\P4!W M)?%(1^!V5T`$%9($&0U!A21!1D-0(4F0T6@E()VALIDR_6LK[T>]#[MX*+\")G*B/XJ.;4E;)"\#I,B.J/JR9G3X]Z7IW&4Y0OS!H?' MVC+\`"UN\?XB@N:C0'/2FQPU7S*D`\,$S1V&YF'O<+S%2Q0)F@3-MKO9)KWA M\5A;AG7..?6J9$:3_LFC53*=3MU-8L[H"UZ,)IY@I:MFC":>8*6K9HPFGF"E MJV:,)EYK6&TF_WZ2!7^;FG;`0\+5-`.>'7_3A$(3O32OU5E)Z-'=T'`2N':$ M^?%H.'KBJ^AT`0F9"YG+W06S-VF>;#%0.`^`QQ8;X)I(@`R$X@G%DSNC@LRE M;2;JZ*0W&(R:8XIQ\M'95C93.']M+4P35SIB9*?;7D833[#253-&$T^PTE4S M1A-/L-)5,T83KS6L],J_-S47]5%$;,\M;(/98F5G,%B>G#D]>A5/WGZ@G2U& M,;53T)ST#D?-C3$=&"9H[C`T:6>+24SM$C2')P>]X?&$LD[S2Q2:(M`1(SO= M8#":>(*5KIHQFGB"E:Z:,9IX@I6NFC&:>*UAI5?^_:CG4YMDG5ICA)A[@H:" M43QW6J&=9H[02LR9PQRAE9@SASE"JU[,;::V,7K?_J\"82ELQB]%P.>"6>IR MGA`OYPE;0.K'41AQS\83A;<%PUW9,D.2V)(E/OJT\&3<&TP.FH1CGG0()R2) MS5O,X:!W?'!"%M,MG)`DV.9BS*0WWN9:8L()2<(PBSGL'1X,R&+,K+VU**?U M,C>#,?)0YHQ>%6`T\00K735C-/$$*UTU8S3Q!"M=-6,T\5K#2J_\F];UZ8@1 M8NX)>@]&\=QIA7::.4(K,6<.C&G5VVSJ:5ZKWCH6.G!9H(' MGN/-0[82@5JL]Z))N(0=8HX\'2ET-Y@CM!)SYC!':"7FS&&.T*H79YD M+Q,>JG;7V9_[E4BO?7D%*11&M]U!^B3PVI6U?7I+0H]3*/5>!;LWZ`_'NXX. MNE&1[*/=/@:-&Y&,DPW9!]G'9N)'XSGQQLF&[(/LX_'M8]`?-9U5;YQD=*Y" M-E,1?VV12SN,=,3(0YDS>GVRT<03K'35C-'$$ZQTU8S1Q!.L=-6,T<1K#2N] M\N_-33*]<4)+S3,)^[9I)BWL56O4/#ES>K0KGKP#H11Y/!J.&C6I!=>$4$I MX=0PY@BGVG)-."6^TE[6V9T]IDL@_:VT+V0?;QE?&#]K9T`QUD'YN883IH2J^,DXS.5 MHR-&B+DGZ#L8Q7.G%=IIY@BMQ)PYS!%:B3ESF".TZL5F&O^'W[(WCQI&PU94[<3H\;;$BYLA+ MDD)WD#E"*S%G#G.$5F+.'.8(K7HQMYEZZ4FV)FWJ:M*DIE*;DM@L$Q(([LK:0;TE02ML;Q?,WE%O<'C<#>D\`!^T!ITLI,U")KW) MT;`;TB$+(0O9@(4<]@['37>0&"@=LA"RD,>WD.&D-SQNW"ANGG1TKD6@/NZ0YK3UGM.FE8.TZH,LA%8.DH60A7RUA=#*0;(0LI";5@X>]0Z.=S3+ M,K^.UJ(TUJNL,Q@CC]L%,^P,5:.))UCIJAFCB2=8Z:H9HXDG6.FJ&:.)UQI6 M' M_#Y`B5OL#Q,RR8.2!]538YN8;3CI#0:--Q+KP;+.(.UP"=-I6S>).:,;$$83 M3[#253-&$T^PTE4S1A-/L-)5,T83KS6L-I-_=V,K#![T5=H.L[VB=E=6E.DM M"3T:''JOO:0=+MON/FLB`;*0]ATNAZ/F=J%QTB$+(0NA'2YD(60A3SSG='+8 M.S@9-(K'//GH7)%LID#6HN;5J[`S&",[W=XRFGB"E:Z:,9IX@I6NFC&:>(*5 MKIHQFGBM8:57_JUR;K0*0)F_%+$?"Y8):_7/H>@[(W$&$+[OPX"B/NV7CH-"&+F'M4YAY_ M/G8R[@TF!TW\:L%PI[79:>8>'ZJ'@][QP0E!E9C3'JJ326^\S;7$NZS-3C.W M`:@>]@X/FM=CZ<"PSMK<3!5D]!:DM&3:3TLFQ[,"L11>Q-V;ZZ9`N!QKK3?W5HRZ<7+J0APTN.>^\WD2L?B,TS\$3L@->%% M3G\1-[,J\'DEB2_;:N2UQA!.2A%D6L^V=>803DH19%K/M#8*$$Y*$619S M-.F-!A1C#*W0M2BZ]3(W@S'RN/TUPPZ=-9IX@I6NFC&:>(*5KIHQFGB"E:Z: M,9IXK6&E5_Y-Q\;KB!%B[@EZ#T;QW&F%=IHY0BLQ9PYSA%9BSASF"*UZ,:=7 M;;.I!7UO'#?&DPSW7#\,GS/!`\_QYB%;B:`J+?PG5^J](#@1P\/@+8_<&_6'C83#&R>8!Z'C>#720?6S$ M/IK7C1LG&[(/LH_-Q(\1V4B/FM(KXR2CRIS12Y:-)IY@I:MFC":>8*6K9HPFGF"EJV:,)EYK6.F5?V]NDNF-$UIJ MGDG8MTTS:6&O6J/FR9G3HUWQY!V(+EY803C=-E.$4\(IX517K@FGA--1?]QT M1*`.S.H,3[V*&9I,T!$C.]V*,)IX@I6NFC&:>(*5KIHQFGB"E:Z:,9IXK6&U MF?S;\.TM'T64'@C@>):_%(UU[--8]:ZL*M-;$GHT-?1>>TE[6^:T-IGL@_:V MD'V0?7QE_*"]+=U`!]G')F:8#H<-LC%.,CI7(9LIA[^VPJ7I*!TQLM/-+*.) M)UCIJAFCB2=8Z:H9HXDG6.FJ&:.)UQI6K?FW^H!/72$_@]^FP7?IC_+O;.H' MM@@2H@>)A"WANN&*6XXW;_ADQ6V[_DFS(AL+-U44E!+X=Y\^7NR?O__/VQ?# ML]]NK/D2/19?=Y"BIJ3`!;337XQ:>S%_OC6XRXC>_B$G;X.(PE.WM#U>!+?GW:5M?=!%%\XDL<1LYL MG9A#BX@>04+O_(!%"P'_!4(P[MGPO6NVA`<6(1.>+6SV4^R))@DQ-A[TV&@P M',KG\E%J3Z=?A/^%;S7V359^)+S(X2ZS\5X`YU(P,9L)*PJ9/Y-C'WP+`3T2 M(;-\[U($H>-[O<:AQ+4(+"<4\LDP\JW?F;^2&QA[[%*`6/'LS)FZ4(#Q*Q[8 M8:_-KI"QM^=G9^K;(;L2\(RXMMP8>9L%_E+29OG+51S)79(P=+T[R!17\,B5 MP(:DL/N$S])M#HFD'470+([B M0/3;:#J%M`!)P,%Z$!RB!4BF5?_X`0X=-A/F^8S;:$E+H(]%OI3RSF1^T M$88D.%X$KPLCMN)K'!+UQ*.B,J9">#C*3#BH[>FZF3`<#)EA"]^%S"E$;>5L M]=FI94%*!<2A$&;*1,,6PQ&!XP."Y9@IRB2?!=%+0+&0+T497.6AICQTK,JS M?>W;O10[-Q\[1Q0[&R1T&H;QLN20&%>^"OR)R`)!9=#AX*!_-!REGAPM[=FP M-Q@,V"IP/,M900SD2S^&UV8CU/P:^,$GM\S60O"'[^)P?\[YZL7;Q.V?B>`< MV;L0U]$K%R+P2SG&#^GW/H,3#6(+(@%\^]2S/PL7)&:?6A#!9+C!$PC`$<6% M(:3+AE\^B]G?OK%&_WT';GQXN@HP`;GPQP-(-/#';U[>`HAVKF\QAJE*(X?/ M68E\=2S"M-4PBM);521W9U+O2F;NJS;VTQO)=S;H'[&EX[IH;5FX3L<( M!695GB7R"(T9W%1X8N;`+X'"&:8",ER*%5`*(*LE;06*LVVP1]^'[.TU9$0R MS?J7`V\Y`Z(=&][38W^/EY")`3+\.+!$6&%.#H+_08*S=#P'6%79HDP@,$8# MP;*7$D/6G*3D(EBFV6^9NO.,3>0.C$=P2-9.YY!$].8O4'(3X1V!1$?V93Y M61WX_FP6B@@R%>6X<.00/!"\%MB)O3@$<955PRTKB.57*DSRU2KPKYTEB!@R MP6>'RJMA^@(YW,KEEJ0.E!1<@O#*JJD,A0_!?TL0A5BN7'\MP.&Q4RF.8D61 M@`O33Y`A@J/.88H6%`0X6)6Z`[`D'_"CN%X)#\L%)7K(>`,8KRQQU^%3QY6N MZ0:_NPLV/G,"2(#O9>+WMO"#3&>YP58CH53[-^T:`YYLF5/:R M9LF2?_&AN%XWI'FI^W>\I##U+>F62N!JM,1^-5)D;&01\0K8!*;@_;:"?;Q" M?'&VAJH=_N"Z_E5F_46*0)8K8;5PK`5[-LI#?MV[X^.!`'-!)>-0J0//?/9:*2XU/62[/DS8(*BJ,T+% M/1L62+<+;K+N(V4SK901A;F_S&7IKA,)UHFJ1SI5S`,1AP47N>0.9MV%F%8S ME^88=VM8ZYXGN6=D&_1:4\',V]3RV-3W.-ZE[UX"+`\/"NX!85'V2@5'5+.4 MP_[P3GX)GN:6\A5)S"R+'FK+)0\2/)&V5A&*$"#!%:T@*"\A^D&. M:W&WCLAI'#H>QESD(G6%1=^W$7_6T$FZ?AQ""\4WIS/J_1(K*;57BTO=[!/ MB_VS]'73.))CVXY=)PI\+8-\V@MGF#FK(11),M],F%Q!7KZ`Z!\D\JK$@K+[ MAD3VTL$4!CN034('YJ/J1;66""*.^0S2XBA?DG;G$K^M/!J0LP9?%3J227Q% M>2"`A)Q116VE?&%"G@L,Q>]XF"$G983?U#(NL/P>Y)VT5JO)&A`"(E:I"`LC MT&K-J07BCQ@2;.46(8T*X?>DI9IA"1AWL;>=RMO%0;W,%Z5#V>"N/%MV/)?X M?O@VOG<.7PVP\X&X*I1(EQA!/(7L?F6HQG(`JIR4@H1JN\FY5X:2S5M)<-+' MEHU<;.N[`G2T"SE_%3QOI76C`MZ)*11\P9J-1KU;G"+\W:LYUZQ*EMI]O7#$ MK%!(?Y(I;H`^$<15F%6IJ"AY79^E4U:IIU;S3#]SP'HE]T@IK'F,Q.':F(D< M5_SKC1V$AL"!I8"XK8!WL/0$M^;84#D7)=;DA:37XNW5O(PPI5RPJKNR:$I3 M<%CI5PKU07]4RZ^R]@"*HI*.YK1)B-A(XHS#FN=-H&1!% M*3/3.G=%J3M!M<\TN*^1YFW+KVE'ODSIR9J:^9<^S1!Y@##)73+::RQ)95?T M%;AD.Y75!ON;]^]MCIXS2>&^))$5N="IRPD?._C#N9S<_;2*TNS\(W;B95"5 M;-0P>"IG>R613@LK'?/J[QM*II_YNMZU*;EQ.6N>SDU*;X%I+&>>N*JZ&CF- ML3^5>+$*>&$KER>IAEPB4-55=9SWX&@\&1#.Y(,J4^)QM(`B^4\8?(+=1-E1 M!"JR:?-:QHR=('B#FO>7;40YX0QE$WH?*_?/X%.1Q&)7L1)Q"DF%Q$V2%:)7 M2N9D\U&E#U+D*=*J=.73PW.(+PC1*B';MZLGP..[:LN^'LD;^KO%SN+<0SA4 M5-6*PF*/IS!UT%<.0F7[555A0KX0KBQ'(*J7`J0,Y_Q:R`1V*A;&?LO*A M5@QFA4TKB:H83`MX0'>E]^QXEDJ](3V&GR")E^V:;*$$T.C8^_"LQ5=.I'KW M0/*DRE;&>G,"55^H4\N?O*[FKG=PDX1<0-^R=?:^HGIIGZ ML#]H-?4W>;OX1ODWKLRK:^-NPI_TQV6V$G**/=U!H8/IE.?E[,+M`PWSE85% M:C5A/#YMP&=] M54C>*6>>[UD\7%1$F]M M:)8,H#PYCO,'Y;;?J#^L4+1+F>IIP[+XQL5%F%L`F+"B*N43?I2:<_IX[!4R MI5)VA,M1BEE%G+:IDHT)31W.9"EI%FRN5W(W1,G&Y0(77MM44)L'DK-02/7P M*,T!Y63VI%)@(4\E-IJ"\0U\>5G_+>G/P-^F-7(*4FIAH$#QZ*CFJ!0'NS`G M5I4,)IC(G;)=KLGL490KX0TA"!X7=!%GS+EN+PYT` MUVS'F#IS;Y[.X4`*/APC!)X=]`^&A3T%A;2C&%?G\T#,T3_G`][,4\I"?:S; M>"JU@B[D;HP$N2T%9]NKTSU3R?Q`X")!"S MI/B8"M>_8GLR\/MQB'/KSU]\W5J>#6[F/GG2O=R'P\9]Q"T[]?.AM-H,/;X' M#YJRL M[@S7EH_)D%=.5A_!?!\BB$+*_&EUPW7-I/V.:S];`Z6R^_))5]6QDBFT&QI^ MVT6*SH"@<$$.XXD=1OGXNV%#H:WS\7>DQ2YH46=E;<8E:W(\_Z=BCS!B/W%/ MSD^J'0]-Y],_C>O>E0/J21+;D<3C7^CB:-UM+P M8V@-2C M`2%5H[#[)/=P;RI&OTU.T)9+TUD^FV!\;JPS#DD27:F7]@XGDP;1&">9!_0J M=_0R5;*2NT-D;S3>R4M5G\)*=J.5\/9Z)8_WPB0ENW-A>XZGT[YDEYG;A.\[ M.=Z6[S/0G1$\GQB>!UUJ>U'`I=O+N\"8*6K9HPF7FM8;2:B:5)X M5Y?2%3?H;C/SH=X52<*L+MZX-QHT%@O&R8900I+8O+T<;K>TWA68;*4>UUD@ MQ-R=JXBQ656$T<03K'35C-'$:PTKBDV[I&UB[@D2;*-X[K1".\T9(5U7+=DCK65YV>BW]FV:F/Y9'OT*(FM!!S6_=MI=;P\.A(5W8[K9HY"G%W,4\G9)V\0<^:8=4FBGF2.T MZL7<9B*I+JN,DW:O4,=IR-MU"JN-VT:E1/>8$B+D+N%$I($ M>UQ[Z:Z`=(8*M0IV*9W=Z0:ST<1W&E;=9JZ3\=%@A;:&//4!EL'R,_@MN7SV MA^_B<'_.^>K%&R>T7#^,`_%I]KIPT_AG=6'N:S^,0GEEU2L>"ON,KY?"B$+ M<1V]*1`8T)A=Q3=/O=/QV\S?EB\E3 MRO!"Y6@1"'G3^"TWE/?DMY/+KFLCX47S`3[S;-(;#`9XK;*CA!WQ:[GTS@M% M\?YZ.1CWN.UPKQJ`PG@:.O!!L.ZS-_G5SW>@M&XB0/J@1'I.*F>>B(ID3H4G M9DXDK_D>]$=E+29W?B.20P?T#42M@#3+67'77>,S/&.(10'WPID(Y'7Q!R=L$7`WH;1,%9*]"OQ+)T3:\#)S M9'7F!&'$%MR=(5WR+FSX!$4!/%H\#E&8HN*'TIO)<;6D%\/[Q&PF\+IN)1R\ MI%S>Z/ZG"'Q%>/G!KX?.!"`4/K(4$A"TNA>NOT$7U))&$B;9$Y1Z MX5:4"FM6$JV29ARL_%"$/3!QO.=[OJCRYJ".PMA%40$7GM\TC.OPJ>,Z(``[ M%BG@X8/J8%,.:"KA$^^WAV%M)UV[&H8B4A>CX]<`LS7K\U?P>@E)\+LAFP.. M`YZ0A\+MLU-YTWG=H.L&DY*!'MOQ8A$B\1)B-B(2PF@LXP2(Q_6O\$YUQN?< M\<*H/I8#=*.-V0)L`<\/1,DD_``,+%%B?"I$U8Y%U8M% MQ1OG)@R!:;ER?9DTJ9`E5CQ(#&<.<4R)]EG\`B:KCR1A44B6#J>(@S>5*#: MMZPX".K^&%]XR0/'C]$)\Q#B8<%YPY`6F.=^6XD157$UF^(N864J MA`?RNO3=2^6T4_E:+G>6ROI<,8<(HV)77;T!)``@?'@4/2KD-Z#3`)UX'(0R M(=#(Q@)`40FAT4JS`9S`V?!(A3-'GUB,` M.N$%O\3(@4,$3I97,-\K99124L>CX='WHQ,895J9L!9Q[F%BREI9>$ M8VDJ22B4H/2#"G1=YX\8$LNH!7(/`5W3"8&?W__X]XL7@_F5"ZX`$#3%`2CY"X=1(M/\V>S'>U!"N()U]2/YPOX3@I1SVA^^NIX&K?O[_4$L#!!0` M```(`"*%!3_TO.G!:@H``"IR```5`!P`96YZ;BTR,#$Q,#8S,%]C86PN>&UL M550)``-@53Q.8%4\3G5X"P`!!"4.```$.0$``.5=:W/B.!;]OE7['[R9+[N5 M8H"\2*>ZNXH\FVX2")!.>J>FIA1;@-*VY)%D`OGU*QF3\)#!&`D[O?-E$L?6 MN3KGZNI>279__%>A8%U!#"G@T+$>1Q8Z^S?W_F,5K#/B^6T;637,Q5]MC@90 M7,,#2,7OXN]]SOV38O'Y^?EW6]S*;$0A(P&U(9,7K$+ALR7_^^<_/DJ0,PHE MQ(G5Z0=6->A9I0.K5#DIETX.*M9=Y\S:*Y7+XX?$$R["/Q\!@];0K!,;<$1P`KNLV#OD;X7);05YJ5#>*^R7?Q\R M9^?SF#G+^DB)"UNP:X6FG_"1#S_M,.3YKK0HO-:GL/MI!^(77)`@VL M80$-VUS\[$&\OHWSSPLS=9MX!EC_TB7/:]OV^F#QAR-KD2TEDHE2/'_DT-,.5/:YLJB:WBD-^+ MOP,T`*YHD57Y&:!TA'#O.W`#:*(+R8##KD4=FU*\2F?["*@]L5'\N"#W;.B( M[BBRP//"U@I(>/SD^2XEW@HE.5F;/T(=2#_ME'>L9XAZ?2Y_+*;TKG:?4-Z! MU*N)Z81Q.5:9"864.,7/5LX54=,3";`W)T#:8=/@?4B-#W,%RNQ8SZ4`*FXB M^O?GZ=\@O)J+JU,C,SN"50W1!LFXL[*Q!S,@>HE%G% ME=8X-!7HS.JA!LIKE(JA):+^8&%8I.*^CL`CCH-.-+J-:6[]4)[LE"Z89P.!EL1DA7X>3)\Y4"*,F)\_;T^<.4&5M( M(M1HN1X)RUB*2^=2+JQP8O_L$U>TR61*ST=&EE46438KVF`7"CJ+Q.BNC:N.@Z2IP&T" MY-3P&?`1!^X4L)%\;C7JNQ@;2=C3&V)%(AEXD@SHA'%=;I-2V(>8H0$<;T#5 M"6,WD#>Z'3`TE(RO94+6-5-"*=>PBVQD M)*%)@/HN1F$2]B*U#K4OGE2QLYVT9R5FUN,L*2DQ5=JR\NR=]4IU5\S$'6[% M%^?VXC^;W:&?/Z>0?K&A#5S(6G``<0`-[7',0VRP--(B(^#R4=28D8@ZBY!U M]%2K,Q,ZYRC1M4(2'ER1^(UN#3[_><"SR6^MU"IQQR!2=92 MU@%P"=_K\*$[Q5?C5"D%N!<&`!$;N#QBUR%-2+N$>I>$ACD0DTF0R(#"CLO9 M]2W>Z,U#=!J88R\PI(C>"B/$V4)@5^)D/MTG4$]-D,YRH.'+`[$BE;T82K'- MK.0O@J3W&;5#1PUO+V1,`#.>=V/E6QT#7BF+FXBW/P,PSFKC!6/GBHH*.'P78Q)V@TX9T@.SY224F\UZ_U3P'W[1$Q1Z]21V/.0UL'E!AYUD?T)Z9 M*5Z),[$[?"WFC_OK[_M__O%@^\'P!S[\X+Q4!KT?(WQW'CQ?5>B'RK>]I[O. MB+F5@?U2:Y:MS4+DSXS<>NCT>C)K%O;N^_@=LO<`A+HX->]^;;E]WG_^] M1G#\M3-T+NS>WO&H3%Z:7\_/G^W3GGU;/72<^Q_UO=WV_0$<[`Z/>9'>'GZY MZ8I+K:?&DZ?&; MD?NG==9N16\4Y=6WESN7WO7/5T/>%L:-IJA3,'D)+XL]GUD!C"D/EBRLY+@W M"K];S#<*:1PJ#,@W!)-90R(<\8L;..%5#JGP:V7B$3-SK=]JZOSZ[46),9"A MBED%D]%PV$RW:=]2' M`3I@"-DUPH0B/IJ0+6J*V5;&NW_7D/>)8_AMPVV:G_4*2W+GFQT26Q18ZP+> MJT71:#X5)6S7S*&0.*CLD]5-1%=0%Y_!IM-()"YFJZ%9@.SU4'9XO?&F^R#I M+.(Y8O88%#IOF),37%7.*7H,PG?=.J0%?4+#$D<\8.8`CS[CWIWV&RFQ+)G< M]M&9U\]HI(WDHL^RC28E`R1L.!W=,7D@Y[7"KLHOW8S?6ME22K6A1;]V!IG1 MV-+@(KH"<2IISZ%/H8W&O&&GZLD1_1+^:D+397!9IZKZU5Q*KO;W`Z9:;W0O M$0;8ENO*<@O2R.'R97BYF/_Y,/HYB0=!5DMJB6Q+ M[G>4,ZF4W=17='^P(Z$QZN4J$YZPF4'O9<96N<:&4FC^:DY,7\8[.GE:EDMJ M4?K0&+Z=!)UHW39$XP&%C>YIP!"&S-#K"$E@\UIUK.DF&-]9=(%T#>4R4CQI=56:]#?57&Y'/=%>C M`R300>M7-YM@%)Y1Z)"J+3R-PNT._^3H.H7UQ`+&XS]>>"MC?=$ MP/\'2B\=V(=:1$[>BVP3UG@'U.X+AVET#7_?,@%J/LO:I.HE8%7S^R83R!8,/^S7(1TPO$>\ M+S^S)NP5EFSO?$MJ6W*9VZRI^?H"Q%6RDT&M/,3[\?7?,`P'RO\`4$L#!!0` M```(`"*%!3^]3A]4`A0``-E4`0`5`!P`96YZ;BTR,#$Q,#8S,%]D968N>&UL M550)``-@53Q.8%4\3G5X"P`!!"4.```$.0$``.U=67/;.!)^WZK]#QK/RVZE M-)+M.$Y2R5;)EIU1XD.QE&NGME(P"4E,*$(#@++E7[\`#XF42(H'P&,&>8DM MB^CFUXW^T#@:;WYIMUOOH`4QH%!OW:]:QOF_Z/S?K7;K',T7(\UH#2S*_JI1 M8PG99]828O8[^_N,TL7K3N?AX>$WC7V5:`:&!-E8@X1_T&JW_]/B__[YCS=< MR#F&7,3KUGAFMWKVM-5]WNJ>OC[LOGY^VOHT/F\==0\/W8?8$Z9A_;P'!+8> MYZ9%WAX$A#W>8_,WA*>=HV[WN.-_\<#]YNM'_D'H^P_'SKV_[4V M_ZA]>-0^/OSMD>AK%=EW=+H6$VS@I./^\<`!K-5Z@Y$)[^"DY;SC:[I:P+<' MQ)@O3*ZZ\]D,P\G;`V@]66T.=O?%<9<+^Y5_\IV9EB#3T+F1SH#)7WDT@Y`> MM'C#G^X&H9=ECR"+F[G#_]J)?;CC^X`\!;\/`886G4%J:,`DA?3=;DN2^@.+ M:0)'E/T\9^(RJ[S]/%-3M(KG@,PN3?206;?U@QU!CGF#*$REA?-%@1;C[753 M2^X*?>%N!L%=[Z7%R^)H[MN,,&$R6GK<`)LDXV./#%!G==M M&!;ML$76U7TZX(LRM)VQ)K!FW\/V6G(VA:,:"`87 M*1`[T+3G<'X/<49\0X_*=5M@FMF4XP]L5&+.:E@&[UY73'A(+?A(H:5#W5>, M/YTK%]L8B@DTD1:28O*4%F%?B`GNH?GVP";M*0"+[^M4@VD'!^Q'$@F3\[(3 M0.Z=-_8>[O#0U($F)?XG3K!J=P^]9/?7!"D=$4J/P7V,744I[$KPB2UDSQX. MZ\SL[ZOBN4(Z7_&>F6`T3V,7BN*!0%B'^.T!XR?7BU]KR*+,S2Y,YUNL)\!I M,*_,C_Q(@Q;`!NH]&G(])B1HH[98,T3&ST2SA#POTB1AA-:664>&[-A[#7ZR MR`)JQL2`>M_C)@GXQPK;4)EP,^R2;J(-HGPP9(IXP(+F$&N,[]W2S2';%OYH M38XQ.&">.0[#SI7-(CU"("6]>T+YG+8,(VQ)D$8*6P.C_/2P#4D1F-UY1!OS M6=0DJ.-F(".?E.:\^Q&,?@>.7M*;AL-X/D?E\Z@L_>+_7?QI&TM@,D&D1\\! MQBO#FGX&IBUE4)-.<)"@:F25C.B%73U?B)\A3,<0SP?6$A+*>YN!XJ!_EIM5;.H/8E>[U0!F(1T@)IR,U!#P*&0_NX^*T*1'LAN$<#?'S M(A`/,6+I!5T-68&2D$\45[M#9",EF>/DR+VN`;X)Z0\@1M! MS<;L]2&Y098FKP_LD5CW8+\/,,\H+T2$?;F&B!94RV'H'FP\S$^#:4B>R"\O MY%<):Z)#[89[,0/[*P/<&Z;3.UC<&E&D_9PAD[5+>`RC*YFY:6K9U<::='EK M>B"#`\Y"*6U09(Z\-NKQ"MT_JR=NI[V1:&QUD9Q!1].0S7*%(5AQ/I$Y[HR6 M5&EZF\F:=B&>D`]N8:)$59M;"IHG#@`0R&J**](-$NL/1IID`1+ M'!<*8%?(FO)Y#[Z[P^^+4LP1):>Y'20:ME!VG3]S""A60OH0+:UA;)\&OW"N M731T28Y9335`"*%@(IUW=0'-YX8['\NGR9%%#6L*+4V2!9+$-7:HE8AA*/'. MO8&ES-PP.1NLRD`I'#6\KV)O%E@L,QDRQ"&+?*ZO2%N$BQ)3[4IREIX1"5(( M_MQ!"UER@=^1T1S?WX5G*^G+F?7INO/2P!P"0Q]8YV!A4&`&I$E)__9+K;(_ M9#1-&@S#DU1Y$W1[;IM\YZ&KM"A-Q`>CL9@T=):7LF M%2IE_ZQ6S`IO,)7,9=`[2-D[0/T"8(NI1@(:]!E8FB%E))!":H/Z7AH,P^NW M@@9KY0S2JIY^2>^BR>.T-J,T>8;:D=B$K4C[0!.RIAPE9$"(79Y5/&D5 M3HGF-X>/5##5%V:&6YOR*F$Z2[#*LD509",-$L(LN(A<=&V@3)))([8)`2P5 M?.%UY^*+.&602Y*X!@SE$M$JOKE[IWEY?!(GJA'CKUB`B3_MC?GJ-4(F/!V,N"3 MM!HDY`X2R!3FM2WZ3(*)(B;,8\Z@I6NIXK7J>'RSH%%\VCJZY1[&P)HZ_8QO M.^$JCA'+CWEMS$N$G4U!A.\*8F'2F5KGB^YRTBFQ"M;6ZI+L4>A`J*^3TSSW M2.*]@:1"#9%RJIU42F.R:'C",^'Y!EKR(:\7VDF.%AI0Q8!=8,OU[8+?#,+R MZHM'WHGD#JCBA35A"C4!*B'A)CH$>L+*HQA?8)7CL+U>N9\ZUK@)2#4*4!.A M9.`>I=/?842DY.IB%:QTJ"#`\+D-(^($O=.Z>]V2R7=AZ'.&'W\#?KN2Q*Z< M2FZ5A5BRV#4=B`6V0CBIQAX!ON]`?03QTM"VSTW&)&'96ZU]G,V+EH"1(.OA M%-L:M3'3\7P&\%3.\=5(.16/"3-&P@BP$7*(VM'A!EDH M'*%D#_GC)3;&'ON0*U[;+[9Q]HMIZ\ZG"?TE]C:PK*U6.M)/Y9]K:L@!F8`5 M]@VK7S+EW8._-I/ET3ZRR!ED:;QW%'L,'B&Y-BR$G?O+7'58@A)NQ3W.>`WI M#.F2*[B7J7X#MC:6:LU0D:H"SL?4\#SZC&6\$SGG[^-$-6)S7BQ.`JI6[7>9 M:OIM`U*C--")J%D5EM,WB.:*@OI&DE\@HT."M#9WZ-'R?--\B M'=7A,\UBY&RZOH&Q$&!^3EA@97U_0&8*G0%B:-(.+V55H9)!I0#'SL:#6[`+ MJ1J82FK?,&V^0E*IN4-*5#9/5K*]P\CGWST8TCVL=S3[Y@K!F1JN<2)8`"W? M1,4FY;*,CTH.QEF4J3XLYW'UO`/5Q/!;RS#*+ZHBK)\6:99(RABL^$7:$QGK+7>DD7.*;RQ^7O<3G:.3$OK2=D4 M:,(>[XR0^E;,7P`X1F"0]V37"\BJ0HWY*S>JOB$#^UW*+RK`+[.^--'#0='# MX3O8J%H"JI:`JB6@:@FH6@([&:$?=)U\=+V_M*=18YGC&M"TC=5Y+)01EN)G ML?\>"X>YO&W_6J*P%2JUE%\S>XM?W2_01]7.''FF3=RLD_M\6T__87O;X[A' M,.?1#!-NIBWB)(\17A@78&UI3YQ"U##,GRJNR M9U=MZ61#"#G(XJ\@0#U85T=*6AHMZ>_;C^.@WSH!D\NL8V!-#38X[!'"THCY M`AC8J9`@[TSU'HD5GD^JVL[[;!$BYES6?L?>G[_/K<72A@4BAALP_(M`9)A[ MG\BJUE>K-O9>4P@X:7L-\$_HY'XCJ-G8T+[I+K!ZLTO[7;KCR_7GX__]\=7;6$_?K-.7NE/ MI\OIMY7UJ6\_O#O%KTX_'/WX-%X1\W2I/77-]_39$[HP!O^=T\71A]/1U>GP M\%T?G%XNC2F^//S1'9P\MSZ/'WZKHY&E+X;WDX6U6@V1=O/QRP?P M\7?X"+NKY]/)S8??GST<7YY-7OSH_GET:[]\/W[4+[3IT7](._GCR^\V$?73WX_:%1H[A[,OUU=+LOC@G MUO+9Z'-W\'7U\\6[R\CT<7TX\E7[>[KR^.KD7FGS3^1ER?XVP]P;W5Q MEYH?+U'O;CRT%OVOU_VQ]?3^T/CY\\.K)7W_F=P^3:Z?_:]U/KIKMZLCPH)3 M&'O]4$!H\_KEID>Z/31"V;+FI`IJ5.GJ>?K@L37Q7,@&`M;+4LJ/GB25X07% M%*JP+D@^%RB(OY`UHI0Z5-OG_]K]N_BL=(ARW!/<@I9;DQIKUG)K(BPA`^3J M2DYM;:A[JTJ.*&IC>#LYLPE3D$@J\Y5&;(63`ED=,WS[60I$14S$#L'*2VYZ MVI^V@6&I5ZQFD%[=)%XA.V:`M_#%"D&G<EVO,#.)KLYA6H%_NA5AL8.7B M6/O7@-<1I*O;2=340!EVW:]$/5;0"YHV!=8"ZI'N!(C2K)I*\%\DZB::+_^] MKC'#W`AM*YY*2*M1I:E&IJZ0(MM(;8;"]=Q32J]V+B&]0A7.)>3V@8(F$++0 MG=X/J^WZ?_EN'AYZ%9Q26.^)$#&ED-18LZ84$F$IOM[L>\DEPG=P86-M!@@; M;0?N<94Y*$J06H^Q;0JGC!H0):$I8$X].(3FUQTS%:%_U/&3I3LE7)D:QI(/ MKJ/WIO`TBJQ+@CJJW2ZD\:1R'U6H12=^Y3C9M+G/#:2:I(.%^C/0=B" M+"URP!NA7HD#WBCIU0YX$[TVQ0@W$D\A22N+W_P_/F>Y!";OV4.(#5X(.;SJ M)RM'32V_OD4A\\$9WLI.#5RG(W`)B(VAE)969JNC9@KEF>I2F>/DE@[3E0C2#<6IZHYLZLV,RG65*RI6%.Q9GFLZ6PXY\.TT:PU#ANUW$IF675ABA%L8IB%<4JBBV)8OE!1PQG M7-TE=*M"\V`LE5GWRFS`=JG]N%6Z>VJ=LBHR562JR%21J2+3,LC4.^<^LA<+ MMW,!R\BU4F\EA1;6*:A75*JI55"N1:IUZ,F[Q8N=B M(@T2<@<)9*_`JR'TX1*:R"EAO'>:.*;D7>[&:SL-7!"SRI=>U9XE1;&*8A7% M*HHM-9N]`-@RK"DO`^44QI.:OL8+:T*^F@!5/1)4M7]),:AB4,6@BD'+9%"6 M9%%L:_P>%FO*,BVO\FRXHG\)6YERZ=&`1=A\^%:_,*LV.BDN5ERLN%AQ<8DG M<-94X%P=L:[N[G'&.2*4;.J_K^]YD7I2IZ!*S3C14Q3W6DP_J]U4BK$58RO& M5HQ=9JD,OJMV#!Y+*W>1(*\17)N,6%V(5.V64E2JJ%11J:+2,D_YS`VWEA$O M5.1<(CN%EE;>%'1J[ERHOHM68Z,A4OF(9T-;`F",_=:^W^)CNJ M=&A\=U_^#DX-?M&<16_`/(&("=1^FZ(ELY#A:LM^V%8RME5IY%O8=>.!R!U? M>).^CXW9]XIC&FJMME%@][UW!]>90#RW,69M7;+0`YZ0:!&X3=^V%O;4HHL/3$>P&R18=$&;4W01J<0M=EYS?&T+XW M#>W21("*PC[89*U#200"X3L6,V/:8_)T+O/2!`)\.=Q'5IF!`+`WR[V69X]@X8'L:OBGBVT]8Y4V"*L+#($6ZT(:.T+23\A"1? M4N^! M=`(D/M[/]VY.?M/A;=X#`ITO_A]02P,$%`````@`(H4%/Q(#^LD`)P``/.D! M`!4`'`!E;GIN+3(P,3$P-C,P7VQA8BYX;6Q55`D``V!5/$Y@53Q.=7@+``$$ M)0X```0Y`0``[3UK<]NVLM_OS/T/.#UGSB13.Y:3)D[2GLXH?B1J'=NUG*:] MG4Z'IB")"46J).58^?47`%^@"!`/D@#3GLYT8M/`[@*[6.P+P'?_V-\'KV$` M(R>!,W"[!=[Q@V3U$.R#XW"UGKH>F`0)^JN;>'<0?0ON8(1^1W]?)LGZY<'! MIT^?'KFH:>QZ$8S#3>3"&'\`^_O?`_S?__[/=QC)<00QBI?@9KD!X\T"C+X! MHZ.7AZ.7WQR!=S?'X/'H\##MA'KX7O#QUHDAN%_Y0?R?KRAD][>1_RB,%@>/ M1Z,G!WG#K]*6+^_QATK[3T](Z\,7+UXWYU%W"E;/O M!7'B!"Y&$'LO8_+Q/'2=Q`L#";H`MP7^;3]OMH\_[1\^WG]R^.@^GGWU?3IS M`'P7A3Z\AG-`2'^9;-?P/U_%WFKM8XK(MV4$YVQ*_"@ZP/T/`KC`DX^QO,!8 M#I]A+/_,/M^$B>.?.[?0_PK@YN^N)]R1O:@`I'H>&"59B]H:H3[^<(X(JI`* M[Q,8S.`L)Q:#:.`TP4#DJ@",08=N!:B/12:,.559PWWV<>+9?3LR8C,B224@WP]I@1B"BHDYLM79=Q( M%<0P8X;&R/[P;WVR'%&W8(%[[;^;?O7]\>7%]/)\^?>2-W\=[HS29:.TJC?Q_L)QUG^,XYB[BK/QDK'. MG?B6##CK>(!7]P'TDSC_0M;[_N@PVQ[^R<'0N21QES>;`,YR'D^GE95K6#R: MV8'%H6$T?2A-UOKDD\!:C^F,,I?>ES*S9&%I;):;*()!TK2T>!LDLR=%A(D- MD44#;Q-,VP*'-'Y)+1_SNK5ITDM]RAWM(Z=>#D.9OB?TS\WWIWC(QSQ.#EVHFCK!8N?'7_#MN-;[F5RB,V(DA)- MO/6+.@$GF`$7_P#+[G9UM1)_:14N/Q>JBCW',%V&47(#H]4DN(-QLL+P^Y`T M)IZ#FMG:JV2Q:.`($FFZCS:6%?#*QG:EJ(E5M-!PATF;JDI";'WXOD3X"3@ATT`P9/1 M7AK)QZ#^]>3YWN/GS_`?3Z`+5[=(13TY)`U&MH)%*C)"RZ=P6O7%]:T3?82) M<^O#*42+UDL\&%^@$?2GP@08#=M"S=1P9+;L!.*B5R%4-B1*CHVT3$D,O`L[ MJ5]98B/J/*ZB8"D)927![_^.;R_.3T>OKO?SY_?'CT+3C]Z=WDYE>[#KHJ M_VD)5)HB(]E+'/22,RPNEO)SC`($:1H_++' M$/(T#8S831[PQFH^8\.AI"EM0T_[T'(W[7G0*HLS=MUP$R3QE;/%[D6?T3`V M)K-Y&C81O'*$K#%8IZUM6X*-K*I8AOQ1ZJ9<$,AH`V>4"/8K*AQD?1B"0D^! M1PU?;'![`._7,(AA3")<(?;*K$8=A!SKE9=6E>#2I#!(O&`!`[N/C,:(V^.BIL-B2L'P>D.>=@4DHZVPE_R3*Q4IXE#VR9+`I7# MV0U\&$(\K`^FC'9]/L7"(#B'R.)((^&]E3*ST!C-DS`(X);^9"U!C)N"??"O M1Z-#Y)-$X`YWVP/.)EF&D?<9-7FR-QJ-\/\@7CJ(YF]!$&8_`B^.<72$!$4V M"3XS.T-ZF5T7U%0,9*<6B"L6U1(@]JRVD4B\FX5!O^)8P]'U#B.R5&CD#>9) M&,@(X>'1J":&'.%[.MI[AD3LQ3=/PL1BK$:5J9@>7L2XZ(A$V9OM M>P%PT[[6MV1YSE;"QW(ST48?CLM:4Q(NP+=01'`)@]B[@Y/`#5?P/(SC"YA< MSF^<^Y[2%$HD&$]UJ5#'3V84);UA>G2`A@,\`LB^F.I)PT[*0WF^=%W(:Y@X M7@!GITX4H/TGIG"?P+GG>KVXDA)8NS\8+HI:B8F2D,Q9VM+RSBO/55KN)">@ MC:ZL>TIF(A5VCD+5Z6@,A\9`'-!LGJ\UA7!H)@1B/BW!>_Z)9PV@XK=-,C9PD[A6!R:*C[5,)U1@B2)E.'>%V*K M*?"=D]@36FEMY=&$A=:$SGPA'8<2*;&C$M.I!`Y'P&1L,M'P=?W2&MS^C#$> M*M.>)X<.*2G*ZA=J$C00&>(;8DV#UG<9:U![ML`:\5F7([']514FN@)FJ!(E ML+Z$G%S=3<'D&+J].K\\24V-J_6O0)KRJG\) MZI>-EVG\.QAL>#=:=%7`L8/#^`F`70HX.B%O]M+ZAL)C2[4"@S$HP]XMBP;6 MJBUF=C!W^NO.<+L"_>MPZ_C)-@/`'$7,*1`C>/@*5B_87Z<@093!)#GY60D5/^R6+"%YT\T)MH]` M#L_#?=QP$9`(!O(A<*M;)T;?$>1;&"<`_>^MT`9+4"4Q(':XXX7!)J-W'9*.S>PDH*0$7M;9EH/(E:U\;J>9MW5 M1(#B51MGNU=/M[DS\=BXH8I%".\V;"]VH8\^P7"#E31I;C7GVL2MVJ4@K$%J MY[(,B,@0I$-.,-*JY4P@8MM%0Q+RT*DH9-&@8'&:7=K69QB'C\S&/<=<:GA7 M"^7MBPON7MJ6%B'W*GJD<;Q&W?Q&4EAV-F/N67&@+YL';5Y291LA&19SAG&. MT&S0J(D4;KB`$P<@1U0.OP5K;PT1,OLG/*4X*[9'Z>EH%7]L8^W&23Q);S2; MO8["N)(U/:OC9N14WPXB++V!TY[GVPZY]2&!G#AV3 M"ZTX.$-(_'N8(_*70JOR:I;&8(X\I[U(L+L5/K931^I M\+;F#LI,A4;Q+0G["6`?%PIAFND#J:2#.M3.;0AA_D&91IY+N83`62PBN,!9 M`>*GXB!Q<2\V^ADLN&)9MD.JA:5_+4?_M>6C""SKS;.AQ+0^A2S'A:]]BOVV M:8?]NS"W94X<(B0;-]E$R+,Z7CK1HI_;39EX;$2V6(3PS;VR*7!)VR'X-%R& M[5AB['%V%^\R$N>R<8E#C8C&^&=8"[`,*Z@B%4QI9VOGT,HKCWJ5#0J-^WB*ZOB4><54T!V1JE=@T-L[Q18)G-*U=`-WGB#E1&"2"P1I\R*N9$F;,)@N-T3`W@P#.:BU;9J)#'BJWNJ$W,(G6V+PQMO$.)@%2A@AJC_&R M711=^@0O4LD(2#!AUK2I[U#!%8ZT56[H68[FM*;;"5P/7UFP!;>;V`M@'.]',+U_#1D3WEUZ M\>"#9.DDN'8["4'L;/>0LLMH`BOG0QC1;?/*:@1A[40$-2[1#L)H53K&J$W^ MAQSOPT=@[,NPUJOX#R,LCNE;YQ[&+_UT#+SDFU.RSB85:&D MEVJ^A2/8HR3)/)N-PE^Z_^D<"1\G MPVI)_)BE1R M)"D'EHO3.GV[BMQ_AD&"?9$A8#SNP!H<,?4\HZ"ERR8=HR/R7ITXU5YF9)P`^/#RABUFI7:#9KFA";G)45G*R'&+:VE%#$*`=%C:)$#UJ_1S^>^@M ME@C,^`Z960MXL5G=PNAR7GN8J#>-I$:`C1,W2A1RA#"'`9P42/ZB8[Z-WA9* M+@5K7;-IR04MKNJSIGTNC(.*=A+Z?F1-E00+X1A%$A4%>1_,*#U;$^(!B;!( M+"2$N''.5&W`]+Y^ZI6G8R=>GOGA)[7$1S,$PT4QC<1P)*OZG-?Q>/H&G)U? MOI_:O3%+BC'ELPO"<9LL5A%2PWP6@\,&ZV\W]<$.O?J1](VV'!X.6!6WE8R+ MLXEJ;RW*`C-YV;829;PW)E!W,,?]TP+>\JZB\A2GM:NXM?A8/M*G,C,F+MQ4 MIHKYPJ(,PVS?WVV.<2.S)T9J9;DL%O'+C;^,4N/=&V-ZG]5.Z^59')DHG%7X M[\$$Z8GN04R0'7\;-K\M(7<\B24&ZL>V[$M`MX>VU"/@1"./9Q\VV;%5+`IX M$)X/RR`[#^5-B*0)J_-W,9R1Q\[NO!F,$M1+#+71J#,Y/(YA2)&` M+_J(23BPV6!QO\0*,7/`3KC";\*&2SL6G<8+$AY8718YSE M1NPF*T-CJ7YKXCR0XKZ_E6RW>>SG!*XC_$8')@#?L[W"9L_GRD5-7<:EF]"9 MOXH[J83L=(L$VVEH2#5:W3H`&=#D_\P)\I5:P($^7]"$^C?A,U;7( M$,.S,J@NQ#W[%'D)W`_G\_0!YUM\T5B\08`@4LL(CEW37(:]M)@)9T1?3^55 M"G!V3#UTVH>,<3"9U4YL(GB9"MQX/WT4W*6:6XW#-#.L\@@E?ZRZ>ND&38^' M'/EQ',-DLEH[7D0>6^KO/0*E4HHMFX:<`*R-DZ2&K(WNY"_ZY M\:I/,-L0*3FNTJ(E,0_:6?[7CA=@F^XR./'B=1A[J=:[RN:M#R$3H>PLJB]_ M4;"`)(ZHX1X`;8$STB=]TFCNW>,T/N94;/WXA"1S:5F3F8D6Q75OG>@C)-') M*70W$7$"1_T/R]>?PU)O\WRI9/_[Q:'I^='7X^L0Y.KOS%M'9 MX8?1Y.DWP<\WGSXS4W?Q^/GV,/Q\]O[.PK66NY#D^D[N0F9FVEPED@62RA!2&E)B!)),78;8DB*S M[E<[8ANNY5(,I^(=2W33HJ4D>P?BM9.5;SOCNLZB)%YV^KB/I=*.(..'9UJ1 M*UHK,BM$7-E@99%T(E?T&FD_T2W\#_D%:G?WL%'*+D]==UO#%[,#M-/V^B7L ME;*Z]"+RC@IBFX#9+8AMH$RR(-;+(0RS(%:"C^RZ2M',V"F(%5`E4Q#+9-CP M"F+[8MQ(/X"+M(\+X2RK#218DDT$+^>OLE=Y^MG*9-`:3A=(D,11'WG/5!;S M(%O^K-$P7OA2X#.]1\E.BK[\.=NL1F3L_KGQ(IB'BJ_0%.-W-4[SK$LO8BB/ MO4.+2C[6*T\?3S0144LG3ET$03;+EF0J2T!%0-5F2-<]IM?!%"WP,J5A1DX5 MT)NN`%&@35I_Q@VY,-O:4Y+]/"TJ,T7Z%2*[F!#HMTZ"\R/;RSDK9V)"6L5$ M&#W/HTR>@MABS;I*@65Q&4&N;1#B+"TE34(M-XUMXODU76],H*40]V8A"+-, M4O3)6`B#%%85KC>:!DU"V64XD.&M64XPR5(TB`23)+$J07-6?.`+2RLI"I5$ MH%%EGKM,*S'PVDTKR1,TB+22-+FB%9*%V;FK0R*E-)BC]-LI^(XR2<6IABXR24W`[&:2&BB3S"3-`_'#Q?QE.>&"B6@5%J("49/LX&!^ MI^6[8`:C"?J`S+8['*)BG[/"85A\+MG?X!L#"5F7Z]Y\D'X)MAG_[WPT4J'7 MXK0H;\'8CK'V)I6\>&P_?&B1ELBTP#7TTX#FC7/_WDN6R]#'F)!R,'>T59L6 M"P?+=&GE'6XLN^+GN*FKCF/1Z5F[>XZNW+!V(JVY;.'?5_(D>$F15=9[WJW$ M9,%O9U/"-7EF<)6JF52?H]_\<`MAJL5!;C6`->JV4TUC6[/7&.4 M`\.L-Q@M8F$?3K2(09U>!3++-QQFW*A!'"3B1KP):Y,$0#8'_@?7.=PY/M;# M5S#RPMGN,;"^8O[2^(V6(JA0UB"S#V99&W*G%?D)Q_6)*..*!/(#+!%8-8QU MI&$W6*\T9WTX1&N";IHX42)*W]1I':-5%T5;M,!^=OP-;`Q-L=@'G`3=K\UTXDZ#1B-I`>WXD"&5RAM&R7X"HQ6@ M*"!*O,0.IO6S)L;UN2EY*U2_$8[HI^S[(J^/;:4W6DU[\7T-A+,ZZ26)'^+& M5Z_O+,T4)[5"P0/<(L,+,L0@Q?P0E+AY/H"=&PK[E>7JO88]LE`SPH'):+L5 MBF`8V\D$A/#"7F&"9/?*V6(NV-ME)#E1;!(R@VWS[@D3>A\JFH?*M(;ET,&- MLR.-*-)I=IX^:>1<]=D3_H@U]0FI9<%U4S"*4XV&EU=;#:,.U5P\59DVGCU, MP2&U=T??9ENLU?>;-=E)O>FL,STM(K#2"/O09?+(36R*RE3)B*:S#N-<,@&& M(V'9V;'ME"6A\NJ*TIQIR&MZ`"=OU*=EA9ZD8&K@J>7\CH13K-Y*Q$Y4I*7/1Z= M"2!1@&RM9Z521Y+)E2(=F5EI=3!XNEFO?8@=7\#LN MU1V00C$,%,G>/(Q65E]8;,78VL%3I6G2SFO)8NM%!`?]D-S_U]J) M;HO$H$_=DE2>5LWNWYT$^QEDD(,FP6T*N%7UVI4XE$YX%_.IZ^.DR"?*R!6$ M6@-XU_[W+'1)&4KED&$7T\"+/Y9.=X2/+9*#FV%QQ302\74FXA$MXK,2%ZY' M2)808/O/";9@MHD(D"6&N,8OU:+?T@+T1_;"XFVE9V<-:,Y_#T?6&N^::4,L MZ\`(T7P8(*@IOG%5\0TNFC,<*1AIJ\!3)\('%H MKKP?0!U!>ML'(`#LBI@TCPI9DIL`;:^%"[X/-X6/S+!?PB5$1II(C^&DXH0< MI-V,YH'K^15(O271QDW(SHYT7';!0?7>PC8^12L$)@]4M2&4>SD!!=)B>5H7 M3"YT6NMYTCV.I8.X#T6H18?9,+8.B3(R3!R$#!@HH8DM0ANZM8V\T&I7>S*U M(N(E,'+167&33(;U.(R3N+QKIKBF7*\LJR-DM:.7G'H*)Q7UD*A_0GDO=2>SN[^ MRJ$/*:S?D8A5:N(ZF'+-VKDT]WKCW+<_FR(!R.#Y$C$UW"ITDFN_P1?2V8T. MJ/"&.L*1!,@:8NPG$Y+SVK M@`\BD+<-%C!P.X@9:((V6JRF02"_>"@'1ORK`EP"SCWGUO-W[XJS4L+6@M=T M,9ONM+4K:U/`VE.1FPH%)@M_U4A3E6!7*CA@K1!.0RQVRN)4YZY-U;H+`R?R MPG=!O(:N-_?@["1<.5XO]QSSD1D.]G,)X?GP6?L]0/4`OZ5]!E!P+F)BI<"\ M<>S:6:-I@MP4++4Y_/&]U\O-5FQ$9H\U,"C@'F'(VB*G-FL-?L/M+=M[C>RJ MGD?@#58W*7V25:S@-V:1QQJ M@\43$Y,@@0AEDGWG<5P9D+T\K3*I-?YJSIKQ9U]:/*?`*EXK(L]Y=#H)20"' M?K,"J;)*M)J9X?D[OU,Q,BX&KY$MBP])709(Y:S#V,.DE._;\[B-N^6GJ]"> M2_5-[YY,>UNW]06C8[%/:D)TGKN:0>^/=$^G'L]*G_>YW"1Q@LR9QILH8^@^ M6H1W!PA.:O^C'W;-?DDS5AJVN6UA[AKENN*`=7;5@Q#C9U8PA1F MP^@C!M+OK#>J?:3NL^Z"F\$LJ8+^GZ'OX7[[)K:]A]YBB8M@[I"QL8`7F]4M MC"[G)YZ_05^9+O^N.+065S5FCV[RS+?@O`C M1,1!1%^)LZ"R-G,@>X"`V4N]Z!S20)X+$P]9:J$*)DPY>DC[FJ)OY(?B7KG#JB%ME>QQ*VR431-GMM#Z M,@^V9.$4KJE:-`1Y2ZLQAQK=K-GG#,ZH(8(#EO$UO(/!!EY`KK61M=@#%]"V M';%#,3-3PQJ46<'EO-Z77D!:>[V/->7X[3ARQ\,5]LYKC]C[&<3ZJ6M[%:\*<\!:[9H3:9+7E8-F MQXB&!5];5X_E98T'=-XNHXC%"?XPS9I`8]>--G!&U=@>;Z*H(:25=:"K"-WE5W;"3<9DL823ID9.V@..7VXEY,*AG MACVXHS1]B!\_[0%G>2`3:>W-:D/J.D[@W'.]AFA(VA,4,=P'5&>0]7YHFR'B M`;+-![EIL6>EX_JYU+Z$L]*\1%)T.;]Q[O7M=1INQ6+'6C*GYWK7)2\&8=AA(,\K M<;T#\E?+JRTE@FGS4\3K5I`5%B7UA'R'ECX-U8A=P\,N-/NIMG9\;A$W:C[` M[N@,'^,B]>9P1I0V*3W#91'\NJZL=;KMD?:D8L3VZF*/@K7:FL9KU&27"GN1 M]&F'T4,"S_*-C9H3H!TZW)U#*^5:9V%T#=<(\M*)T]M)\E)/89D6+H\O^V;7 MOA3%K[9=!?$`F:M008AEW:]0/:`-B1-L]%!'>H9^W-BXB(2;F$-([6J&%&;7?C8%9_,9"WC5#] MBB+Y`1QI$PV'I?CEIL!\'B,-B`A2OJGME39EYGKMV5T5^KGV%F.4AEW_HIZJ M=*/$1;(5?].RU\\8`'.Z>>,T[EUP#X$W2SG=K6!`UO.A?3^#.RJN[`OFP6SP M&!$00>1^GL#T7ZK0\-A9>XGC-\1>2`_P(._[$/D35$%FUM^Z6A(/D1-=D9H8 MFP=ELC22RE&9W;.*0S@KD]'$XD+CB`WO&*PSKOG)>!X+F,=^]P!U58#E7:1I M4"R&B"?!PG.0$K72G85+6`7G7U2X1'IR9,,EBK/=[IZ(GT-_$R1.M#WS?&2K MM_>#V6"-GS+=(:#YE&G1&*2MK6VQ0KY4#YJR!FFV'J9VR1#;LDF;@=V;ERR9 M+]R[E1K'9=:.I-QIB>"!Y4V/HD00&NA"95UM;GW//?-#)^E*7=$@397JU#`W MZZBT(2`M[14C<#E054R[HS)\6K>,B,BFW?+0SY`R;KLC$`1_!'DVQ45&=I1C M)X&+,.KL[HDJ4/,W1%7P-R\WTA3D;2W?.L%D1G7%U8?6ZAQC&5/O)8-6`C9W MXH-#@63ZC.1&:LDSR]FS&G_8N;/J6$WGW^6S(73+?SOK,/XV2XB`<9)$WNTF M=?R3$%PYU0"]G0N;9=(B38D0;>7\'OK^CT'X*9A")PX#Y#3&\09&7:EI'GCS M"IM#2;/JQIWV/^)>(.\&TGX6&UL550)``-@53Q.8%4\3G5X"P`!!"4.```$.0$``.U=;7/;N!'^ MWIG^!]7]TD[&L6PG<9));D9^R^GBV(HEQTD[G0Q-0A(3"M`!I&SEUQ?@BT5* M)$6``$'Z>%\N423LXMG%XL$"6+S[Q^YNYP.``!LNL#IWRXY]\B]W]N_.;N<$ MS>9#T^[TH4O_U73M!:"?P07`]._TWZ>N.W^[MW=_?__'OO7O%>6]X7-<'`!M(`5*0XR$R(< M1J\1CB0XQAUPWN]D-41Z=\1E"Y12='/52FQ8%=;-([L3PYA_?^1N(^-NW9XA M1/XB8&R0.W\E$/YPCRFZ!QR71)_XJN]V]\,%P3\S).SQHKC1#C4PZ-,_$J7: MKJ0DX8V[6@\G.V!@,]*)_G'#SY*KJ?`;>W.?Z>^:4]MY=-$Q1C,._W%1MD$1 MM@!^O[/_O"O'3X8F@`:V4>_!5FN`A*`P%%6+?_X8204]B4X2>S'<[&]B508J=<>0TP M6SY>H15?5FW%3P;^"5RV4A@"T\.V:P-RB:"I;KQMD5C_Z6P;9*$I7VF=V-3: M,%U031<%6]`)S754=G8KMVA6-[/I-4NN2V[.:J76:N7)QH5MW-F./Z)IA!ZZ MR/PY10Y5B+!H[2Y5IC8*R]8=(8NE/8I#*;YR2Z[.A3(B<34%TB)I/]5;`83)?6."I4!$'Q5,U&J"T=:Q4'V>8:,(&1 M>$9&DL5.T&QF!QL?;"L+0=>&$P!-11;,$]=@1IN+HG@:IQRMK39)D)\6T&?6 M`@Z>/(&R-1V@:<4YB"3Z*BK;FT\3H_LP"\]03(5)W'*E&0_S/P35VFQ#1I-& MW"9`,@Y,B"4"+,MF0!G.P+"M/CPQYC:=96,:*LD(;)>J=P!R&K0(BE*.6(BG M[KR9Y[#3Q3Z99M=G,9@"2.P%"&[V72!"+H%[-1X9#XJ20%PJ:*9&O`[`"[", MQ(*8+UP#U[`AL,X,#&F?2$SU4S"V35L)5RH@M5$CO@B*XDD'22N=31I1#0W6 MGPW?E4MNH-8R16V];("[8VV M]D9;>Z.MO=&6`WI[HZV]T5;K&VWQF9YVW;3]CM,_.\!'`%J]&<*N_>EL*2.OD*DY[E3A.U?*ZZMSL8;$FLS)W&8=A,V&3E-:?;L$^)59\M0 M6CVX';<1(ZSTI2'3M+KR7%;/T*++^JK,&!?94%LF4)-RT*GLKE^5A,]3L`UV`!H)=U.UC62:4U&?48O+D,9Q,7:0>W M!0V%EH;C+D.]E)@I*4'OD,CRRX2-UB#1L/,Q-!QP->ZS_1@3$')-<:)]9`7= M3JE6#DK9'<5:TGY2*-LJ!:&0LVST*8#$QYH=DU*SO)>K8(U]19%%M&V>^"JQ`4#"7BLJ$I8J1S<5 M*V+H=(!D5=X37\2H-UG=K)7GJ@G&F6<L=V16T5+G;AY.R!#7RUE#5;F&[[ M%:.O.6#IJ4>4'_%#+:N;4R.!>DGN5I?>/E<^(B>%_%9/JXA+^D'M`>L#1D1) M!DFN@IIIE02?$3:-KMI*OD;!LY4..PAGS6QHLUZS5RH5QHY"Z7J8]NMD:N") MFIH@J7)T6)V"E,0;CW)8=R5L6_UN31;\^W&1WU6%Z25VBLFIB8[ M*,5617%X9)46Y#*8/Q4'6H2NPW4B(.?G-=Y;R>MTB530VNZ*8*!;/=X1:*@H M'90F1L_0V>Z"\:&3"H^$-:>@K:C1J3H*J?^Z"%U4@M=*:\`(K-C>!!:"8,*. MFY0G$*P#EPBB9.Q5O6K+EM@,2VZ#35I!7"ZC9BI$_^)XEO]ISM#,?'*7MU7- MZ[1"+LVL*8"7Q#2[:'"-N-$Y[750ML6CFJX.FQV#,<)A#9Z1\0#()QLB[+\O M''2&+DZ3K005(3X!=XHLQ8^(5:E^(X[-5VI/C56!'_4/A](Q@&"LIO12EJB& MG-[.1$I[Z=_MOJHG9#1B=5L$/`G79"08]M0F9J`>L%;:1:7<>JZ+[3O/?X)J MA*[!G%U[AY,S_PE[]?8OHURC`H`4:TA\7DK,LZB>:I-=20$-L?`:*N(WX&JXUBM[,:@BPVIZ>8"'IH5QC1Q!VEU+#9693@PR/7?0_0ZW.\:+YD2M\&41\ELH7\NHK;J4)47; MQ%S(:8H76FJK++55EMHJ2W7H3'55EA[#!DN4/-X^Z)FNO0@>3N(J`UBTL=IX M32J%*8Z)O(I+[=&"W/*"G%ZZ_:"!CL.=-2/:D\G*G*(W+.* M`JD+NBB^0$IYI[UPPL/-#/_HZYJV@Y89>*R-!XAZL(,E!O"J@@/,%K8=*5[ MO"P[\5>J4*/B2[6FDG5'42CXQ%^%6GL,2D74R1.G*4.F8US&8U:N!71=A8QK M<34^MZ%!48$3OWJ+"K_(E:ETCQ"Z7)O-#1O[Q9_4E6/9(E%7AD*W8VPSA)Q*/4(^ M\L&P(0/B"M+EV1P1.XAET4.3*IQDFT@MV6?=+K+5#@)7++.N]`LYRB<#_P3^ MZGP(3`_['8J45N$EN?+^LHPCWPH"%SDEEWV@*&!`9\!3$/R_#Q\[>&+,;==P M%.5*MDEM9*YD*Y2E@$(PB6/T+-7/AWX>$IWJ\J=E=1(\U&0XF-H+2-?R@IR M4OB";[$54SP]@:S"@>FB16*"HU)Y[4)Q$ MTIY[7F,-VG//Q41:=7CA1ZR1"8`5[A/ZBKH>!E?C8X_0GA%%%4B+B-5E8EZ' M3KYN70!.7;GK@;$,%U`]\T_/QB!:Y`X<`[*B0ZS,4,H+2I),7ERZIF!=RO`< MV$HM$EA^V`'X\?O6C^^?!E??ZC]&#=69.#EXO M]]&OP1^GI_?F\<3\W'MI6;??+@Z>#6]?@,6SA]?N'O[\\O?+,?WH^L?5*Y,< M@NGMIXN%TWUU0N#BV?!+M_]U^?/5A_.'"P(&P^'9Y//+K^;UU]>'%T/GVIS= MD-O1`,Y/OUY.[OY\V+^]/AQ>_[2(>]C_-K5OR/\Z M)\/KW5TY$R>S,#7I)X,5L':75^.T;%$5XVB[$C5(QY0<2@6`UEF`?V,BJ,P7 M"@E^"E-KKM&EI>0D+XE3.JTY*U=4(\U+9ZX!56#U7-@0^EYX*JBVWK1<<86T MIN6$W:>D$?347>#W?;T!YR\07&2FYL033$D:3DY@+ M/?,)ZPM%-86"FL+A=6B,]45"GMM?*(M.?;,].W>Y.OO-MO(` M=NG@'&&#G;KR2\GYI_X=1#PL2*R4*U$Z5]#RK]KQKZH\EX>JM42M)6HM4:M# M9ZHG:JKBD0IO5*9K0S;RU-FJH=N!`7OD\GL&6UGBMZV-EK<]/=Y6T&]:VE6/ M:;*E72WMJC/MR@@G*IPI2U1#2$\F4LWE+%WN<]?^521V91!@$O`\UE99'L/? M:GO&Z0E2&V'G:H\\U6%J:JE.2W7J3'4*AQK&P"!E,`B;T`JT=269-BO(BKP982/4%*).)2+1NJP^S5LJ&6#=69#:5$ MED144>%56V4VXGCX=N0:>EI\17O$:D,.O?G<\?$SG!49%+R9S]UH>U#\B5(@ M0>]JSXC79>IJJ5!+A6I-A0I&&"64J*CLVCA;/C1RLKI,TA/4$")LMJU?IUR, M(&UOI.3"=J.#.DJ'"G;&&U<:?R=Z3Y`#E7.S]HAW'>:P MEA.UG*C.G(@OQJCP,4X-ZC'P MG]FJGBC$8P+FYMF@E#Q3S1J.E!G1[Y5'.=&:EL@A`FX2@[4PSXWHB8>9<2 MUX!6[E.M?)$D5T:C[%$$L]`R+\I:9N#=.;9Y[B##E66(>).-B3@I:(00OQ0- M.SVJ@\7T.'<,"5Z>;$[3V2X1:-=P"&%])43:$^V=`F)B>^Z3+GGPQEMM#AU) M!R7$^J@$'0F#$6T9&TZ?DN2'CV`I+6:O-:MK35TB2J\#$T+^6B#!$6LUF)&O MP1QAMG1BJRXO)[?$B7IZZPT**?DHA29X(QQA@N:_(,>C$.#EN>T`+`W]]6:; MY_,;P$2KGJ[H5!FTZS=W0HGG!&%I(2;9:`-YX!HJ$=9EEIA!P[?`<3Y"=`^' MP"`(`JM/B`>P+."SFF^@"3*1BHQQ(&&]/P#81I:TI6EZLTT*-AG`1)@?B@:; MJ-W5>O>`L``00E#@``!#D!``#M7&US MVCH6_KXS^Q]TV9F==C(4`TE(V"8SA)>$E@`!\K9W[G2$+4")D5Q))I!?OY*- MP8!M3)IVO+?TRRV2CO2<\QQ)1\?G]O,?Z32X1`0Q*)`!^C.`RQ_$^"-(@S(= M6UT=@SH1LE<7>()D&YD@)G_+_I$05C&3>7EY^:3+H5S'#'%J,QUQU0#2Z7.@ M_OSS'Y_5(F6&U!)%T!O9H&0/@78(M$(QJQ4/"^"V5P8Y+9MUA:3$E!>Y/D)C M"*9CD_#BM,],?);RK:E:/E$VS.0T+9_!A`M(=)2:CR?V.'BT(5A&S"R4D2,0 MPWH*",B&2#3A&'$+ZFA%#)%72I0V&85..\YKW@*RA\0<.N4K`U_R'NQLYN&Z MT7747."F)`9T2M(+^*Z M9IQ>;^C&R%7SJ^X^Y-+\R$1C1$2-LG$%#:!MBK/4=QN:>("1D?*Q:8C%?/ZY MCC)N9\KQ`P"4)T!"J(`"4W(.W-9YNV5A,J#G7IML54"*'IH.&@!'BZ*RP%F* MX[%E*A=QVD8,#TQ]@W$_8_28C>$,AT1DT4;:*,Q:@E-P66-E[:P9U@ M0WK5;*H[(]=$9F,).94Y?S=]+(9^N3YR32X]P.%K3:WW(\I`@U^NF%P3$QR@ MUGLII4/SERLEU]1M,Y"L5;74Z)Y4!*B_W';J(8>?,ZF\)C@UL:$._`MHJH.Y M.T)(I``V7*6_A0[Q>XFW]M+RY_+4E'=/5[J7<\ZH>ZK5[+8:]4JI5ZV`BU*C MU"Q70?>J6NUU/V?6Q4'`[#9'1HN<.W]?=][Y#/,AT;*K_K$NN67A-1[6I!=4 M9%:XV-Q1[\'2MS9DT@8C)+!$Q6.0MBZQE<-00%M='!6Z0%>KR4=1U>_(_U]6FI*U5`ZUVM5/JU>6`_4:,2UL9\E'-I"\A M?"VZ@Q598>IPC:E53LF7&9:5*!?$PX/[<>;D?2UA7,=9-R MFR'U`W&=84MU`SH`%S;'!'&^MWNDW;4UPVMQ?/YXW?87D&.NK-[VF6]_'&TU M_H;UM52`FBNV+ZS;OH:)#!$P-$%=/L^9KD_LSZ=MO`00HYB) MI.5TG18ER$$;SI3Y]S;?:O,@HVM;;^6LMK$=!-6?1]0T$./__M=)+EOX#ZA^ MM[&8[<^D6#P$$A'GEE9YWE4N5*Z9H1$B7&69/S0HYQ^!^S8))F//Q@8;P71L MO;:SN8V-85N6F\65-[=Z<`#UXI!T#"@;A\9/?S="G(\6?]Y?W^7_^O-!M^SI M(SDZ-5X+D^'CC-Q6[)?+`CLM?,T]W?9FW"Q,]%?-_"(.7FD5U_\[%E;N:Z'; M*+2SEQ58J$WPD-6R3UK]Z)#<]5Z>"@>#2?MZENL2PVKW!Q:9S=I4;][G7PDJ]=#(Z?M.^YEGWRI3E M(\.X?VSD#KKWAVAR,#T1&79S=-4FUB5 MAVN];+&#I]/'\O1R5FK?]6F_4(-_@7*W,__>\RZN'.++,<*>;'[#G:&,:N0# MH$[2;49U^?`"'>F.D.DC)_:IH`DRJ:7\?7_[QB(GC)UML4_V<)V;*F0$DZ$, M?Q!3E\!8OI"[(\B"3_T]%P%P+WE1ID3(XTHEN1L8]K&YSUY$,U2ANI.+*Q&C*DTG9K[0 MWB4K?.:N>I<*J%7BI+Z-F.Y M+86QL%7O):.VY2V"Y?0Q"BJ6$-?,NJ:AS51I1(GS9&D5"&M>*!6JA>_N3IPJ M0=C"]?&1NOC^SEN#EH5<.$G2+S[6B)VF4BRM09W,\RM>>D7>][[DRJJR\J6/ M!&2S('4'T.1;]'7[^NZ6.4OI#!E8O-T,\13(G(=O1;>&VI02)6,L(PREBRJ9 MKD[5XPVI&%4I)ZV,V`3+17ZF.0S4_Q%K[*Z+_YY>M4M+C!!S7T]S\>0X?P2V MT,W=I(2Z>T.B]8O*'Z9M.*T"R0!5S-N3[/:[*Q-Q"'BY//7QIHV8F\US$AGN M`\V6G4D\`M^(.]SEO0E7)U-/(G<^^5I(L!EV0OTF=V@BH1I=ATN>`>("CKH/ M?3>I5[&7(*JCX84[]F)LC=%QRSLX2NI_#4I:V!87:=257C*>['F13(]VD-P' M.C;1TA/4W$%'1(]*AU$(;KDJL)4QQ00;,KZ?)=IDOU3;Z%>-GSRW4BFA-HN- M-,K-5B:9E\S]'Z@;A31*W284-D/^%T8/3<6%2?7GY&@:!V24DD[5:6M0TG5J M.\GI!.H8`V/X5:`*.)WZS8N9/V_AK*>F4H`2J//;8$>>5KY2RCJIH+[*F2_+ M*=V"LF5-I>PL(R8@)CT&58#M)DF6^?($&NVG:QCZV%*+)=HTVP"&:N8O/G0M MJ#Z-)5K7W2%'1)+^>C\WOE"1AIHP@9KOA'9[^.ROKUN:+XG7X,Z((T]*-\F& MHY-LR=X"/ZI!N'/$RD`&3.T9Q?V'`XK":W]C@NFG)E"#X(>>D+Y\A/,(3Z`[ M;(<8N1]6BJVDI3K(5&GX93R=Z+WP0^BC8N>E7&O@KWV:+U"F7'#'W$YY5!O. MW#=K\BST7HJ$;A'W*NK!::(=)1;*B(]IBV(?%5EZI3YZTK?'&W&'7Q!1)3G) M43L62H=LI_#%_>SO)E+_!U!+`0(>`Q0````(`"*%!3^6\*:#J5\``%F9!@`1 M`!@```````$```"D@0````!E;GIN+3(P,3$P-C,P+GAM;%54!0`#8%4\3G5X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`"*%!3_TO.G!:@H``"IR```5`!@` M``````$```"D@?1?``!E;GIN+3(P,3$P-C,P7V-A;"YX;6Q55`4``V!5/$YU M>`L``00E#@``!#D!``!02P$"'@,4````"``BA04_O4X?5`(4``#95`$`%0`8 M```````!````I(&M:@``96YZ;BTR,#$Q,#8S,%]D968N>&UL550%``-@53Q. M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`(H4%/Q(#^LD`)P``/.D!`!4` M&````````0```*2!_GX``&5N>FXM,C`Q,3`V,S!?;&%B+GAM;%54!0`#8%4\ M3G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`"*%!3]S=<=UWQ4``&6'`0`5 M`!@```````$```"D@4VF``!E;GIN+3(P,3$P-C,P7W!R92YX;6Q55`4``V!5 M/$YU>`L``00E#@``!#D!``!02P$"'@,4````"``BA04_KR`9MV4)``"+2``` M$0`8```````!````I(%[O```96YZ;BTR,#$Q,#8S,"YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``*\8````` ` end XML 27 R10.htm IDEA: XBRL DOCUMENT v2.3.0.11

Notes Payable
3 Months Ended

Jun. 30, 2011

Debt Disclosure [Text Block]
(5) Notes Payable

 The 4% convertible senior notes mature on June 1, 2013 unless earlier redeemed, repurchased or converted. The 4% notes are senior unsecured obligations and rank equal to all future senior unsecured debt of the Company. The 4% notes are convertible at the option of the holders into the Company’s common stock at a conversion price of $9.55 per share (104.712 shares per $1,000 of principal amount). If the closing price of the Company’s common stock for at least 20 trading days in the 30-consecutive-trading-day period ending on the date one day prior to the date of a notice of redemption is greater than 140 percent of the applicable conversion price on the date of such notice, the Company, at its option, may redeem the 4% notes in whole or in part, at a redemption price in cash equal to 100 percent of the principal amount of the 4% notes to be redeemed, plus accrued and unpaid interest, if any, to the redemption date. Upon occurrence of a “fundamental change,” as defined in the indenture governing the 4% notes, holders of the notes may require the Company to redeem the notes at a price equal to 100 percent of the principal amount plus accrued and unpaid interest or, in certain cases, to convert the notes at an increased conversion rate based on the price paid per share of the Company’s common stock in the transaction constituting the fundamental change.

 During the first quarter of 2010, notes totaling $115.6 million principal amount were converted into approximately 13.5 million shares of the Company’s common stock, reducing the outstanding principal balance of the notes outstanding to $134.5 million. The net effect of forgone interest and the write-off of deferred debt issuance costs amounted to $0.8 million and was charged to interest expense during the first quarter of 2010 at the time of the notes conversion. The $0.8 million was adjusted in the fourth quarter of 2010 to credit interest expense and charge additional paid-in capital to reflect the capital nature of the transaction. The noncash adjustment was not material to the first or fourth quarters nor to the full year 2010 results of operations.

 Interest on the 4% notes is payable on June 1 and December 1 of each year. Accrued interest amounted to $0.4 million as of June 30, 2011 and December 31, 2010.

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20,22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19, 20, 22
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 29 R18.htm IDEA: XBRL DOCUMENT v2.3.0.11

Income Taxes
3 Months Ended

Jun. 30, 2011

Income Tax Disclosure [Text Block]
(13) Income Taxes

 During the three and six months ended June 30, 2011, the Company recorded $5,000 of income tax expense related to the Canadian subsidiary. During the three and six months ended June 30, 2010, the Company recorded a net income tax benefit of $0.2 million consisting principally of a Canadian transfer pricing refund. The Company did not recognize a U.S. Federal income tax provision for the first half of 2011 or 2010 because the estimated annual effective tax rate was zero. The sale of the specialty pharmaceutical business in January 2010, including the sale of in-process research and development, was a taxable transaction for federal income tax purposes, although it resulted in no federal income tax liability due to the tax basis the Company had in divested assets and the net operating loss generated in 2010. As of June 30, 2011, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not its deferred tax assets will not be realized.

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R11.htm IDEA: XBRL DOCUMENT v2.3.0.11

Stockholders’ Equity
3 Months Ended

Jun. 30, 2011

Stockholders' Equity Note Disclosure [Text Block]
(6) Stockholders’ Equity

 On December 21, 2010, the Company announced a share repurchase program, under which the Company may use up to $200.0 million to purchase the Company’s outstanding common shares. Transactions in the Company’s stock are recorded on a settlement date basis. During the three months ended June 30, 2011, the Company repurchased and retired 5,125,169 shares at a cost of $54.8 million, or an average cost per share of approximately $10.69. This brings the cumulative number of shares repurchased and retired under this program through June 30, 2011 to 9,008,242 shares at a total cost of $96.7 million. The plan continues to be in effect.

X

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph d

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7, 11A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R5.htm IDEA: XBRL DOCUMENT v2.3.0.11

STATEMENTS OF CASH FLOWS (USD $)
In Thousands
6 Months Ended

Jun. 30, 2011

Jun. 30, 2010

Cash flows from operating activities:

Net (loss) income $ (6,637) $ 194,185

Income and gain from discontinued operations 0 179,002

(Loss) income from continuing operations (6,637) 15,183

Adjustments to reconcile (loss) income from continuing operations to net cash (used in) provided by operating activities:

Depreciation 2,555 2,858

Amortization and write-off of debt issuance costs 269 1,851

Share-based compensation 1,965 4,737

Write-down of property and equipment 0 895

Loss on disposal of fixed assets 61 0

Gain on sale of marketable securities (80) (128)

Changes in operating assets and liabilities (3,127) 14,625

Net cash (used in) provided by operating activities of continuing operations (4,994) 40,021

Net cash provided by operating activities of discontinued operations 0 436

Net cash (used in) provided by operating activities (4,994) 40,457

Cash flows from investing activities:

Proceeds from sale of business, net 0 262,608

Purchases of property and equipment (530) (397)

Proceeds from sales of fixed assets 4 0

Proceeds from sales and maturities of marketable securities 18,043 44,034

Purchases of marketable securities (759) (1,544)

Net cash provided by investing activities of continuing operations 16,758 304,701

Net cash used in investing activities of discontinued operations 0 (105)

Net cash provided by investing activities 16,758 304,596

Cash flows from financing activities:

Repurchases of common stock (96,054) (18,136)

Proceeds from issuance of common stock 5,563 25,289

Withholding taxes – share-based compensation (894) (3,328)

Redemptions from employee stock purchase plan, net (42) (138)

Net cash (used in) provided by financing activities (91,427) 3,687

Net (decrease) increase in cash and cash equivalents (79,663) 348,740

Cash and cash equivalents at beginning of period 397,530 ^[1] 50,440

Cash and cash equivalents at end of period $ 317,867 $ 399,180

[1] Condensed from audited financial statements.

X

- Details

Name: enzn_AdjustmentsToReconcileLossIncomeFromContinuingOperationsToNetCashUsedInProvidedByOperatingActivitiesAbstract

Namespace Prefix: enzn

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: enzn_CashFlowsFromFinancingActivitiesAbstract

Namespace Prefix: enzn

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: enzn_CashFlowsFromInvestingActivitiesAbstract

Namespace Prefix: enzn

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: enzn_CashFlowsFromOperatingActivitiesAbstract

Namespace Prefix: enzn

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The component of interest expense comprised of the periodic charge against earnings over the life of the financing arrangement to which such costs relate. Alternate captions include Noncash Interest Expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 8

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 8
-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents cash provided by or used in the investing activities of the entity's discontinued operations during the period. This element is only used by those entities that separately report cash flows attributable to discontinued operations. If using this element, it is an indication that the cash flows of the entity which are detailed in reconciling to cash provided by or used in investing activities reflect only cash flows attributable to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents cash provided by or used in the operating activities of the entity's discontinued operations during the period. This element is only used by those entities that separately report cash flows attributable to discontinued operations. If using this element, it is an indication that the cash flows of the entity which are detailed in reconciling to cash provided by or used in operating activities reflect only cash flows attributable to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The gains (losses) included in results of operations resulting from the sale or disposal of property, plant and equipment, which do not qualify for treatment as discontinued operations. This item does not include any gain (loss) recognized on the sale of oil and gas property or timber property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6390789&loc=d3e2443-110228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 37, 41, 42, 43, 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_GainLossOnDispositionOfProperty

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the parent which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 29
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4613673-111683

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph b(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.13)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the overall income (loss) from a disposal group apportioned to the parent that is classified as a component of the entity, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount which may be allocable to noncontrolling interests, if any. Includes the following (net of tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 29
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph b(2)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapital

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(c))
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27405-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(c)-(e)
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 7

+ Details

Name: us-gaap_MarketableSecuritiesGainLoss

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash from (used in) the entity's investing activities specifically EXCLUDING the cash flows derived by the entity from its discontinued operations, if any. This element is only to be used when the entity reports its cash flows attributable to discontinued operations separately from the cash flow provided by or used in investing activities. Such reporting would necessitate the entity to use the Net Cash provided by or used in Discontinued Operations, Total element provided in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-Footnote 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) the entity's continuing operations. This element specifically EXCLUDES the cash flows derived by the entity from its discontinued operations, if any. This element is only to be used when the entity reports its cash flows attributable to discontinued operations separately from the cash flow provided by or used in operating activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-Footnote 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire common stock during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 20
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow paid by the company to cover an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.

+ Details

Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15, 16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromDivestitureOfBusinesses

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph i
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 19
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 16
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 16
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 16
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from the stock plan during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 19
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromStockPlans

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

+ Details

Name: us-gaap_TangibleAssetImpairmentCharges

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 32 R7.htm IDEA: XBRL DOCUMENT v2.3.0.11

Basis of Presentation
3 Months Ended

Jun. 30, 2011

Basis of Accounting [Text Block]
(2) Basis of Presentation

Interim Financial Statements
 The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and Rule 10-01 of the U.S. Securities and Exchange Commission Regulation S-X. Accordingly, these financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the year. Interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010.

Principles of Consolidation
 The condensed consolidated financial statements include those of Enzon Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.

Use of Estimates
 The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include the valuation of certain investments, long-lived assets, legal and contractual contingencies and assumptions used in the calculation of share-based compensation and income taxes. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience, the current economic environment and other factors that management believes to be reasonable under the circumstances. Management adjusts such estimates and assumptions when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in estimates will be reflected in the financial statements in future periods. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in these financial statements.

Reclassifications
 Certain prior-period amounts have been reclassified to conform to the current period presentation. In 2010, cash flows from discontinued operations were previously included in continuing operations within cash flows from operating and investing activities. The Company has made the appropriate reclassification to the current period presentation of the prior period statement of cash flows. There is no change in either the net cash provided by operating activities or the net cash provided by investing activities to the prior period statement of cash flows, and the reclassification between continuing and discontinued operations in the prior period is not deemed material.

X

- Definition

The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R16.htm IDEA: XBRL DOCUMENT v2.3.0.11

Restructurings
3 Months Ended

Jun. 30, 2011

Restructuring and Related Activities Disclosure [Text Block]
(11) Restructurings

 During the second quarter of 2011, the Company recorded a restructuring charge in the amount of $0.7 million for severance payments and benefits related to the departure of the Company’s Executive Vice President, Human Resources & Administration that are payable under the terms of the Severance and Release Agreement. This amount was partially offset by the reversal of an unused restructuring accrual of approximately $61,000 for outplacement services and benefits for former employees. As of June 30, 2011, the entire $0.7 million was included in accrued expenses under current liabilities.

 During the first quarter of 2011, the Company recorded a restructuring charge in the amount of $0.4 million related to the excess of committed lease costs over potential sublease income for office space in Bridgewater, New Jersey that was vacated during the quarter when the Company relocated its corporate offices to Piscataway, New Jersey.

 A fourth quarter 2010 workforce reduction resulted in an expense of $3.0 million for separation benefits. The affected employees were notified in December 2010, and the majority of the terminations occurred during the first quarter of 2011. Separation payments will be made for up to a year following the respective separations. As of December 31, 2010, the full $3.0 million was an accrued expense, of which $2.7 million was reported as a current liability. The Company made separation payments of $0.4 million and $1.0 million during the first and second quarters of 2011, respectively. As of June 30, 2011, there is $1.6 million remaining in accrued expenses under current liabilities.

 During the first quarter of 2010, the Company’s workforce reduction involved 64 employees and resulted in an expense of $6.1 million for separation benefits. These actions related primarily to the sale of the specialty pharmaceutical business and affected employees who were previously engaged in activities related to the divested business but who did not transfer to the employment of the purchaser. These employees were provided with separation benefits after certain transition periods, during which they assisted with an orderly transfer of activities and information to the purchaser. In addition, the Company reassessed its staffing requirements subsequent to the sale in light of the lessened demands on many of its general and administrative functions. As of June 30, 2011, all of the required separation payments have essentially been completed.

 Effective February 22, 2010, the Company’s then President and Chief Executive Officer resigned from the Company. For the quarter ended March 31, 2010, the Company expensed $3.8 million for severance payments and benefits that were payable under the terms of this individual’s employment agreement. This amount was reduced during the quarter ended June 30, 2010 by approximately $0.2 million once the termination agreement was executed. Payments due pursuant to the termination agreement were made during the third quarter of 2010.

X

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4)
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
-Paragraph 20
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140864-122747

+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R2.htm IDEA: XBRL DOCUMENT v2.3.0.11

CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands

Jun. 30, 2011

Dec. 31, 2010

ASSETS

Cash and cash equivalents $ 317,867 $ 397,530 ^[1]

Short-term investments 41,083 31,170 ^[1]

Other current assets 4,189 5,916 ^[1]

Total current assets 363,139 434,616 ^[1]

Property and equipment, net of accumulated depreciation of $39,983 at June 30, 2011 and $38,286 at December 31, 2010 19,485 21,574 ^[1]

Marketable securities 3,316 31,394 ^[1]

Other assets 759 1,273 ^[1]

Total assets 386,699 488,857 ^[1]

LIABILITIES AND STOCKHOLDERS’ EQUITY

Accounts payable 1,430 4,192 ^[1]

Accrued expenses and other 11,050 14,195 ^[1]

Total current liabilities 12,480 18,387 ^[1]

Notes payable 134,499 134,499 ^[1]

Other liabilities 4,266 4,114 ^[1]

Total liabilities 151,245 157,000 ^[1]

Commitments and contingencies

Stockholders’ equity:

Preferred stock - $.01 par value, authorized 3,000,000 shares; no shares issued and outstanding at June 30, 2011 and December 31, 2010 0 0 ^[1]

Common stock - $.01 par value, authorized 170,000,000 shares; issued and outstanding 50,631,943 shares at June 30, 2011 and 58,817,561 shares at December 31, 2010 506 588 ^[1]

Additional paid-in capital 365,331 454,657 ^[1]

Accumulated other comprehensive income 556 914 ^[1]

Accumulated deficit (130,939) (124,302) ^[1]

Total stockholders’ equity 235,454 331,857 ^[1]

Total liabilities and stockholders’ equity $ 386,699 $ 488,857 ^[1]

[1] Condensed from audited financial statements.

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19
-Subparagraph a
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14, 17, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.30(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 12

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Topic 210
-SubTopic 10
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
-Section S99
-Name Accounting Standards Codification
-Publisher FASB
-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Concepts (CON)
-Number 6
-Paragraph 25
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 18
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.18)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Section 45
-SubTopic 10
-Topic 210
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765
-Publisher FASB
-Name Accounting Standards Codification
-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 9
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 17
-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 19

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 25
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 32
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.32)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 25

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 21
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total debt and equity financial instruments including: (1) securities held-to-maturity and (2) securities available-for-sale that will be held for the long-term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 17
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

+ Details

Name: us-gaap_MarketableSecuritiesNoncurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 8
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 17
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 24
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 02
-Paragraph 29

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 8

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph a
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 12
-Paragraph 5
-Subparagraph b, c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 1
-Subparagraph g

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A3
-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.11 Html 9 111 1 true 0 0 false 3 true false R1.htm 000 - Disclosure - Document And Entity Information Sheet http://www.enzon.com/role/DocumentAndEntityInformation Document And Entity Information false false R2.htm 001 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.enzon.com/role/ConsolidatedBalanceSheet CONSOLIDATED BALANCE SHEETS false false R3.htm 002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.enzon.com/role/ConsolidatedBalanceSheet_Parentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) false false R4.htm 003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.enzon.com/role/ConsolidatedIncomeStatement CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 004 - Statement - STATEMENTS OF CASH FLOWS Sheet http://www.enzon.com/role/ConsolidatedCashFlow STATEMENTS OF CASH FLOWS false false R6.htm 005 - Disclosure - Description of Business Sheet http://www.enzon.com/role/Note Description of Business false false R7.htm 006 - Disclosure - Basis of Presentation Sheet http://www.enzon.com/role/Note0 Basis of Presentation false false R8.htm 007 - Disclosure - Financial Instruments and Fair Value Sheet http://www.enzon.com/role/Note00 Financial Instruments and Fair Value false false R9.htm 008 - Disclosure - Short-term Investments and Marketable Securities Sheet http://www.enzon.com/role/Note000 Short-term Investments and Marketable Securities false false R10.htm 009 - Disclosure - Notes Payable Notes http://www.enzon.com/role/Note0000 Notes Payable false false R11.htm 010 - Disclosure - Stockholders’ Equity Sheet http://www.enzon.com/role/Note00000 Stockholders’ Equity false false R12.htm 011 - Disclosure - Comprehensive (Loss) Income Sheet http://www.enzon.com/role/Note000000 Comprehensive (Loss) Income false false R13.htm 012 - Disclosure - Supplemental Cash Flow Information Sheet http://www.enzon.com/role/Note0000000 Supplemental Cash Flow Information false false R14.htm 013 - Disclosure - Sale of In-Process Research and Development Sheet http://www.enzon.com/role/Note00000000 Sale of In-Process Research and Development false false R15.htm 014 - Disclosure - Earnings Per Common Share Sheet http://www.enzon.com/role/Note000000000 Earnings Per Common Share false false R16.htm 015 - Disclosure - Restructurings Sheet http://www.enzon.com/role/Note0000000000 Restructurings false false R17.htm 016 - Disclosure - Share-Based Compensation Sheet http://www.enzon.com/role/Note00000000000 Share-Based Compensation false false R18.htm 017 - Disclosure - Income Taxes Sheet http://www.enzon.com/role/Note000000000000 Income Taxes false false R19.htm 018 - Disclosure - Commitments and Contingent Liabilities Sheet http://www.enzon.com/role/Note0000000000000 Commitments and Contingent Liabilities false false All Reports Book All Reports Element us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare had a mix of decimals attribute values: 2 0. Element us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare had a mix of decimals attribute values: 2 0. Process Flow-Through: 001 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: 002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Process Flow-Through: 003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 004 - Statement - STATEMENTS OF CASH FLOWS enzn-20110630.xml enzn-20110630.xsd enzn-20110630_cal.xml enzn-20110630_def.xml enzn-20110630_lab.xml enzn-20110630_pre.xml true true EXCEL 36 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]D,V$S9#4V85]D.64V7S0Q,V-?.3EE-5\U.64Y M-F$R,S@X,&(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K M#I7;W)K#I7 M;W)K#I%>&-E;%=O3PO>#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I7;W)K M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG M96YT7TQI83PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE M#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T M#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\ M8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@ M36EC'1087)T7V0S83-D-39A7V0Y939?-#$S M8U\Y.64U7S4Y93DV83(S.#@P8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO M+R]#.B]D,V$S9#4V85]D.64V7S0Q,V-?.3EE-5\U.64Y-F$R,S@X,&(O5V]R M:W-H965T'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^14Y:3TX@4$A!4DU!0T555$E#04Q3($E.0SQS<&%N/CPO'0^,3`M43QS<&%N/CPO M'0^+2TQ,BTS,3QS<&%N/CPO'0^9F%L2!#96YT3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,#'0^665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^3F\\2!&:6QE M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^06-C M96QE2!796QL+6MN;W=N(%-E87-O;F5D($ES M'0^3F\\'0^2G5N(#,P+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q,3QS<&%N M/CPO'0^43(\'1087)T7V0S83-D-39A7V0Y939?-#$S8U\Y.64U7S4Y93DV83(S.#@P M8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D,V$S9#4V85]D.64V M7S0Q,V-?.3EE-5\U.64Y-F$R,S@X,&(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!A M;F0@97%U:7!M96YT+"!N970@;V8@86-C=6UU;&%T960@9&5P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYBF5D(#,L,#`P+#`P,"!S:&%R97,[ M(&YO('-H87)E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'1087)T7V0S83-D-39A M7V0Y939?-#$S8U\Y.64U7S4Y93DV83(S.#@P8@T*0V]N=&5N="U,;V-A=&EO M;CH@9FEL93HO+R]#.B]D,V$S9#4V85]D.64V7S0Q,V-?.3EE-5\U.64Y-F$R M,S@X,&(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!A;F0@97%U:7!M96YT M("AI;B!$;VQL87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D M('-H87)E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q M+#`V,BD\"!E>'!E;G-E M("AB96YE9FET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S"!E>'!E;G-E("AB M96YE9FET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S#PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,V$S9#4V85]D.64V7S0Q M,V-?.3EE-5\U.64Y-F$R,S@X,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO9#-A,V0U-F%?9#EE-E\T,3-C7SDY935?-3EE.39A,C,X.#!B+U=O M'0O:'1M M;#L@8VAAF%T:6]N(&%N9"!W2!A;F0@97%U:7!M96YT/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S&5D M(&%S2!O<&5R871I;F<@86-T:79I=&EE M2!O<&5R871I M;F<@86-T:79I=&EE'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5S(.*`DR!S:&%R92UB87-E M9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA65E('-T;V-K('!U2!F:6YA;F-I;F<@86-T:79I=&EE7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA3X-"B`-"B`@("`@(#QF;VYT('-I>F4],T0R/CQB/B@Q M*2!$97-C3X-"B`-"B`@("`@(#QF;VYT M('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.T5N>F]N#0H@("`-"B`@("`@(%!H M87)M86-E=71I8V%L2D-"B`@(`T*("`@("`@:7,@82!B:6]T96-H;F]L;V=Y M(&-O;7!A;GD@9&5D:6-A=&5D('1O('1H92!R97-E87)C:"!A;F0-"B`@(`T* M("`@("`@9&5V96QO<&UE;G0@;V8@:6YN;W9A=&EV92!T:&5R87!E=71I8W,@ M9F]R(&-A;F-E6%L='D@F5D(%!% M1WEL871I;VX@3&EN:V5R(%1E8VAN;VQO9WD@*$-U28C,30T*("`@#0H@("`@("!-97)C M:R`F86UP.R!#;RXL($EN8RX@5&AE($-O;7!A;GD@;W!E28C M.#(Q-SMS(%!R:6YC:7!A;"!%>&5C=71I=F4@3V9F:6-E<@T*("`-"B`@("`@ M("AC:&EE9B!O<&5R871I;F<@9&5C:7-I;VX@;6%K97(I(')E=FEE=W,@=&AE M($-O;7!A;GDF(S@R,3<[3X-"B`-"B`@ M("`@(#QF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U1H90T*(`T*("`@ M("`@0V]M<&%N>28C.#(Q-SMS('!I<&5L:6YE(&1R=6<@9&5V96QO<&UE;G0@ M<')O9W)A;7,@=71I;&EZ92!T=V\-"B`@(`T*("`@("`@<&QA=&9O2!A;F0-"B`-"B`@ M("`@('1H:7)D+6=E;F5R871I;VX@;65S2X- M"B`@("`@#0H@("`@("!4:&4@0V]M<&%N>2!C=7)R96YT;'D@:&%S(&9O=7(@ M8V]M<&]U;F1S(&EN(&-L:6YI8V%L#0H@("`@#0H@("`@("!D979E;&]P;65N M=#H@4$5'+5-.,S@@86YD('1H92!(>7!O>&EA+4EN9'5C:6)L90T*("`@(`T* M("`@("`@1F%C=&]R+3$F(SDT-3L@*$A)1BTQ)B,Y-#4[*2P@4W5R=FEV:6X@ M86YD($%N9')O9V5N(%)E8V5P=&]R#0H@("`@(`T*("`@("`@*$%2*2!M97-S M96YG97(@4DY!("AM4DY!*2!A;G1A9V]N:7-T0T*("`@("`-"B`@("`@('!H M87)M86-E=71I8V%L(&)U28C.#(Q-SMS('!R;V1U8W1S M(&%N9"!C;VYT6%L=&EE3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]D,V$S9#4V85]D.64V7S0Q,V-?.3EE-5\U.64Y M-F$R,S@X,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#-A,V0U M-F%?9#EE-E\T,3-C7SDY935?-3EE.39A,C,X.#!B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'`@86QI9VX] M,T1J=7-T:69Y/@T*("`@("`-"B`@("`@(#QF;VYT('-I>F4],T0R/CQB/B@R M*2!"87-I6EN9R!U;F%U9&ET960@8V]N9&5N28C.#(Q-SMS($%N;G5A;`T* M("`-"B`@("`@(%)E<&]R="!O;B!&;W)M(#$P+4L@9F]R('1H92!Y96%R(&5N M9&5D($1E8V5M8F5R(#,Q+`T*("`@#0H@("`@("`R,#$P+CPO9F]N=#X-"B`@ M("`@#0H@("`@/"]P/CQB'!E2!F2!H87,@;6%D92!T:&4@87!P2!I;G9E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,V$S9#4V85]D.64V M7S0Q,V-?.3EE-5\U.64Y-F$R,S@X,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO9#-A,V0U-F%?9#EE-E\T,3-C7SDY935?-3EE.39A,C,X.#!B M+U=O'0O M:'1M;#L@8VAA2!"86QA;F-E(%-H965T($=R;W5P:6YG(%M486)L M92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'`@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S:7IE/3-$ M,CX\8CXH,RD@1FEN86YC:6%L($EN3X-"B`-"B`@("`@(#QF;VYT('-I>F4],T0R/B8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.U1H90T*(`T*("`@("`@8V%RF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@ M("`@("`@("`@/&9O;G0@F4],T0R/D-AF4],T0Q('=I9'1H M/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO M=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S M:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`- M"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@ M("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@("`@ M/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O M/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@ M("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T* M("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@ M("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^#0H@(`T*("`@ M("`@("`@(#QHF4],T0R/C0T+#,Y.3PO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO M<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@ M("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^ M#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0S('=I9'1H/3-$,3`P M)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@ M("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/&AR('-I>F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S M:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^ M#0H@("`-"B`@("`@(#QTF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@ M/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@ M(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^ M#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'`@86QI9VX],T1J=7-T:69Y/@T*(`T*("`@("`@/&9O;G0@F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U1H90T*(`T*("`@("`@ M86UOF5D(&-OF4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@ M("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@ MF4] M,T0R/D=R;W-S/&)R("\^#0H@#0H@("`@("`@("`@("`@56YR96%L:7IE9#QB MF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D(&-O;'-P M86X],T0R('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@("`@/'`@86QI M9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F5D/&)R M("\^#0H@#0H@("`@("`@("`@("`@2&]L9&EN9R!,;W-S97,\+V9O;G0^#0H@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@ M/'`@86QI9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@ MF4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@ M("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@ MF4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X-"B`@ M#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M<"!A;&EG;CTS1&-E;G1EF4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@ M("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@ M/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R M:6=H=#X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@ M(#QT6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K M9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP M/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/B9N8G-P.R0\ M+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^ M#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)A8VMGF4],T0R/C0T-3PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^ M#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9& M.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@ M(#QF;VYT('-I>F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@ M("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/B8C.#(Q,CL\+V9O M;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A M8VMG6QE/3-$ M)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^ M#0H@("`-"B`@("`@(#QTF4],T0R/DYO;BU5+E,N(&=O=F5R;FUE;G0@9&5B=#PO M9F]N=#X-"B`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@ M("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$ M,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@ M("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H M=#X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/C4L-#F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H M=#X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/C0U/"]F;VYT M/@T*("`@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@ M("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@ M("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O M;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@ M/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT MF4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@ M("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T* M("`@("`@("`@(#QP(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C M135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@ M("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R M.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP(&%L:6=N/3-$6QE/3-$)V)A M8VMG6QE/3-$ M)V)A8VMG6QE M/3-$)V)A8VMGF4],T0R/B@Q,CPO9F]N=#X-"B`@("`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9& M.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@ M(#QF;VYT('-I>F4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^ M#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R/C,L,S$V/"]F;VYT/@T* M("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T* M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D M92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@ M#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@ M(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@ M(#QHF4],T0Q M('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@ M("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\ M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO M<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0Q('=I9'1H/3-$,3`P)2!N M;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@ M(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@ M("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF M(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@ M/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M("`@(`T*("`@("`@("`@(#QHF4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D M92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@ M#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@ M(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@ M("`@("`\+W1R/@T*("`@#0H@("`@("`\='(^#0H@(`T*("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@ M#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@ M(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@ M(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^ M#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<"!A;&EG;CTS1')I9VAT M/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\ M+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<"!A;&EG;CTS1')I M9VAT/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0S M('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@ M("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0S('=I9'1H/3-$,3`P)2!N M;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@ M(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@ M("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/&AR('-I>F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D M92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0S M('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@ M("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`\+W1A8FQE M/CQBF4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.RH@26YC M;'5D960@:6X-"B`-"B`@("`@('-H;W)T+71E3X-"B`-"B`@ M("`@(#QF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U1H90T*(`T*("`@ M("`@86UOF5D(&-OF4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@ M/&9O;G0@F4],T0R/D=R;W-S/&)R("\^#0H@#0H@("`@("`@("`@("`@56YR96%L M:7IE9#QBF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@("`@ M/'`@86QI9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@ MF5D/&)R("\^#0H@#0H@("`@("`@("`@("`@2&]L9&EN9R!,;W-S97,\+V9O M;G0^#0H@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/'`@86QI9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@("`@("`@ M/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT MF4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@ M/&9O;G0@F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O M;3X-"B`@#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N M;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@ M(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@ M("`@("`\<"!A;&EG;CTS1&-E;G1EF4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@ M("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@ MF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@ M("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI M9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O M;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`- M"B`@("`@(#QT6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@ M("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/B9N M8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@ M(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)V)A8VMGF4],T0R/CF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C M135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@ M("`@("`@(#QF;VYT('-I>F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@ M("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/B8C.#(Q M,CL\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO M=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0R/E4N4RX@9V]V97)N;65N="US<&]N MF4],T0R/DYO;BU5+E,N M(&=O=F5R;FUE;G0@9&5B=#PO9F]N=#X-"B`-"B`@("`@("`@("`\+W`^#0H@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R/C4L-34S/"]F;VYT/@T* M("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T* M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG M6QE/3-$)V)A M8VMGF4],T0R/C@V/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@ M("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@ M(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@ M("`-"B`@("`@(#QTF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T* M("`@("`@("`@("`@/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@ M(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I M>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@ M("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT M('-I>F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^ M#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/C8Q+#8U,3PO9F]N=#X-"B`@ M(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@F4],T0R/B9N8G-P.R0\+V9O M;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A M8VMGF4],T0R/C8R+#4V-#PO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO<#X-"B`- M"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I M>F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0S('=I9'1H/3-$ M,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^ M#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`- M"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@ M("`@("`@("`@/&AR('-I>F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$ M;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@ MF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I M>F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`\ M+W1A8FQE/CQBF4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.RHF(S$V,#LF(S$V,#M);F-L=61E9`T*("`-"B`@("`@(&EN('-H;W)T+71E M2!M=71U86P@9G5N9"!S:&%R97,I#0H@("`- M"B`@("`@('1O=&%L:6YG("9N8G-P.R0S+C,@;6EL;&EO;B!F86ER('9A;'5E M(&%S(&]F($IU;F4@,S`L(#(P,3$@86YD("9N8G-P.R0S+C$-"B`@(`T*("`@ M("`@;6EL;&EO;B!F86ER('9A;'5E(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$P M+B!4:&5R92!I3X-"B`-"B`@("`@(#QF M;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.T9A:7(-"B`@#0H@("`@("!V M86QU92!I2!A=F%I;&%B;&4@<75O M=&5D('!R:6-E28C.#(Q-SMS('-H;W)T+71E3X- M"B`-"B`@("`@(#QF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.TUA='5R M:71I97,-"B`@(`T*("`@("`@;V8@;6%R:V5T86)L92!D96)T('-E8W5R:71I M97,L(&5X8VQU9&EN9R!S96-U6QE/3-$1D].5"U325I%.C%06#X-"B`@("`-"B`@("`@("`@/'1D('=I M9'1H/3-$,3,E('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@("`@/'`^ M#0H@("`@(`T*("`@("`@("`@("`@)B,Q-C`[#0H@("`-"B`@("`@("`@("`\ M+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=VED M=&@],T0U-B4@=F%L:6=N/3-$8F]T=&]M/@T*("`-"B`@("`@("`@("`\<#X- M"B`@("`@#0H@("`@("`@("`@("`F(S$V,#L-"B`@(`T*("`@("`@("`@(#PO M<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!W:61T M:#TS1#,E('9A;&EG;CTS1&)O='1O;3X-"B`-"B`@("`@("`@("`\<#X-"B`@ M("`@#0H@("`@("`@("`@("`F(S$V,#L-"B`@(`T*("`@("`@("`@(#PO<#X- M"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!W:61T:#TS M1#$E('9A;&EG;CTS1&)O='1O;3X-"B`-"B`@("`@("`@("`\<#X-"B`@("`@ M#0H@("`@("`@("`@("`F(S$V,#L-"B`@(`T*("`@("`@("`@(#PO<#X-"B`- M"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!W:61T:#TS1#$P M)2!V86QI9VX],T1B;W1T;VT^#0H@(`T*("`@("`@("`@(#QP(&%L:6=N/3-$ MF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D(&-O;'-P86X] M,T0R('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@("`@/'`@86QI9VX] M,T1C96YT97(^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F5D/&)R("\^#0H@("`@(`T*("`@("`@("`@("`@($-OF4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@("`@/&AR('-I>F4],T0Q M('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@ M("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\ M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO M<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`\+W1R/@T*("`@ M#0H@("`@("`\='(^#0H@(`T*("`@("`@("`\=&0@8V]LF4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@ M("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^ M#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<"!A;&EG;CTS1')I9VAT/@T* M("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0R/C0Q+#`X,SPO M9F]N=#X-"B`@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X- M"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T* M("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`\+W1A M8FQE/CQBF4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U-A;&5S#0H@("`-"B`@("`@ M(&1U2`F;F)S<#LD-3@L,#`P+"!B65A2!T;R!O<&5R M871I;F<@97AP96YS97,N(%)E86QI>F5D(&=A:6YS(&%N9"!L;W-S97,@;VX- M"B`@(`T*("`@("`@2!L979E M;"!E86-H#0H@("`@(`T*("`@("`@0T*("`-"B`@("`@(&%N9"P@:68@:70@:7,@;W1H97(@=&AA;B!T96UP;W)A M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"B`-"B`@("`@(#QF;VYT('-I>F4] M,T0R/CQB/B@U*2!.;W1E7,@ M:6X@=&AE(#,P+6-O;G-E8W5T:79E+71R861I;F28C.#(Q-SMS(&-O;6UO;B!S=&]C:RP@'!E;G-E(&1U65A6%B;&4@;VX@ M2G5N92`Q(&%N9"!$96-E;6)E7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"B`@("`-"B`@("`@(#QF;VYT('-I>F4],T0R/CQB/B@V*2!3=&]C:VAO M;&1E3PO8CX\+V9O;G0^#0H@("`@#0H@("`@/"]P M/CQB28C.#(Q-SMS(&]U='-T M86YD:6YG(&-O;6UO;B!S:&%R97,N#0H@("`@#0H@("`@("!43X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D M,V$S9#4V85]D.64V7S0Q,V-?.3EE-5\U.64Y-F$R,S@X,&(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#-A,V0U-F%?9#EE-E\T,3-C7SDY935? M-3EE.39A,C,X.#!B+U=O'0O:'1M;#L@8VAA3X-"B`@("`@#0H@("`@("`\9F]N="!S:7IE/3-$,CX\8CXH M-RD@0V]M<')E:&5NF4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D(&-O;'-P86X],T0U('9A;&EG;CTS1&)O M='1O;3X-"B`@#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P M)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@ M("`@("`@("`\<"!A;&EG;CTS1&-E;G1EF4],T0R/C(P,3$\+V9O;G0^#0H@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI M9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D(&-O M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@("`@/'`@ M86QI9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0R/C(P,3`\+V9O;G0^#0H@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T* M("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O M;3X-"B`@#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N M;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@ M(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@ M("`@("`\<"!A;&EG;CTS1&-E;G1EF4],T0R/DYE="`H;&]S6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR M('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T* M("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H M/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO M=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0R/D]T:&5R(&-O;7!R96AE;G-I=F4@ M;&]SF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@ M("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI M9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O M;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@ M("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^ M#0H@("`@(`T*("`@("`@("`@(#QP(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O M;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP(&%L:6=N/3-$ M6QE M/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R/D-UF4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@ M("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\ M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO M<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP(&%L:6=N/3-$F4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@ M("`@(#PO=&0^#0H@("`@(`T*("`@("`@/"]T6QE/3-$34%21TE.+4Q%1E0Z,36QE/3-$)V)A8VMG M6QE/3-$)V)A M8VMG6QE/3-$ M)V)A8VMGF4],T0R/B@U.#PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^ M#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF M;VYT('-I>F4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R/B@Q-CPO9F]N=#X-"B`@("`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD M+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@ M("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/BD\+V9O;G0^#0H@("`- M"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R M/B@X,#PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T* M("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4] M,T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@ M(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R/B@Q,C@\+V9O;G0^#0H@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135& M1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@ M("`@(#QF;VYT('-I>F4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\ M+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@/"]TF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR M('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T* M("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H M/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO M=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR M('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T* M("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@ M("`@(#QT6QE/3-$34%21TE.+4Q%1E0Z,3F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X- M"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/B@R,3$\+V9O;G0^ M#0H@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`- M"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/B@Q+#(Y-3PO9F]N=#X-"B`@ M(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@ M(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/BD\+V9O M;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@ M("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$ M,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@ M("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@("`@(`T*("`@("`@("`@(#QP(&%L:6=N/3-$F4],T0R/BD\+V9O;G0^#0H@ M("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T* M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@ M("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V M,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T M9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@ M(`T*("`@("`@("`@(#QP(&%L:6=N/3-$F4],T0R/BD\+V9O;G0^#0H@("`-"B`@ M("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@ M/"]TF4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S M:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4] M,T0Q('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@ M("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P M)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@ M("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S M:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^ M#0H@("`-"B`@("`@(#QTF4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B M86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@ M(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/B9N8G-P M.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO M=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)V)A8VMGF4],T0R/B@W+#(W.3PO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO M<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT@F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@ M("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/B@V+#DQ-SPO9F]N M=#X-"B`@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@ M("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@F4],T0R/B9N8G-P.R0\ M+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^ M#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)A8VMGF4],T0R/B@V+#DY-3PO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO<#X- M"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\ M+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/C$Y,RPR.#$\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K M9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP M/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@ M("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$;6%R9VEN+6QE9G0Z."4^#0H@#0H@("`@("`\ M='(@6QE/3-$34%21TE.+51/4#HS4%@^#0H@("`-"B`@("`@("`@ M("`@(#QF;VYT('-I>F4],T0R/DEN9F]R;6%T:6]N(&AAF5R;RX\+V9O;G0^#0H@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`\+W1A8FQE M/CQB3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]D,V$S9#4V85]D.64V7S0Q,V-?.3EE-5\U.64Y-F$R,S@X,&(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#-A,V0U-F%?9#EE-E\T,3-C7SDY M935?-3EE.39A,C,X.#!B+U=O'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<"!A;&EG;CTS1&IUF4],T0R/CQB/B@X*2!3=7!P;&5M96YT86P@0V%S:"!&;&]W#0H@("`-"B`@ M("`@($EN9F]R;6%T:6]N/"]B/CPO9F]N=#X-"B`-"B`@("`\+W`^/&)R+SX\ M<"!A;&EG;CTS1&IU"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2P@ M=&AE2`Q,RXU(&UI;&QI;VX@&EM871E M;'D@)FYB6UE;G1S M('=E2X\+V9O;G0^#0H@("`-"B`@("`\+W`^/&)R+SX\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA3X-"B`-"B`@ M("`@(#QF;VYT('-I>F4],T0R/CQB/B@Y*2!386QE(&]F($EN+5!R;V-E3X-"B`-"B`@ M("`@(#QF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U=H96X-"B`@#0H@ M("`@("!T:&4@0V]M<&%N>2!S;VQD(&ETF%T:6]N+B!02!P:&%R;6%C975T:6-A;',@8G5S:6YE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!A;&EG;CTS1&IUF4],T0R/CQB/B@Q,"D@3&]S2!D:79I9&EN9R!T:&4-"B`-"B`@("`@ M(&EN8V]M92!A=F%I;&%B;&4@=&\@8V]M;6]N('-T;V-K:&]L9&5R2!T M:&4@=V5I9VAT960-"B`@#0H@("`@("!A=F5R86=E(&YU;6)E28C.#(Q-SMS M#0H@("`@(`T*("`@("`@8V]N=F5R=&EB;&4@;F]T97,@<&%Y86)L92X@26X@ M=&AE(&-A0T*("`@#0H@("`@("!A;B!A9&0M8F%C:R!O9B!I;G1E MF4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D(&-O;'-P86X],T0U('9A;&EG;CTS1&)O='1O;3X- M"B`@#0H@("`@("`@("`@/'`@86QI9VX],T1C96YT97(^#0H@("`@(`T*("`@ M("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D(&-O;'-P86X],T0U('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@ M("`@("`@("`@/'`@86QI9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@("`@ M("`@/&9O;G0@F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D(&-O;'-P86X],T0U('9A;&EG;CTS1&)O='1O M;3X-"B`@#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N M;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@ M(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@ M("`@("`\<"!A;&EG;CTS1&-E;G1EF4],T0R/C(P,3$\+V9O;G0^#0H@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1C96YT97(^#0H@("`@ M(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS M1&)O='1O;3X-"B`@#0H@("`@("`@("`@/'`@86QI9VX],T1C96YT97(^#0H@ M("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0R M/C(P,3`\+V9O;G0^#0H@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@ M("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@ MF4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D(&-O;'-P86X],T0R('9A M;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I M9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@ M(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M("`@("`-"B`@("`@("`@("`\<"!A;&EG;CTS1&-E;G1E6QE/3-$34%2 M1TE.+4Q%1E0Z."XV-5!4.U1%6%0M24Y$14Y4.BTX+C8U4%0^#0H@(`T*("`@ M("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@ M("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^ M#0H@("`@(`T*("`@("`@("`@(#QP(&%L:6=N/3-$6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O M;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`- M"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD M+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@ M("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O M=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP(&%L M:6=N/3-$F4] M,T0R/BA,;W-S*2!I;F-O;64@9G)O;2!C;VYT:6YU:6YG#0H@("`-"B`@("`@ M("`@("`@(&]P97)A=&EO;G,\+V9O;G0^#0H@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@ M("`@("`@/&9O;G0@F4],T0R/B@W+#`V.#PO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO M<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@ M("`@("`@("`@(#QF;VYT('-I>F4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@ M("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@ M("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,CXF;F)S<#LD/"]F;VYT M/@T*("`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@(#QF M;VYT('-I>F4],T0R/B@U+#4W,3PO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO M<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@ M("`@("`@("`@(#QF;VYT('-I>F4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@ M("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@ M("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,CXF;F)S<#LD/"]F;VYT M/@T*("`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@(#QF M;VYT('-I>F4],T0R/B@V+#8S-SPO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO M<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@ M("`@("`@("`@(#QF;VYT('-I>F4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@ M("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@ M("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,CXF;F)S<#LD/"]F;VYT M/@T*("`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@(#QF M;VYT('-I>F4],T0R/C$U+#$X,SPO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO M<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@ M("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M(#PO='(^#0H@("`-"B`@("`@(#QT6QE/3-$34%2 M1TE.+4Q%1E0Z,C4N.5!4.U1%6%0M24Y$14Y4.BTX+C8U4%0^#0H@(`T*("`@ M("`@("`@("`@/&9O;G0@F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@ M("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@ M("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$ M,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^ M#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`- M"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE M/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@ M("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$ M;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X- M"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O M;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@ M("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@ M("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@ M("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@ M("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`\+W1R M/@T*("`@#0H@("`@("`\='(^#0H@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K M9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP M/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/B9N8G-P.R0\ M+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^ M#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)A8VMGF4],T0R/B8C.#(Q,CL\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^ M#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A M8VMGF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135& M1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@ M("`@(#QF;VYT('-I>F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@ M("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/C$W.2PP,#(\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@ M("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT6QE/3-$34%21TE.+4Q%1E0Z,C4N.5!4.U1%6%0M24Y$14Y4 M.BTX+C8U4%0^#0H@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\ M+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X- M"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T* M("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T* M("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@ M("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@ M("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H M/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO M=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S M:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`- M"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\ M+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X- M"B`@("`@#0H@("`@("`\+W1R/@T*("`@#0H@("`@("`\='(^#0H@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M<"!S='EL93TS1$U!4D=)3BU,1494.C$W+C-05#M415A4+4E.1$5.5#HM."XV M-5!4/@T*("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/DYE="`H;&]S MF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T* M("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO M='(^#0H@("`-"B`@("`@(#QT6QE/3-$34%21TE. M+4Q%1E0Z,C4N.5!4.U1%6%0M24Y$14Y4.BTX+C8U4%0^#0H@(`T*("`@("`@ M("`@("`@/&9O;G0@F4] M,T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@ M("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@ M("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@ M(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P M)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@ M("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$ M,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@ M("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S M:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@ M("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^ M#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@ M#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@ M("`@(#QHF4] M,T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@ M("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@ M("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@ M(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`\+W1R/@T* M("`@#0H@("`@("`\='(^#0H@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@("`-"B`@("`@("`@("`\<"!S='EL93TS1$U!4D=)3BU,1494 M.C@N-C505#M415A4+4E.1$5.5#HM."XV-5!4/@T*("`-"B`@("`@("`@("`@ M(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T* M("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@ M/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@ M("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@ M(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0R/E=E:6=H=&5D(&%V97)A9V4@8V]M;6]N M('-H87)EF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9& M.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@ M(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135& M1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP(&%L:6=N/3-$6QE/3-$)V)A8VMG M6QE/3-$)V)A M8VMG6QE/3-$ M)V)A8VMGF4],T0R/C4U+#,V.#PO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO<#X- M"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT6QE/3-$34%21TE.+4Q%1E0Z,3F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S M:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@ M("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^ M#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@ M#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@ M("`@(#QHF4] M,T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@ M("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@ M("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@ M(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P M)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@ M("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$ M,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@ M("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S M:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@ M("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^ M#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@ M#0H@("`@("`\+W1R/@T*("`@#0H@("`@("`\='(^#0H@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<"!S='EL M93TS1$U!4D=)3BU,1494.C@N-C505#M415A4+4E.1$5.5#HM."XV-5!4/@T* M("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@ M("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@ MF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X- M"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT6QE/3-$34%21TE.+4Q%1E0Z,3F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@ M("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^ M#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF M;VYT('-I>F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\ M+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/B@P+C$S/"]F;VYT/@T* M("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T* M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@ M("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)A8VMGF4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`- M"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/C`N M,C<\+V9O;G0^#0H@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@ M("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT6QE/3-$34%21TE.+4Q%1E0Z,3F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\ M+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X- M"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T* M("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T* M("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@ M("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@ M("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H M/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO M=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S M:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`- M"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\ M+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X- M"B`@("`@#0H@("`@("`\+W1R/@T*("`@#0H@("`@("`\='(^#0H@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M<"!S='EL93TS1$U!4D=)3BU,1494.C(U+CDU4%0[5$585"U)3D1%3E0Z+3@N M-C505#X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^ M#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0R/B8C.#(Q,CL\+V9O;G0^#0H@("`-"B`@ M("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X- M"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O M;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@ M("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@ M("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R M/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@ M("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*("`@("`-"B`@("`@("`@("`\<"!A;&EG;CTS1')I9VAT/@T*("`@(`T* M("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT6QE/3-$34%21TE.+4Q%1E0Z,3F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$ M;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X- M"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O M;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@ M("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@ M("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@ M("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@ M("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$ M,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^ M#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`- M"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE M/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@ M("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$ M;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X- M"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O M;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@ M("`@#0H@("`@("`\+W1R/@T*("`@#0H@("`@("`\='(^#0H@(`T*("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/DYE="`H;&]SF4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@ M("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/B9N8G-P M.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO M=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)V)A8VMGF4],T0R/B@P+C$R/"]F;VYT/@T*("`-"B`@("`@("`@("`\+W`^ M#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@ M("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@ M("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`- M"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@ M/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0R/CQU/BA, M;W-S*2!%87)N:6YGF4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@ M("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@ M("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@ M("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0R/BA,;W-S*2!I;F-O;64@9G)O;2!C M;VYT:6YU:6YG#0H@("`-"B`@("`@("`@("`@(&]P97)A=&EO;G,\+V9O;G0^ M#0H@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O M=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T* M("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K M9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP M/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/B9N8G-P.R0\ M+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^ M#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)A8VMGF4],T0R/B@W+#`V.#PO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO<#X- M"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\ M+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/B@U+#4W,3PO9F]N=#X- M"B`@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@ M#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@F4],T0R/B9N8G-P.R0\+V9O M;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A M8VMGF4],T0R/B@V+#8S-SPO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO<#X-"B`- M"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^ M#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/C$U+#$X,SPO9F]N=#X-"B`@ M(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@F4],T0R/D%D9"!B86-K(&EN=&5R M97-T(&5X<&5N#PO9F]N=#X-"B`@("`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@ M(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR M('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T* M("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H M/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO M=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0R/D%D:G5S=&5D("AL;W-S*2!I;F-O;64@9G)O;2!C M;VYT:6YU:6YG#0H@(`T*("`@("`@("`@("`@;W!E6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG MF4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/BD\+V9O;G0^#0H@ M("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T* M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@ M("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT6QE M/3-$34%21TE.+4Q%1E0Z,3F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O M/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@ M("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T* M("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@ M("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QH MF4],T0S('=I M9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@ M(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X- M"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H M861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T* M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@ M("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V M,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T M9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@ M(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O M/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@ M("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T* M("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@ M("`\+W1R/@T*("`@#0H@("`@("`\='(^#0H@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<"!S='EL93TS1$U! M4D=)3BU,1494.C$W+C-05#M415A4+4E.1$5.5#HM."XV-5!4/@T*("`-"B`@ M("`@("`@("`@(#QF;VYT('-I>F4],T0R/D1IF4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@ M("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<"!A M;&EG;CTS1')I9VAT/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T* M("`@("`@("`@("`@/&9O;G0@F4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\ M+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@ M("`@("`@("`@("`\9F]N="!S:7IE/3-$,CXF;F)S<#LD/"]F;VYT/@T*("`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@ M/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I M>F4],T0R/B8C.#(Q,CL\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@ M("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@ M("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@ M("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/B9N8G-P.R0\+V9O;G0^ M#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@ M(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@ M("`@("`\<"!A;&EG;CTS1')I9VAT/@T*("`@(`T*("`@("`@("`@("`@/&9O M;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^ M#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$34%21TE.+4Q%1E0Z,36QE/3-$)V)A8VMG M6QE/3-$)V)A M8VMGF4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^ M#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/BD\+V9O;G0^ M#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@ M(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG MF4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG MF4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0S('=I9'1H/3-$,3`P)2!N M;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@ M(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@ M("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/&AR('-I>F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D M92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0S M('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@ M("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0S('=I9'1H/3-$,3`P)2!N M;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@ M(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@ M("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT6QE M/3-$34%21TE.+4Q%1E0Z."XV-5!4.U1%6%0M24Y$14Y4.BTX+C8U4%0^#0H@ M(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@ M("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@ M("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@ MF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X- M"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT M('-I>F4],T0R/C4S+#`U-#PO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO<#X- M"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@ M("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@ M("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@ M("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@ M(#QF;VYT('-I>F4],T0R/C4V+#8T,#PO9F]N=#X-"B`@(`T*("`@("`@("`@ M(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`- M"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0R/E=E:6=H=&5D+6%V97)A9V4@:6YC6QE/3-$)V)A M8VMG6QE/3-$ M)V)A8VMG6QE M/3-$)V)A8VMGF4],T0R/B8C.#(Q,CL\+V9O;G0^#0H@("`-"B`@("`@("`@("`\ M+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R M/B8C.#(Q,CL\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@ M("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R/B8C.#(Q,CL\+V9O M;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A M8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R/C$L-#$V/"]F;VYT/@T* M("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T* M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R M:6=H=#X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/B8C.#(Q M,CL\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO M=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S M:7IE/3-$,CX\F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@ M/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I M>F4],T0R/B8C.#(Q,CL\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@ M("`@("`\9F]N="!S:7IE/3-$,CX\F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@ M("`@(#QF;VYT('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^#0H@("`-"B`@("`@ M("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@ M("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,CX\F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@ M("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/C$W+#$U,SPO9F]N=#X- M"B`@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@ M#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@ M("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT6QE/3-$34%21TE.+4Q%1E0Z,3F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\ M+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X- M"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T* M("`@("`@("`@(#QHF4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T* M("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@ M("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@ M("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0Q('=I9'1H M/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO M=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S M:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`- M"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0Q('=I9'1H/3-$,3`P)2!N;W-H861E M/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\ M<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\ M+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X- M"B`@("`@#0H@("`@("`\+W1R/@T*("`@#0H@("`@("`\='(^#0H@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9& M.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@ M(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135& M1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP(&%L:6=N/3-$6QE/3-$)V)A8VMG M6QE/3-$)V)A M8VMG6QE/3-$ M)V)A8VMGF4],T0R/C4U+#,V.#PO9F]N=#X-"B`@(`T*("`@("`@("`@(#PO<#X- M"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT6QE/3-$34%21TE.+4Q%1E0Z,3F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S M:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@ M("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^ M#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@ M#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@ M("`@(#QHF4] M,T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@ M("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@ M("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@ M(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P M)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@ M("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@ M("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$ M,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@ M("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@("`@(`T*("`@("`@("`@(#QHF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S M:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@ M("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^ M#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@ M#0H@("`@("`\+W1R/@T*("`@#0H@("`@("`\='(^#0H@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<"!S='EL M93TS1$U!4D=)3BU,1494.C@N-C505#M415A4+4E.1$5.5#HM."XV-5!4/@T* M("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@ M("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@ MF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X- M"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`@(#QT6QE/3-$34%21TE.+4Q%1E0Z,3F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@ M("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI M9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O M;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)V)A8VMGF4],T0R/D-O;G1I;G5I;F<@;W!EF4] M,T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@ M(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)V)A8VMGF4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@ M("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/B@P+C$R M/"]F;VYT/@T*("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^ M#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@ M("`@("`@("`@/&9O;G0@F4],T0R/D1IF4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<"!A;&EG;CTS1')I9VAT/@T* M("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q M/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@ M("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O M;G0@F4],T0R/B8C M.#(Q,CL\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@ M(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X- M"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@ M("`@("`@(#QF;VYT('-I>F4],T0R/B9N8G-P.R0\+V9O;G0^#0H@("`-"B`@ M("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<"!A M;&EG;CTS1')I9VAT/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T* M(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$34%21TE.+4Q%1E0Z,C4N.3505#M415A4+4E.1$5. M5#HM."XV-5!4/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,CY. M970@*&QO6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R/B9N8G-P.R0\ M+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^ M#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)A8VMGF4],T0R/B@P+C`Y/"]F;VYT/@T*("`-"B`@("`@("`@("`\+W`^#0H@ M#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)A8VMGF4],T0R/BD\+V9O;G0^#0H@("`- M"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0S('=I M9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@ M(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@ M("`@#0H@("`@("`@("`@/&AR('-I>F4],T0S('=I9'1H/3-$,3`P)2!N;W-H M861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T* M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@ M("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@ M/&AR('-I>F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O M/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/&AR('-I>F4],T0S('=I M9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@ M(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C M,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\ M+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`-"B`@("`\+W1A8FQE/CQB M6QE/3-$34%21TE.+51/4#HM,U!8/@T*("`@(`T*("`@("`@ M("`@("`@/&9O;G0@F4],T0R/D9O"!M;VYT:',@96YD960@2G5N90T*("`@#0H@("`@("`@("`@("`S,"P@ M,C`Q,2!A;F0@=&AE('1H&5R8VES97,@;V8@2!D:6QU=&4@96%R;FEN9W,@<&5R('-H87)E(&EN('1H92!F M=71U6UE;G1S('1H870@=V]U;&0@:&%V92!B965N(&9O0T*("`@#0H@("`@("`@("`@("!T:&4@;F]T92!H;VQD97)S(&]N(&-O M;G9E6QE/3-$34%21TE.+51/4#HM,U!8/@T*("`@(`T*("`@ M("`@("`@("`@/&9O;G0@F4],T0R/D%S7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA2!R96-O&5C=71I=F4@5FEC92!06%B;&4@=6YD97(@=&AE('1E&EM871E;'D@)FYB2!R96-O&-E2!T:&%T('=A2!R96QO8V%T960@:71S#0H@("`@#0H@("`@("!C;W)P;W)A=&4@;V9F:6-E M2!O9@T*("`@#0H@("`@("!T:&4@=&5R;6EN M871I;VYS(&]C8W5R65A2!M861E#0H@("`@(`T*("`@("`@2X@07,@ M;V8-"B`@("`@#0H@("`@("!*=6YE(#,P+"`R,#$Q+"!T:&5R92!I65E2!T2!O9B!I=',@9V5N97)A;"!A;F0@861M:6YI28C M.#(Q-SMS('1H96X-"B`@("`-"B`@("`@(%!R97-I9&5N="!A;F0@0VAI968@ M17AE8W5T:79E($]F9FEC97(@6UE;G0@86=R965M96YT+B!4:&ES(&%M;W5N="!W87,@2!A<'!R;WAI;6%T96QY("9N8G-P.R0P+C(@;6EL;&EO;@T*("`@ M(`T*("`@("`@;VYC92!T:&4@=&5R;6EN871I;VX@86=R965M96YT('=A&5C=71E9"X@4&%Y;65N=',@9'5E#0H@("`@#0H@("`@("!P=7)S=6%N="!T M;R!T:&4@=&5R;6EN871I;VX@86=R965M96YT('=E3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]D,V$S9#4V85]D.64V7S0Q,V-?.3EE-5\U.64Y M-F$R,S@X,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#-A,V0U M-F%?9#EE-E\T,3-C7SDY935?-3EE.39A,C,X.#!B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R3X-"B`-"B`@("`@(#QF;VYT('-I>F4],T0R/CQB/B@Q,BD@ M4VAA2`R,#$Q M+"!T:&4@0V]M<&%N>28C.#(Q-SMS('-T;V-K:&]L9&5R2!R96-O9VYI>F5D#0H@ M(`T*("`@("`@&5S(&]N M(&)E:&%L9B!O9B!E;7!L;WEE97,-"B`@#0H@("`@("!R96QA=&5D('1O('-H M87)E+6)A0T*("`@(`T*("`@("`@65E3X-"B`-"B`@("`@(#QF;VYT('-I>F4],T0R M/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.T1U"!M M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2P@=&AE($-O;7!A;GD@'!E;G-E(&]F("9N8G-P.R0Q+CD@;6EL;&EO;BX@4VAA"!M;VYT:',@96YD960@2G5N92`S M,"P@,C`Q,"P@=&AE#0H@(`T*("`@("`@0V]M<&%N>2!R96-O9VYI>F5D('-H M87)E+6)A'!E;G-E(&]F("9N8G-P.R0U+C,- M"B`-"B`@("`@(&UI;&QI;VXL(&]F('=H:6-H("9N8G-P.R0P+C8@;6EL;&EO M;B!I&5S#0H@("`-"B`@("`@(&]N(&)E:&%L9B!O M9B!E;7!L;WEE97,@3X-"B`-"B`@("`@(#QF;VYT M('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.TEN#0H@("`@(`T*("`@("`@8V]N M;F5C=&EO;B!W:71H('1H92!S86QE(&]F('1H92!S<&5C:6%L='D@<&AA2!E;&5C=&5D('1O(&%C8V5L97)A=&4@=&AE('9E&5C=71I=F5S#0H@ M#0H@("`@("!A;F0@;65M8F5R'1E;G0L(&%N(&%D:G5S=&UE;G0L(&EN(&-E28C.#(Q-SMS(&9O'!E M;G-E(&EN('1H92!F:7)S="!Q=6%R=&5R(#(P,3`@;V8@87!P2`F;F)S<#LD,BXQ#0H@(`T*("`@("`@;6EL;&EO;BX\+V9O;G0^#0H@("`- M"B`@("`\+W`^/&)R+SX\<"!A;&EG;CTS1&IU3X-"B`-"B`@("`@(#QF;VYT('-I>F4],T0R M/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.U1H90T*(`T*("`@("`@=V5I9VAT960@879E"!M;VYT:',@96YD960-"B`-"B`@("`@($IU;F4@,S`L(#(P M,3$@86YD(')E;&%T960@8F%L86YC97,@;W5TF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI M9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@ M("`@/'`@86QI9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@("`@("`@/&9O M;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@ M("`-"B`@("`@(#QTF4],T0Q/B8C,38P.SPO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/'`@86QI9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@("`@("`@/&9O M;G0@F4],T0Q/B8C,38P.SPO9F]N M=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X- M"B`@#0H@("`@("`@("`@/&AR('-I>F4],T0Q('=I9'1H/3-$,3`P)2!N;W-H M861E/3-$;F]S:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T* M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@ M("`\<#X-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V M,#L\+V9O;G0^#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T M9#X-"B`@("`@#0H@("`@("`\+W1R/@T*("`@#0H@("`@("`\='(^#0H@(`T* M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG2`Q+"`R,#$Q/"]F;VYT/@T*("`-"B`@("`@("`@("`\+W`^ M#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R/C,L.3DS/"]F;VYT M/@T*("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@ M(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG M6QE/3-$)V)A M8VMG6QE/3-$ M)V)A8VMGF4],T0R/CF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@(#PO='(^#0H@("`- M"B`@("`@(#QT6QE/3-$34%21TE.+4Q%1E0Z,3F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@ M("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@ M(#QF;VYT('-I>F4],T0R/C$V-CPO9F]N=#X-"B`@("`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T* M("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0R/D5X97)C:7-E9"!A;F0@=F5S=&5D/"]F;VYT M/@T*("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@ M(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG M6QE/3-$)V)A M8VMG6QE/3-$ M)V)A8VMGF4],T0R/B@V-34\+V9O;G0^#0H@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C135&1D9&.R<^#0H@ M("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT M('-I>F4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@("`@("`\+W`^#0H@#0H@ M("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0R/B@R,S$\+V9O;G0^#0H@#0H@("`@ M("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R M.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`-"B`@ M("`@("`@("`@(#QF;VYT('-I>F4],T0R/BD\+V9O;G0^#0H@("`-"B`@("`@ M("`@("`\+W`^#0H@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@/"]T MF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H M=#X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/B@R.3@\+V9O M;G0^#0H@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@ M("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@ M("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T* M("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@ M("`-"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0R/B@T-CPO9F]N=#X-"B`@ M("`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`- M"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@ M("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@ M("`@("`@("`@/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0R/D]U='-T86YD:6YG(&%T($IU;F4@,S`L(#(P,3$\+V9O;G0^ M#0H@("`@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@ M("`@#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG MF4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S M:&%D92`O/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@ M("`@#0H@("`@("`@("`@("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^ M#0H@(`T*("`@("`@("`@(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@ M#0H@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@ M("`@(#QHF4] M,T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O/@T*("`@#0H@ M("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@ M("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@ M(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`\+W1R/@T* M("`@#0H@("`@("`\='(^#0H@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@("`-"B`@("`@("`@("`\<#X-"B`@("`@#0H@("`@("`@("`@ M("`\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^#0H@(`T*("`@("`@("`@ M(#PO<#X-"B`-"B`@("`@("`@/"]T9#X-"B`@("`@#0H@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`- M"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@ M/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P M.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D M/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@ M#0H@("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@ M("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@ M("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@ M(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T* M("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T* M("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@ M/&AR('-I>F4],T0S('=I9'1H/3-$,3`P)2!N;W-H861E/3-$;F]S:&%D92`O M/@T*("`@#0H@("`@("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@("`-"B`@("`@("`@("`\:'(@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@/"]P M/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T*("`@ M("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^ M#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO M9F]N=#X-"B`@#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T* M("`@("`-"B`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@ M("`@("`@("`@/'`@86QI9VX],T1R:6=H=#X-"B`@("`-"B`@("`@("`@("`@ M(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@("`@("`@("`@ M/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@/'`^#0H@("`@(`T* M("`@("`@("`@("`@/&9O;G0@F4],T0R/D]P=&EO;G,@97AE6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG MF4] M,T0R/C,L,#$V/"]F;VYT/@T*("`-"B`@("`@("`@("`\+W`^#0H@#0H@("`@ M("`@(#PO=&0^#0H@("`@(`T*("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMGF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O M;&]R.B`C135&1D9&.R<^#0H@("`@(`T*("`@("`@("`@(#QP/@T*("`@("`- M"B`@("`@("`@("`@(#QF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@(#PO='(^#0H@("`-"B`@("`@(#QTF4],T0Q/B8C,38P.SPO9F]N=#X-"B`@ M#0H@("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`@#0H@("`@("`@("`@ M/'`^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]P/@T*(`T*("`@("`@("`\+W1D/@T*("`@("`-"B`@("`@ M(#PO='(^#0H@("`-"B`@("`\+W1A8FQE/CQB3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,V$S9#4V85]D.64V7S0Q,V-? M.3EE-5\U.64Y-F$R,S@X,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO9#-A,V0U-F%?9#EE-E\T,3-C7SDY935?-3EE.39A,C,X.#!B+U=O'0O:'1M;#L@ M8VAA'0@ M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!A;&EG M;CTS1&IU3X-"B`-"B`@("`@(#QF;VYT('-I>F4],T0R/B8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.T1U"!E>'!E;G-E(')E;&%T960@=&\@=&AE($-A;F%D:6%N#0H@("`-"B`@ M("`@('-U8G-I9&EA"!M;VYT M:',@96YD960@2G5N92`S,"P-"B`@("`@#0H@("`@("`R,#$P+"!T:&4@0V]M M<&%N>2!R96-O&%B M;&4@=')A;G-A8W1I;VX@9F]R(&9E9&5R86P@:6YC;VUE('1A>"!P=7)P;W-E M2!D=64@=&\@=&AE('1A>`T*("`@ M#0H@("`@("!B87-I2!H860@:6X@9&EV97-T960@87-S M971S(&%N9"!T:&4@;F5T#0H@("`@#0H@("`@("!O<&5R871I;F<@;&]S2!C;VYT:6YU97,@=&\@<')O=FED92!A('9A M;'5A=&EO;B!A;&QO=V%N8V4@86=A:6YS=`T*("`@("`-"B`@("`@(&ET2!B96QI M979EF5D+CPO9F]N=#X-"B`@("`-"B`@("`\+W`^/&)R+SX\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQAF4] M,T0R/CQB/B@Q-"D@0V]M;6ET;65N=',@86YD($-O;G1I;F=E;G0-"B`@(`T* M("`@("`@3&EA8FEL:71I97,\+V(^/"]F;VYT/@T*(`T*("`@(#PO<#X\8G(O M/CQP(&%L:6=N/3-$:G5S=&EF>3X-"B`-"B`@("`@(#QF;VYT('-I>F4],T0R M/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.U1H90T*(`T*("`@("`@0V]M<&%N>2!H87,@96UP M;&]Y;65N="!A;F0@6UE;G1S#0H@("`-"B`@("`@(&%N M9"!P87EM96YT2X\+V9O;G0^#0H@("`-"B`@("`\+W`^/&)R+SX\<"!A M;&EG;CTS1&IU6QE/3-$)TU!4D=) M3BU224=(5#HP24X[($U!4D=)3BU,1494.C!)3CLG/@T*("`@(`T*("`@("`@ M/&9O;G0@'1087)T7V0S83-D-39A7V0Y939?-#$S8U\Y.64U 17S4Y93DV83(S.#@P8BTM#0H` ` end